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ABSTRACT
In the West of Scotland in the last thirty years there has been a definite decrease in the 
incidence and mortality from gastric cancer but the survival of patients who develop 
adenocarcinoma of the stomach remains poor.
This thesis is introduced by an audit of gastric cancer in a single centre over a period of
twenty years. This aims to describe changes in the presentation, diagnosis and
management of the condition during the period of study. Overall, despite improvements in 
investigation the disease still presents at an advanced stage and rates of curative resection 
are low. Advances in surgical technique and post-operative care have not improved long 
term survival with little significant additional benefit from current adjuvent medical therapy.
The tyrosine kinase growth factor receptors have been investigated in a number of human 
cancers including breast, colon, ovarian and squamous carcinoma. In gastric cancer, the 
level of expression and prognostic value of EGFr and c-erbB-2 have been reported with 
some considerable variation using standard immunohistochemistry. To assess the use of 
growth factors as tumour markers or potential therapeutic targets, reliable quantitative and 
reproducible measurements of expression must be established.
This study reports the quantitative expression of EGFr and c-erbB-2 using
radioimmunohistochemistry (RIHC) and compares the results with expression using
conventional immunohistochemistry (IHC). The correlation of established clinico- 
pathological factors with EGFr, c-erbB-2 and the gene amplification of c-erbB-2 using 
fluorescence in situ hybridisation is investigated.
In both EGFr and c-erbB-2 expression there is good overall correlation analysis using RIHC 
and IHC (p<0.0005) but the separation of results is significantly better with RIHC particularly 
in the higher expressing tumours. In comparing tumour to mucosal samples, 22.4% of 
tumours expressed c-erbB-2 at a higher level, using RIHC and 43.3% with IHC. EGFr was 
expressed in 22.4% of cases more than the mucosal range with RIHC and 41.8% with IHC. 
There was no correlation of EGFr and c-erb-2 (r2 = 0.004, p = 0.594).
In this study there is significant correlation of c-erbB-2 with well and moderately well 
differentiated tumours (p=0.008) and no serosal involvement (p=0.066). EGFr in this study
also appears to correlate with well and moderately well differentiated tumours (p=0.079). 
There was no correlation between EGFr, c-erbB-2 and patient survival.
This thesis has demonstrated IGF-I induced cellular proliferation with a dose dependent 
inhibition by the tyrophostin RG13022. IGF-I is found to be a less potent stimulator of the 
MAP kinase pathway than EGF and RG13022 is less able to inhibit this pathway.
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PARTI
GASTRIC CANCER: AN 
INTRODUCTION
Chapter 1
Chapter 1 
Gastric cancer -  The Clinical Problem
The survival of patients diagnosed with gastric cancer in the West of Scotland is poor. In 
our institution over twenty years the five year survival has reduced from 11% to 6% 
despite the improvements in endoscopic diagnosis, surgical technique and post­
operative care. A decline in the incidence of gastric cancer has been recognised with a 
number of factors involved in the decline but we have yet to fully determine an 
explanation for this and the variation in the incidence of gastric cancer between 
countries throughout the world.
In the introduction to this thesis I will outline a number of factors which are recognised 
as contributing to the variability in incidence and presentation of gastric cancer in areas 
of variable risk. I hope to set the scene of gastric cancer diagnosis and treatment in the 
West of Scotland in the time period studied. In an attempt to describe the clinical 
problems of gastric cancer in the West of Scotland, particularly the advanced stage at 
presentation and difficulties thereafter, in managing the disease, I will present original 
observations from the West of Scotland population.
In subsequent sections, the current knowledge of tumour biology, prognostic factors and 
tumour markers in gastric cancer will be reviewed. Following on from recent advances in 
the understanding of the molecular biology of cancer and improved techniques of 
investigation, I will describe a series of investigations which may further our knowledge 
of the behaviour of gastric cancer. In particular, an analysis of the level of expression 
and gene amplification of c-erbB-2 and of EGFr expression will be described in a series 
of gastric cancers with a discussion of the merits of the various methods of detection. I 
will co-ordinate this information with knowledge of in vitro inhibition of gastric cancer cell 
growth using novel inhibitors to the EGFr and c-erbB-2. In more detail I will describe the 
IGF-I receptor and preliminary proliferation studies of gastric cancer cells exposed to 
IGF-I in vitro and demonstrate inhibition of this activity.
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Epidemiology
Section i: The changing incidence of gastric cancer
The incidence of gastric cancer has slowly declined in Scotland over the last three 
decades as it has worldwide but there remains a significant number of patients 
developing the disease. In Scotland it is the fourth most common cause of death from a 
malignant disease (Smans 1985). The incidence in the Scottish population has reduced 
from 22.1 to 18 per 100,000 in males and 12.1 to 7.6 per 100,000 in females in the 
period from 1960-1990 with a further reduction to 14.5 per 100,000 males in 1997 and 
6.8 per 100,000 females. In 1960-1990 there has been a more pronounced decrease in 
mortality from 27.6 to 15.7 per 100,000 in males and from 23.7 to 11.2 per 100,000 in 
females. Despite this the overall five year survival has shown only a 2% improvement in 
the last thirty years (McKinney 1993). In Scotland this equates to five year survival of 
11.5% between 1991 and 1995 (NHS Publications 2001).
Section ii: Geographical variation of gastric cancer
The frequency of gastric cancer shows marked differences when comparing the 
population in Western Europe and in the U.S.A. with the much higher risk areas of 
Japan, China, Eastern Asia, Asiatic Russia and the Andean South America (Correa 
1991). The predominant histological type of gastric cancer in these areas is the 
intestinal type and is particularly prone to temporal and regional variation (Lauren 1965, 
Correa 1973).
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Section iii: The influence of genetic factors
The incidence of the less common diffuse type is more or less equal in high and low risk 
areas but corresponds to a higher proportion of cases in areas with a lower incidence 
and overall risk of gastric malignancy. There is an association between the diffuse type 
tumour and blood group A (Correa 1973). Migrants from high risk countries retain a 
higher risk and subsequent incidence of disease if they settle in a country of lower 
incidence and this can be retained for several generations (Haenszel 1972, Waterhouse 
1983). Therefore, geographic, environmental and genetic factors are all implicated.
Section iv: Dietary factors
Dietary factors are involved in the development of gastric cancer and have been 
evaluated with regards to their promotional and protective effects. In Japan, milk has 
been shown to be protective possibly involving better utilisation of Vitamins A and E 
(Hirayama 1968). Diets, which are low in animal fat and protein intake are found to 
occur in both high and low risk areas but in general those areas at high risk have low 
dietary intake of fat and protein. A similar picture is found with the intake of complex 
carbohydrates and it may be that cooking of grains, prominent in the diet in high risk 
countries, may be involved. A low content of Vitamin C in the diet is thought to be a risk 
(O’Toole 1996) and a lack of fresh fruit and vegetables (Correa 1983). Vitamin C is 
known to be a scavenger of mucosal damaging reactive oxygen metabolites and inhibits 
nitrosation in the production of potentially mutagenic N-nitroso-nitorosamines. Gastric 
juice ascorbic acid is reduced by Helicobacter pylori infection.
A high salt intake is associated with increased risk of gastric cancer possibly as a 
consequence of the induction of chronic gastritis and this has been demonstrated in 
animal models (Sato 1959). Finally nitrate consumption has long been thought to be a 
factor increasing the risk of gastric cancer (Natl Acad Sciences 1981). It is not, however, 
the amount of dietary nitrogen that is responsible but the carcinogens produced when
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nitrate is reduced by intragastric bacteria in an environment of reduced gastric acidity 
such as is found with bacterial overproliferation in chronic atrophic gastritis (Correa 
1975). In contrast to this theory, atrophic gastritis may not be associated with bacterial 
overproliferation but achlorhydria may be a marker of abnormal mucosa consequent to a 
chemical reaction between nitrate and amine at an acid pH (Cunningham 1987). 
Nitrosation can occur at an acid pH (Reed 1993) although the rate of acid catalysed 
nitrosation is dependent on nitrate concentration. This may be a way in which the 
varying amount of dietary nitrates are important in providing a possible method for the 
regional variation in incidence which corresponds to dietary differences.
Section v: Chronic gastritis and dysplasia
Chronic gastritis and atrophy are linked with protein malnutrition, chemical irritation by 
spices and smoked fish, osmotic stress due to high salt intake, pernicious anaemia and 
Polya gastrectomies (Hill 1987). In addition to gastric atrophy these conditions have 
been found in association with cases of intestinal metaplasia of the gastric mucosa and 
dysplasia. Bile reflux following gastric surgery is also known to cause dysplasia of the 
gastric mucosa. Intestinal metaplasia and dysplasia are recognised precursors of gastric 
cancer particularly of the intestinal type which accounts for the majority of gastric cancer 
in countries such as Japan. In the United Kingdom, the effect of dietary and 
environmental factors has been difficult to satisfactorily evaluate. There is an association 
between gastric cancer and low socio-economic groups which may be in some way 
related to dietary factors and Helicobacter infection (Eurogast study group 1993, Sitas 
1991).
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Section vi: Helicobacter pylori infection
The role of Helicobacter pylori (Hp) infection and the development of chronic 
inflammatory conditions of the stomach has stimulated investigation into its role in 
carcinogenesis. A high incidence of Helicobacter infection is found in high risk areas and 
is now considered a significant risk factor in gastric cancer (Parsonnet 1991, Forman 
1991). Further acid suppression for symptomatic control of dyspepsia without 
eradication of Helicobacter pylori may further exacerbate the carcinogenic potential.
Section vii: Gastric cancer - how can we improve?
The incidence of diffuse tumours is relatively uniform worldwide but represents a larger 
proportion of tumours in low risk areas. Although the development of intestinal type 
tumours from chronic gastritis to dysplasia and invasive carcinoma is recognised, the 
development of diffuse tumours is less clear. In all tumours the aggressiveness and 
metastatic potential are unpredictable. In an area of relatively low incidence of gastric 
cancer such as the West of Scotland, screening programmes for the disease such as 
those in Japan (Oshima 1986) would not be economically viable. Therefore, our efforts 
must focus on the early detection and treatment of the cancer possibly by screening 
high risk groups such as in ‘dyspepsia’ clinics (Allum 1986). The establishment of better 
methods of outcome prediction and new treatment programmes are also essential.
In order to focus on the difficulties in establishing a diagnosis and management strategy 
at an early stage, I have brought together a review of the literature and a series of 
original observations on the pattern of presentation and treatment in gastric cancer over 
twenty years in a Glasgow hospital. The catchment area of the hospital is in a 
significantly deprived area of the city which is an important factor in the analysis of 
outcomes in the survey. The general health of the population is poor with significant
6
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cardio-respiratory disease and poor nutrition. Health education is less effective, with 
disease presenting at an advanced stage. There are high levels of smoking, drug and 
alcohol abuse and each of these factors contributes to the poor outcomes which are 
described. I will describe the demographics of the population, the clinical symptomology, 
treatment, prognostic factors and outcome. Together with findings from a number of 
other studies I will highlight the difficulties in the management of gastric cancer in the 
east end of Glasgow and the need to establish new methods of intervention.
7
Chapter 2
Chapter 2 
Changing trends in gastric cancer in the West of Scotland 
Results of an audit over twenty years
During the two periods of 1974-1984 and 1986-1994, audits of the treatment and 
outcome of gastric adenocarcinoma in one Glasgow teaching hospital have been 
undertaken. The purpose was to outline areas of potential improvement in treatment 
(Cunningham 1987) and observe trends within factors which may aid prediction of 
outcome. During the time periods outlined, 328 and 369 patients respectively were 
diagnosed as having histologically confirmed gastric adenocarcinoma in Glasgow Royal 
Infirmary. The data was gathered from case notes and pathology reports using similar 
data collection forms in both groups. The information was processed in the Cancer 
Surveillance Unit which was also the source of the patient list of reported cases of 
gastric cancer in the hospital. The earlier period of data was reviewed, analysed 
separately and then analysed in conjunction with the later set. The later data set was 
reported for the first time.
The first series of data from 1974-1984 was collected by a Research Fellow in the 
Department of Surgery at Glasgow Royal Infirmary in the last two years of that period 
with the project supervised by Professor C. McArdle in both periods of study. Data 
collection forms were developed and of the 330 patients identified from the Cancer 
Register, 328 had sufficient clinical data to be included in the analysis.
In the later set, the Cancer Surveillance Unit identified 406 patients with gastric cancer 
during the time period. However, 37 patients (9%) were excluded because there was no 
histological diagnosis of gastric cancer. Clinical data for the remainder of the patients 
was included. There is obviously a potential for bias when a group of patients are 
excluded from an analysis and using the criteria in this study, the bias would apply to 
both time periods. Within the group excluded there are certain to be patients who were 
suffering from gastric cancer and obviously no histological type could be determined.
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Diagnosis from clinical examination or barium studies with no surgery performed; rapid 
deterioration and death making endoscopy inappropriate or patient frailty would mean 
exclusion from this study. However, there are those patients who present with weight 
loss, coffee-ground vomiting or an abdominal mass who deteriorate prior to 
investigation and are labelled as a potential gastric cancer without documented 
evidence. The diagnosis of gastric cancer in these cases is by no means certain and 
inclusion would be inappropriate. Using the same criteria in both time periods allows 
comparison in these groups. Bias from potentially excluding elderly and advanced 
disease is recognised but the analysis of those patients having potentially curative 
surgery would remain focused.
Ensuring the quality of data collected in the earlier series is more difficult than in the 
later series where the case-note survey was completed by myself. The sets of data 
were held by the Cancer Surveillance Unit for both time frames and had been analysed 
in co-operation with Professor D. Hole, Professor of Epidemiology at Glasgow 
University.
Demographics 
Section i: Age distribution of patients
There appears to be little difference between the proportion of patients in each age 
group (Table 1) and the peak age group between 65 and 74 reflects that of other 
centres in the UK and Europe (Lindahl 1988, Irvin 1988, Athlin 1995). The diagnosis 
continues to be uncommon under 55 years and a higher proportion of male patients 
cresent under the age of 75. Between 1974 and 1984, 84% of males and 72% of 
:emales were under 75 years and between 1986 and 1994 the same difference 
*emained.
in the latter time period, females predominate over the age of 75 and this reflects, in 
Dart their improved life expectancy and the increased risk of cancer with age (Figures 1 
and 2).
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The age distribution of patients is summarised in Table 1 and
Table 1
Figures 1 & 2
Age group 1974-1984 1986-1994
<55 52(16% ) 34 (9%)
55-64 83 (25%) 107 (29%)
65-74 125 (38%) 128 (35%)
75+ 68 (21%) 100 (27%)
Figure 1 Age of patients 1974-1984
Number of patients 40'
— i------m—,— ---- 1-m — y— — ■- —■= -]— — — — — •*—
<45 45-54 55-64 65-74 >75
Age of patients
□  Male
□  Female
Figure 2 Age of patients 1986 -1994
Number of patients
90
80-I
70
60
50-
40-
30-
20 -
10-
<45 45-54 55-64 65-74
Age of patients
>75
□  Male 
B Female
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Section ii: Distribution of patients by sex
The male to female ratio has changed from 1.45:1 to 1.6:1 (Table 2) and is at the lower 
end of the ratio of 1.5-2.5:1 found in most European and North American centres (Cady 
1989, Viste 1986).
Table 2 Distribution of patients by sex
Sex 1974-1984 1986-1994
Male 194 (59%) 227(61.5%)
Female 134(41% ) 142(38.5%)
Symptomology
Section iii: Presenting symptoms and duration of onset
Little change was recorded in the relative frequency of presenting symptoms from the 
patients over the two decades (Table 3). There has been no defining symptom to 
emerge to separate the process of underlying gastric malignancy from benign disease.
Table 3 Presenting symptoms
1974-1984 1986-1994
Anorexia / weight loss 272 (83%) 226 (61%)
Dysphagia / vomiting 210 (64%) 190 (51%)
Dyspepsia / Abdominal pain 211 (64%) 205 (56%)
Anaemia 92 (28%) 60 (16%)
Emergency bleeding / 55(17% ) 54 (15%)
perforation
This difficulty in distinguishing benign and malignant disease symptomatically, until the 
cancer is advanced has, in high risk countries, led to population screening. One such
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approach involves the use of barium studies with photofluorographic imaging to 
examine the population over 40 years with suspicious cases having endoscopy. In 
Japan, this amounted to screening 5.2 million people annually in 1985 and has resulted 
in the proportion of early gastric tumours increasing. The detection of increasing 
numbers of gastric cancer in the early stages appears to improve survival in the disease 
(Yamazaki 1989). However, the lower incidence of the disease in Scotland would not 
make this an economically viable option and in addition, formal evaluation of screening 
for gastric cancer with randomised trials has not, and is now unlikely to be performed. 
The accelerated decline in mortality with respect to incidence which is attributed to 
screening in gastric cancer must take account of figures which show that the population 
invited for annual screening has never reached the target of 30%. In addition the effect 
of lead time bias and detection of pre-malignant lesions must be further investigated 
(Pisani 1996).
Dyspepsia clinics and programmes to improve the early detection of gastric cancer 
(Allum 1986) have had some success. Co-operation between GP practices and 
specialised units for early referral of symptomatic patients in this initiative with good 
compliance in attendance for endoscopy achieved an increase in the percentage of 
early lesions. Unfortunately, the non-specific nature of symptoms (Meyers 1987) implies 
that substantial resources would be required and this option is probably only achievable 
in central specialist centres (Humphreys 1995).
There are a number of issues which must be addressed when one examines the 
duration of patient symptoms prior to presentation (Table 4). The health education of 
the population must improve to alert patients with dyspepsia to the potentially sinister 
nature of their symptoms in particular when there are more than 20% of patients 
presenting after more than 6 months. Interestingly, although we continually strive for 
early detection to ensure more successful surgery and longer survival, those patients in 
our study who presented with symptoms of more than 6 months duration had a longer 
five year survival (Table 5). This was a consistent finding in both decades studied and 
on multivariate analysis of both sets of patients there was no relationship with clinico-
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pathological factors used commonly to predict outcome such as tumour differentiation, 
serosal, nodal or resection margin involvement or with age, sex or tumour site. When 
we examined all the resected cancers over both decades (Tables 8 and 9) those 
patients who presented with symptoms for longer than 6 months had significantly better 
survival (p=0.001). Many groups have suggested a prolonged period of symptoms prior 
to presentation leads to poorer prognosis (Brookes 1965, Barber 1961) but as many 
have agreed with our findings and suggested a population of slower growing tumours 
for some as yet unknown reason (Fujita 1978). Consistently, younger patients with 
longstanding symptoms have a poorer outcome in published series (Tso 1987, Siewert 
1995).
Table 4 Duration of symptoms
1974-1984 1988-1994
< 3  months 122(38.9%) 212(57% )
3 - 6  months 117(37.3%) 77(21% )
> 6 months 75 (23.9%) 80 (22%)
missing 14
Table 5 Relationship between patient survival and duration of symptoms
Duration of symptoms
No. of patients (%)
% survival 
2 5
<3 MONTHS 212 (57) 19 6
3-6 MONTHS 77 (21) 13 2
>6 MONTHS 80 (22) 36 24
Section iv: Location of tumour
With the decline in the incidence of gastric cancer worldwide there has been a proximal 
shift of disease although antral tumours remain the most common (Hansson 
1993,Antonioli 1982, Bizer 1983, Harrison 1995). This change is less pronounced in
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Japan (Kampschoer 1989). Between the two periods of time of this study there has 
been an increase in both the antral and proximal tumours, with a corresponding 
decrease in the unspecified tumours but overall little difference in the relative 
percentages of each site (Figures 3 and 4). Although the number of antral tumours in 
both series is in agreement with other hospital and population based series, the 
proportion of proximal tumours was initially higher than other series (Lauren 9.3%, 
Allum 5.6%) and the subsequent increase in proximal tumours was less. (Paterson 18% 
to 39%; Kampschoer 17% to 27%,Meyers 21% to 44%,Husemann 6.6% to 37.5%).
Figure 3 Location of tumour 1974-1984
□  1974-1984 (total)
■  1974-1984 (curative)
Nu mber of patients 60
cardia body antrum unspecified
Location of tumour
Figure 4 Location of tumour 1986-1994
160
140 □  1986-1994 (total)
■  1986-1994 (curative)120
100
Number of patients 80
40-
20 -
unspecifiedcardia body antrum
Location of tumour
Figures 3 and 4 show that the proportion of tumours in each location of tumours is similar in each 
time period but there are fewer proximal tumours in the curative resection group in the last decade.
14
Chapter 2
There may be several reasons to explain these changes. The initial high incidence of 
cardia tumours may be due to mis-classification of lower oesophageal 
adenocarcinomas to the stomach. We have cross-checked the patients in our survey to 
oesophageal adenocarcinomas on the Cancer Register and found no correlating 
patients. However, this register relies on the initial assessment of site by the 
investigating surgeon and in the earlier series there may have been a tendency to 
assume lower oesophageal adenocarcinomas tumours were oesophageal extensions of 
cardia tumours. Within the time periods outlined the incidence of adenocarcinomas as a 
proportion of total tumours of the oesophagus in this centre has increased from 27% to 
37% (Hole 1997). This would suggest that the incidence of proximal gastric 
adenocarcinomas although initially higher than expected when compared to other 
studies, may be accurate. The dramatic increase in the incidence of gastric and 
oesophageal adenocarcinomas over the last twenty years in many series (McKinney 
1993, Meyers 1987, Powell 1990, Lund 1989, Blot 1991) may have occurred at an 
earlier time in our population and an explanation for the higher initial figure may be that 
the increase in incidence pre-dated our study. A common aetiology may be involved in 
these increases of tumour in both sites. In Sweden where there has been a definite 
coding for cardia tumours since 1970 (Hansson 1993) there has been a steady rise in 
the incidence of cardia tumours with a male preponderance. In the West Midlands and 
Birmingham study (Allum 1986) the percentage of patients with cardia tumours was 
5.6% .The criteria for inclusion in the study of cardia tumours was such that any tumour 
extending beyond the cardia itself was excluded. If we reclassify our series we have 
18% of tumours in this confined group. Other studies have included resected but not all 
biopsy proven tumours (Paterson 1991) and may reflect changes in resection.
We examined all resected cases over twenty years and found that 24% curative 
resections were of proximal tumours and that 24% of all tumours resected were 
proximal in site (Table 8). As a hospital based survey with a specialist upper 
gastrointestinal unit, the tertiary referral pattern may also influence the relative numbers
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of tumours at each site. There remains, however, a need for acknowledged definitions 
of proximal tumours as highlighted in German studies (Siewert 1995).
Survival and location of tumour
Figure 5 Survival in curative resections 1974-1984
cardia
body
antrum
100 n
80 --
60 --
40 -■
20 - -
20 1 3 4 5
years
Figure 6 Survival in curative resections 1986-1994
100 
90 
80 
70 
60
% survival 50 
40 
30 
20 
10 
0
0 1 2 3 4 5
years
Long term survival related to the site of the tumour (Figures 5 and 6) in the 1974-1984 
group showed that the poorer outcome was associated with tumours of the cardia. Five 
year survival was 13% compared to 28% and 27% for body and antral tumours 
respectively (p<0.05). This is not the case in the later set where only 11% of the 
curative resections were of cardia tumours as opposed to 30% in the earlier series and 
the five year survival was 45%. However, in this cohort of patients there were only six 
patients with cardia tumours who underwent curative resection. When we examine 
survival (Tables 8 and 9) of the resected cardia tumours over the twenty year period,
cardia
antrum
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the five year survival appears lower at 8% (p=0.11) compared to 17% and 21% for the 
body and antrum (p=0.96) although the differences are not significantly different.
Section v: Surgical procedures
In the period from 1974-1984, 15.5% of patients had no surgical treatment increasing to 
39% in the later group. The total resection rate reduced from 49% to 46%; curative 
resections from 39% to 14.6% and palliative resections increased from 9.8% to 
31.2%.With the introduction of a YAG laser to the department in 1986 there appears to 
have a decline in intubation procedures in consequence. The types of procedures are in 
Table 6, Figures 7 and 8
Figure 7 Surgical procedures 1974-1984
laparotomy
18%
no surgery 
16%
intub:
8° /
curative
10% palliative 
10%
resection
38%
Figure 8 Surgical procedures 1986-1994
no surgery
laser
16%
intubation 1%
palliative
curative
resection
15%
6% resection
31%
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Table 6 Surgical Procedures and Findings
Primary treatment 1974-1984 1986-1994
Curative resection 
Palliative resection
128 (39%) 
32 (9.8%)
54 (14.6%) 
115(31.2%)
Bypass 
Intubation 
Laparotomy only 
Laser 
No surgery
Regional chemotherapy
33(10.1% ) 
26 (7.9%) 
58(17.7% )
51 (15.5%)
23 (6%) 
4(1% )
28 (7%)
59 (16%) 
84 (22.8%) 
2 (0.5%)
Resection 
No resection
161 (49.1%) 
167 (50.9%)
169 (45.8%) 
200 (54.2%)
Site
Fundus / cardia
Body
Antrum
80 (26%) 
108 (35.1%) 
120 (39%)
100 (27%) 
117(32% ) 
150 (41%)
Direct Invasion (resected cases only)
Serosa
Colon
Pancreas
Liver
67(47.2%)
10(6.6%)
30(19.6%)
4(2.6%)
7(4.2%)
15(18.8%)
2(1.2%)
Liver secondaries 11 (7%) 11 (6.5%)
Histological findings (resected cases only)
Serosa involved 111 (76%) 
Resection margins +ve 38 (25.7%) 
Lymph node +ve 72 (64.3%) 
Mean number of nodes sampled 3
127 (77.9%) 
36(22.1% ) 
99 (63.1%) 
7
30 day mortality
Resected cases 18(11.2%) 17(10% )
Curative resections
1974-84
1974-79
1980-84
12.9%
17.6%
8.4%
1986-94
1986-90
1991-94
7.4%
11.4%
0%
The direct invasion data has not been analysed formally. Although it may have given some reasoning to labelling 
a resection as palliative rather than curative, the availability of this information in the later series was inconsistent. 
In addition, misinterpretation of, for example, invasion of pancreas rather than adherence could not be 
represented reliably using this information.
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Section vi: Survival in the treatment groups
As one would expect, changes in the relative numbers of patients undergoing palliative 
procedures did not result in any significant improvement in length of survival (Figure 9 
and Table 1, Appendix A). In contrast there has been an apparently significant increase 
in the survival of patients undergoing curative resections. The 5 year survival increased 
from 22% to 41% (p=0.079) and for palliative resection there was a small improvement 
(0 to 8%). On closer examination of the data it is apparent that there has been a shift in 
the numbers in each group due to a stricter definition of a potentially curative resection. 
This not only raises survival of the ‘curative’ group but by adding to the palliative group 
those patients who are borderline palliative also raises the survival in that cohort. This 
theory is reflected in the analysis of the total number of resected patients which remains 
unchanged over time. The resected patients had a five year survival of 18% and 16% 
with a median survival of 14 and 15 months in the time periods 1974-84 and 1986-94 
respectively.
Figure 9 The changes in survival between the two decades as determined 
by operative procedure
curative 1974-1984 
curative 1986-1994 
palliative 1974-1984 
palliative 1986-1994
0 1 2 3 4 5
Survival (years)
The operative procedures displayed are curative and palliative resections as determined by the surgeon.
Number of patients 
(%)
100
80 --
60 --
40 --
20 - -
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Section vii: Histopathological factors and survival
In the later group, 41% of patients undergoing potentially curative resection survived 
five years from diagnosis. The apparent improvement in 5 year survival from 22% in the 
1974-1984 group probably reflects a change in the criteria, from the surgeon’s 
perspective, for curative resection, rather than a reduction in the biological 
aggressiveness of the cancer. These criteria and the clinical assessment of gastric 
cancer may vary between surgeons. However, improved pre-operative staging with 
conventional and spiral CT scanning, laparoscopy with peritoneal washings and 
laparoscopic ultrasound have more accurately identified the stage of disease. When a 
surgeon describes the surgical procedure as curative or palliative he is using a 
combination of clinical skills, operative experience and the results of advanced 
investigations. This is one aspect of the stage migration phenomenon which allows us 
to place a patients tumour in a stage group with more accuracy. Subsequently the 
survival of patients stage for stage reflects this contribution of additional, valuable 
information.
Therefore, I examined the effect on survival of tumour differentiation, involvement of 
resection margins, serosa and lymph nodes in the curative resection group during both 
time periods.
There was a tendency to a better outcome in those patients with well differentiated 
tumours who had curative resections, but this was not statistically significant. There was 
no difference in the proportion of patients with each type of tumour in the group of 
patients having a curative resection or the total number of patients in time period.
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Figure 10 Survival of patients in curative resection group as expressed 
by serosal involvement
Number of patients
(%)
100
0 1 2 3 54
-Serosa +ve 1974-1984 
Serosa +ve 1986-1994 
Serosa-ve 1974-1984 
Serosa -ve 1986-1994
Survival (years)
Figure 11 Survival of patients in curative resection group as expressed 
by nodal involvement
Node+ve 1974-1984 
Node +ve 1986-1994 
Node -ve 1974-1984 
Node -ve 1986-1994
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In both sets of patients, those with resection margin involvement relapsed and died 
(Table 2,Appendix A). Although serosal and lymph node involvement can never be 
considered in isolation the contribution of each to prognosis has been sought. Serosal 
involvement remained the most important predictor of survival (Figure 10). The patients 
with serosal involvement had significantly poorer survival (p<0.005). The involvement of 
lymph nodes associated with serosal involvement further reduced survival as observed 
in the first series of patients. Lymph node status itself showed a different trend (Figure 
11). For the earlier patients it was only important when serosa was not involved but in
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the later group lymph node involvement alone had no effect on survival, although the 
number of patients with no lymph node involvement was very small.
In order to overcome some of the difficulties of small numbers we analysed these 
factors in the group of resected tumours (Table 7). An analysis of the factors in 
combination showed that the involvement of either serosa or nodes influenced survival 
to a similar degree. On multivariate analysis, lymph node involvement was significant 
when over 50% of the nodes examined were involved by tumour. Serosal involvement 
and resection margin disease were also statistically significant factors on multivariate 
analysis (Table 9).
Table 7 Survival of resected cases by degree of involvement
(based on 331 resections over the period 1974 -1994)
Extent of involvement Number 
of cases
% surviving
2 years 5 years (median 
survival)
>60m
Lymph serosa resection
node margin
neg neg neg 37 78 58
neg pos neg 48 54 20
pos neg neg 21 52 21
neg neg pos 0
pos pos neg 100 34 8
neg pos pos 12 17 0
pos neg pos 2 0 0
pos pos pos 37 5 0
29m
32m
15m
4m
7m
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Table 8 Survival of resected cases by other factors
(based on 331 resections over the period 1974 -1994
Factor
Site
Cardia
Body
Antrum
Number 
of cases
78
121
129
% surviving
2 years
26
37
45
5 years
8
17
21
Differentiation
Well 30
Moderate 95
Poor 178
Not known 28
43
46
34
29
30
24
11
14
Duration of main symptom
< 3  months 152
3 - 6  months 
> 6 months
87
79
34
30
56
12
9
37
Age group
<55
5 5 -6 4
65 -74
>75
59
92
121
59
44
38
39 
31
20
20
17
8
Sex
Male
Female
201
130
All resected patients
331
Serosa
Negative
Positive
71
238
Resection margin
Negative 237
Positive 74
35
42
38
69
30
49
7
16
19
17
49
8
22
0
Lymph nodes
Negative 98
<50% 48
>50% 117
59
44
21
33
11
5
23
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Table 9 Multivariate analysis of survival time for resected patients
Factor Number RHR 95%c.i. p value
of cases
Serosa
-ve 71 1
+ve 238 2.56 (1.79-3.65)
Resection margins
-ve 237 1
+ve 74 2.24 (1.675-3.03)
Nodal status
-ve 98 1
1-50%+ve 48 1.22 (1.75-3.39)
51-100%+ve 79 1.99 (1.54-3.17)
Duration of symptoms
< 3 months 152 2.44 (1.75-3.39)
3 - 6  months 87 2.21 (1.54-3.17)
< 6 months 79 1
Site of tumour
Cardia 78 1.29 (0.94-1.78)
Body 129 1
Antrum 129 1.01 (0.76-1.33)
0.001
0.001
0.33
0.001
0.001
0.001
0.11
0.96
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Discussion
This study examined the changes in the treatment of gastric cancer and the resultant 
improvement in the survival of patients in one centre over a twenty year period. The 
initial results indicated that far from improving the outcome in patients with gastric 
cancer the five year survival had apparently reduced, from 11% in the first ten years to 
6% in the second decade (p=0.013).
Section i: Changes in surgical approach to gastric cancer
The total resection rates of gastric tumours in published series shows considerable 
variation from 29.3% to 75.9% (Lindahl 1988, Irvin 1988, Allum 1989, Cady 1989, Gall 
1985).The total resection rate in this series is around 50% but contrary to the increase 
in resection rate observed in many hospital based series in Europe and the USA, the 
rate in this study is lower in the most recent decade .There is a more marked difference 
in the number of resections considered to be curative. Although some centres suggest 
as Cady (1989) that the rate of curative resection has remained constant at 34% which 
is consistent with our observations from 1974-1984, the majority of centres have seen 
an increase in curative resections to between 45% and 60% (Meyers 1987, Haugstvedt 
1993, Stipa 1994, Boku 1990). This was not reflected in our later series in which we 
found a substantial decrease. A possible explanation for this may be the catchment 
area of the hospital. This series of patients represents a population rather than simply a 
hospital based study despite a degree of tertiary referral status. The area is significantly 
deprived with co-morbid disease amongst the highest in the U.K.
With a change in the proportion undergoing curative resection there was a 
corresponding increase from 9.8% to 31.2% of patients having a palliative resection 
which is significantly higher than other comparative series (Lindahl 1988,Allum 1989, 
Cady 1989, Gall 1985). Palliative resection is known to give an improved survival over
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intubation in advanced disease (Cunningham 1987, Allum 1989) and this may have 
prompted a change in the surgical policy towards palliative resection. More likely it is 
the changing perception amongst the surgeons that resections previously described as 
curative are now in reality palliative based on experience and sophisticated 
investigations. This leads to difficulties when comparing groups in older published 
reports of curative resections. If we were to define this group in terms of the Japanese 
histological criteria (Japanese Research Society 1981) it is only possible to show 
'relative' curative resections. These are patients with no serosal involvement but we 
cannot comment on the whether there is adequate lymph node clearance as a D2 
lymphadenectomy was not routinely performed in many of the earlier patients. On this 
basis 42% of the total number of curative resections and only 6% of all patients are in 
this category (which coincidentally corresponds to the five year survival of the curative 
resection and total patient groups).
The laparotomy rate in our study has also fallen from 85% to 60% when other studies 
report rates around 80% to 90% (Lindahl 1988, Irvin 1988, Lund 1989, Gall 1985) and 
the proportion of patients who underwent an exploratory laparotomy has almost halved. 
Again this reflects improved staging by CT scanning and diagnostic laparoscopy (Ajani 
1995, Stell 1996) particularly in proximal tumours where diagnostic laparotomy rates are 
only 9%. The introduction of laser therapy has had a considerable impact on the 
management of proximal tumours with good palliation and a median survival of 3.6 
months compared to 2 months and 0.8 months for intubation in both series.
Section ii: Variation in survival and operative mortality
The overall five year survival has decreased from 11% in the 1974-1984 group to 6% in 
the 1986-1994 group despite an increase in the five year survival in the curative 
resection group from 24% to 41%. Between 1970 and 1990 the five year survival for 
curative resection in the Japanese experience was around 60% and in non-Japanese
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centres 40% (Akoh 1992). In a selected group from the late 1980s the curative resection 
five year survival varies between 45% to 55% (Cady 1989, Stipa 1994) and overall 
survival shows a wide range from 4.5% to 30% in Europe and the USA (Lindahl 1988, 
Irvin 1988, Allum 1989, Cady 1989, Gall 1985, Roder 1993, Akoh 1992). Over twenty 
years the resections which are considered curative histopathologically in as much as 
there is no serosal, lymph node or resection margin involvement have a five year 
survival of 58%.
The 30 day mortality in resected cases was stable at 11.2% and 10% (Table 6). In 
curative resections there has been a decrease of 5% and in the last five years the 30 
day mortality was 0%. In the palliative group the rate was unchanged (9% to 11%). This 
contributes to the improved survival in the curative resection group of patients and also 
to the more significant decrease in mortality from gastric cancer with respect to the 
decrease in incidence. There was considerable variation in the operative mortality with 
site (Figure 12 and Table 3, Appendix A). Cardia tumours have almost twice the 
operative mortality of body and antral tumours for both curative and palliative 
resections
Figure 12 30 day mortality of patients undergoing curative resection
expressed according to the location of tumour
30 Day Mortality
□  1974-1984
□  1986-1994
cardia body antrum
Location of tumour
total
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Section iii: The influence of histopathological factors
The influence of factors known to effect prognosis have been examined to establish an 
explanation for the changes in the survival after resection. The poorer prognosis related 
to the involvement of resection margins (British Stomach Cancer Group 1984) and 
poorly differentiated tumours (Yu 1995) is consistent with other studies but the influence 
of lymph node involvement requires further comment (Pacelli 1993). The majority of 
Japanese centres consider the involvement of the loco-regional nodes to be the most 
important prognostic factor in curative resections and the surgical clearance of these 
nodes is the aim of the standard practice of extended lymphadenectomy (Roder 1995, 
Tsuchiya 1995). However, in Europe the majority of patients present at a more 
advanced stage, 70-80% at stage 3 and 4 (Fielding 1984), and the involvement of 
serosa seems to be more important (Athlin 1995, Bozzetti 1986, Yu 1995). One must 
also consider the influence on survival of the Japanese methods of pathological 
reporting, in particular, the detailed sampling of nodes for micro-metastases and the 
correction this makes to staging of the disease.
In the earlier series of patients serosal involvement was a significant factor in survival 
(p=0.004) and lymph node involvement was only of importance when there was no 
serosal involvement. The number of patients in the curative resection group is limited in 
the later series but confirms that serosal involvement has an over-riding effect on 
survival. In multivariate analysis of all resected cases, serosal involvement significantly 
reduces prognosis (p=0.001).
In resected cases there is a significant effect on survival when more than 50% of 
resected nodes are involved by tumour (p=0.001). The value of information on nodal 
status in our practice may be important but the proportion of nodal involvement is 
dependent on the extent of lymph node resection. The eventual relationship between 
nodal involvement and prognosis may be the same when a radical lymph node 
resection is performed.
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A number of trials in the U.K. and Europe have attempted to determine the benefit to 
prediction and actual survival of extended lymphadenectomy. Initial results suggested 
an increase in morbidity and mortality which may be related to adjusting to new surgical 
techniques, patient selection and the need to modify the practice of splenectomy and 
distal pancreatectomy (Roder 1995, Lee 1995, Cuschieri 1996, Bonenkamp 1995, Sue- 
Ling 1995). The conclusion from Bonenkamp et al (1999) suggests that there is no 
survival advantage in Dutch patients undergoing extended lymphadenectomy and the 
MRC trial tended to concur. Siewert, however, in selected groups showed improved 
survival in particular Stages 2 and 3a.
The influence on survival of tumour site reveals that proximal tumours have a poorer 
prognosis with five year survival in both decades of 5%. The resection rate (33%) is 
less than at other sites with only 6% considered curative and although the five year 
survival in this group is 45% in the total resection group it is only 2.7%.
Section iv: Summary of findings
Despite the initial impression that there has been no improvement in the treatment of 
gastric cancer over the last twenty years, it would seem that there have been some 
small advances. Those patients undergoing curative resection are more likely to survive 
the initial post-operative period and in the long term. Palliative resection is more 
effective in prolonging life although we cannot comment on quality of life. Fewer 
patients undergo unnecessary operations and this is particularly important in an ageing 
patient population. However, the majority of patients continue to present with advanced 
disease and only early detection of disease would seem to improve overall outcome.
The need for more radical surgery and the development of specialist centres are still a 
matter of great debate. The apparently changing nature of the disease with proximal 
tumours showing similarities with the increasing oesophageal adenocarcinoma
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population and antral tumours in decline may reflect the results of treatment of 
Helicobacter pylori, dietary, socio-economic or cultural changes. The surgical workload 
from gastric cancer is not changing (Sedgwick 1991) and conventional therapy is 
producing minimal improvement in prognosis. We must concentrate expertise and 
resources to detect and treat tumours at an early stage, provide markers for high risk 
groups, implicate those tumours with poor prognosis and advance novel therapies for 
the disease.
This retrospective study of gastric cancer patients from one district in Glasgow has 
served to illustrate the difficulties in treating gastric cancer. An ageing, deprived 
population which presents late and often with advanced disease would benefit from 
early intervention and innovative surgery. However, the principle aim of this thesis is to 
bring together the study of gastric cancer at a molecular level to discover alternative 
therapies for the disease. In particular, if the recent development of monoclonal 
antibodies to c-erbB-2 for the treatment of advanced breast cancer can be considered 
for use in gastric cancer there is a need for reliable methods of c-erbB-2 detection.
With this in mind, I have aimed in the forthcoming chapters to outline the role of c-erbB- 
2 in carcinogenesis; describe its role, if any, in predicting prognosis in gastric cancer 
and highlight the importance of reliable measures of receptor expression. I have 
similarly examinated EGFr and will proceed to study the level of expression of these 
growth factors in gastric cancer specimens, comparing methods and expression of each 
factor.
In addition, I have sought to examine whether the high level of IGFr in foetal gastric 
mucosa has bearing on the behaviour of gastric cancer. Using proliferation studies I 
have detailed preliminary work which may determine whether the inhibition of IGFr is a 
worthwhile target to develop further in gastric cancer.
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TYPE I GROWTH FACTORS IN 
GASTRIC CANCER
Background information and historical review
Chapter 4
Chapter 4
The role of growth factors and their receptors in
carcinogenesis
Section i: Introduction
In the progression from normal epithelial cells to invasive cancer, it has been suggested 
that gastric cancer follows a series of well-defined histological steps particularly in the 
intestinal type of tumour. The natural history of the disease and in particular the diffuse 
type of gastric tumour is not entirely clear (Correa 1991). The advances in molecular 
biology in recent times have allowed identification of many of the molecular changes 
involved in tumour initiation and progression (Tahara 1995). Tumour formation occurs 
when there is an imbalance within the normal physiological processes of cellular 
proliferation and cell death (Harrington 1994). Gastric cancer displays multiple gene 
alterations including oncogenes, growth factors or cytokines, cell cycle regulators, 
tumour suppresser genes, cell adhesion molecules and genetic instability (Figure 13).
In the preceding chapters where I have described the population from which the 
specimens of gastric cancer have been obtained, there is a high presentation of 
advanced cancer with poor outcome. I was interested to determine whether higher 
expression of c-erbB-2 was implicated in advanced and metastatic disease which the 
genetic pathway suggests.
In the development of malignant cells, the alteration of the expression of normal cellular 
genes by mutation, translocation, amplification or other mechanisms may contribute, in 
particular in those genes involved in cellular differentiation and proliferation. Among the 
molecular changes implicated in the aetiology of carcinogenesis are those mediated by 
growth factors (Stemmerman 1994). These are small polypeptides which are involved in 
the regulation of cellular proliferation (Carpenter 1979) and regulate cellular 
proliferation by acting on specific target tissues. Their receptors are found on the
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plasma membrane of cells and the expression of receptors found in each cell varies 
among between tissues (Gullick 1991). Binding of the growth factor transmits the signal 
within the cell to modify the metabolic activity and stimulate the cell cycle (Kazlaukas 
1994).
Figure 13 The genetic pathways in the development of gastric cancer as 
proposed for different histological types
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c-met 6kb expression
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Genetic mutation within the cells results in alteration of protein products and this can 
occur at any stage in the signal transduction pathway from receptor to nuclear proteins. 
Receptors and intracellular proteins altered in this way are capable of transforming 
normal cells and promoting the proliferation of malignant cells (Tahara 1995).
The genes encoding the growth factors, the growth factor receptors and many of the 
elements in cellular signalling have been identified. When mutation in one of these 
genes with stimulatory function occurs it results in an alteration in activity. This is a 
dominant effect and only one copy of the gene need undergo mutation. This is called an 
oncogene. The normal allele is called a proto-oncogene. Inactivation of an inhibitory 
gene to cause increased activity and the possibility of uncontrolled cellular proliferation 
is a recessive effect and the gene is termed a tumour suppresser gene. Many of the 
proteins involved in cellular signalling have been identified as proto-oncogenes and 
produce stimulatory or inhibitory changes in cellular activity.
Oncogenes were identified in the early part of the twentieth century when it was found 
that sarcoma could be transmitted between chickens and the causative agent was found 
to be an RNA virus. Subsequently investigators found that sequences homologous to 
the oncogene region of the virus were present in the DNA of all tissues of virus -free 
chickens and the concept of the proto-oncogene was developed. The viral oncogene v- 
erb-B is homologous to the gene encoding EGFr in humans (c-erbB-1).
In comparing the proto-oncogene which has been identified for EGFr and the receptor 
protein product of the oncogene there are both intra and extracellular regions which are 
missing. The activity of EGFr is altered in several ways. On binding of EGF the normal 
receptor internalises the growth factor/receptor complex to regulate receptor numbers 
and prevent overstimulation. This process does not occur in the altered gene state. The 
binding of EGF is required for receptor activation in unaltered receptors but the
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oncogenic EGFr would seem to be constantly stimulated due to the lack of much of the 
extracellular regulatory domain (Hunter 1985).
Section ii: Structure and function of growth factors
The growth factor receptors are transmembrane proteins with an extracellular domain 
containing the NH2 terminus which binds the growth factor and is called the 'ligand' 
binding domain. There is a transmembrane alpha helical domain which spans the lipid 
bilayer and the intracellular area where the events leading to signal transduction take 
place. This is the “catalytic” domain and contains the COOH terminus (Ullrich 1990).
On binding of the growth factor, the receptor undergoes a conformational change which 
activates the intracellular catalytic domain of the receptor (Ullrich 1984). This leads to 
the activation of a series of cytosolic enzymes called protein kinases which catalyse the 
transfer of the terminal phosphate group of ATP to serine, threonine or tyrosine 
residues on specific intracellular proteins initiating a complex cascade of intracellular 
events. The protein kinases are an interacting group. Tyrosine kinases are found on the 
catalytic domain of the transmembrane receptors and their kinase activity produces 
phosphorylation on the tyrosine residues of intracellular proteins (Cantley 1991). The 
others phosphorylate serine or threonine residues and are cAMP-dependent protein 
kinase, the diacylglycerol-dependent cGMP-dependent protein kinase, protein kinase C 
and Calcium-calmodulin dependent protein kinase.
The growth factors are classified for convenience into major groups determined by the 
initial type of phosphorylation . Thereafter the sub-groups are determined by grouping 
factors with similar extra and intracellular domain sequences (Fantl 1993). Within the 
tyrosine kinase group of growth factor receptors of which this work is particularly 
concerned, the Type I group includes epidermal growth factor receptor and a group of
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similar proteins c-erbB-2,c-erbB-3 and c-erbB-4. The Type II receptors include insulin­
like growth factor receptor I and the insulin receptor.
In Type I receptors, ligand binds to the extracellular regulatory domain and activates the 
catalytic domain by effecting a conformational change in the receptor. In receptors 
such as EGFr, receptor pairing is promoted by ligand binding and alignment of the 
receptors causes activation and the transfer of the terminal (gamma) phosphate group 
of adenosine triphosphate (ATP) to the hydroxyl group of tyrosine residues located on 
specific target proteins on the partner receptor and within the cell.
Tyrosine kinase receptors undergo auto-phosphorylation to enhance signal 
transduction and to regulate the concentration of receptor and ligand at the cell surface 
(Hunter 1984). This involves the transfer of a phosphate group from the receptor but 
rather than to another intracellular protein the phosphate group moves to another area 
on the receptor to enhance or regulate the function of the receptor. This process also 
initiates internalisation of the receptor to regulate the number of receptors present in a 
tissue type. The receptors are internalised into coated vesicles and degraded in the 
lysosomal compartment (Schlessinger 1988). Truncated receptor may be unable to 
internalise and cause increased transforming activity.
Type II receptors such as insulin-like growth factor I receptor appear to be covalently 
linked prior to ligand binding rather than requiring ligand binding to initiate the change 
but the tyrosine kinase activity thereafter follows a similar pattern (Keller 1993). 
Tyrosine phosphorylation initiates a phosphorylation cascade involving secondary 
messenger pathways the result of which is a change in genome transcription and cell 
division. The complex method of signalling allows amplification of the receptor signal 
and interactions with the intracellular events from other growth factor receptor signalling 
(Fantl 1993).
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Section iii: Receptor ligands
In the Type I growth factor receptor group we are principally concerned with the activity 
of EGFr and c-erbB-2, also called neu, the human epidermal growth factor 2 or simply 
HER2. More recently the group are described as the HER family. EGFr (HER1) 
interacts with soluble polypeptide growth factors which act as ligands. There are a 
number of cognate ligands to the EGF receptor including EGF, TGFa, heparin binding 
EGF, amphiregulin and cripto all of which share a common structure.
EGF is a 53 amino acid peptide which binds exclusively to the EGF receptor and does 
not directly interact with the other Type I tyrosine kinase receptors. There is evidence 
that EGF stimulates the growth of skin and corneal epithelial cells, cells of the 
gastrointestinal tract and inhibits gastric secretion. In epithelial tumour cells, EGF has 
been shown to enhance growth, in vitro, in skin, bladder, breast, gastrointestinal tract 
and gynaecological malignancies (Hamburger 1981).
In gastric cancer the overexpression of both EGFr and EGF in the same tumour 
specimen, produced pathological findings suggestive of more proliferative and invasive 
activity than in specimens with overexpression of only one or no overexpression 
(Sugiyama 1989, Yonemura 1992). This suggests an autocrine mechanism exists 
between EGFr and its ligands. This is also seen with combined over expression of 
TGFa and EGFr in advanced gastric cancer (Bennett 1989).
TGFa is a 50 amino acid peptide which exhibits 40% homology to the EGF molecule 
and also functions exclusively through the EGF receptor. An increase in the synthesis 
and secretion of TGFa occurs in a number of carcinoma cell lines including skin (Coffey 
1987), breast (Bates 1988) and gastric (Tahara 1990). Synchronous expression of 
TGFa and EGFr without gene amplification may indicate a transcriptional abnormality 
which would repress expression of mRNA for EGFr and TGFa (Kitadai 1993). The 
coexpression of high levels of TGFa and EGFr are also found in breast cancers (Lundy
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1991). Cripto expression is associated with gastric cancer and intestinal metaplasia and 
there is evidence of good correlation between tumour stage, prognosis and cripto 
expression (Kuniyasu 1994).
There is no cognate ligand for c-erbB-2. However, cell surface monomers form 
homodimers with the same receptor or heterodimers with other members of the HER 
family (Alroy 1997). C-erbB-2 can be stabilised and transactivated in heterodimers by 
ligand interacting with the partner in the heterodimer such as EGFr (Pinkas-Kramarski 
1998). This allows c-erbB-2 to participate in signal transduction in the absence of a 
cognate ligand. Heterodimers containing c-erbB-2 are highly potent and are the 
preferred heterodimerisation partner in the HER family (Graus-Porta 1997).
Section iv: Growth factor signal transduction
In the Type I receptor pathway, binding of the ligand leads to a complex series of 
interacting signalling pathways at the level of the cell membrane which precipitate 
nuclear signals activating transcription of genes (Figure 14). The ability of the cell to 
respond to different ligands, the interaction of ligands and heterodimerisation of 
receptors may influence signal transduction. In addition, positive and negative feedback 
within the complex cytoplasmic activity described below may explain the diversity of 
processes effected by growth factors which include cell growth, differentiation, migration 
and viability.
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Figure 14 The EGF receptor signal transduction pathway
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Binding of ligand to the type I receptor leads to receptor dimerisation and 
autophosphorylation. This creates a binding site for Grb2 which is an 'adaptor1, protein 
to connect a series of signalling proteins.
Grb2 binds through the SH2 (Src homology-2) domain which is a specific binding site 
for tyrosine phosphoproteins. Thereafter the SH3 domain binds SoS1 which acts as a 
Ras activator. Ras functions as a guanine nucleotide releasing protein and converts 
inactive RasGDP to the active GTP bound form by nuceotide exchange Activation of 
the G protein Ras has a number of interacting consequences including the activation of 
the kinase Raf1 leading to the activation of the mitogen activated protein kinase (MAP 
kinase) pathway and its subsequent activation of nuclear transcription factors 
(McCormick 1993, Egan 1993, Batzer 1993,Schlessinger 1994). Mutations in the Ras 
oncogenes disrupt the GTP-ase activity of the G-protein in affected cells which leads to 
abnormal stimulation and cellular proliferation (Gibbs 1984).
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In Type II receptors the 185 kilodalton cytoplasmic protein insulin receptor substrate I 
(IRS-I) acts as an intermediary signalling protein but continues to activate the src- 
homology 2 domains including those of Grb-2 and subsequently phosphatidyl inositol 3 
kinase (Siddle 1992). In studies using IRS I deficient mice the activation of the 
phosphadidyl inositol 3 kinase mechanism is effected by an alternative substrate to a 
lesser degree. It is slightly larger and immunologically distinct but not fully investigated 
as yet.
Another method of intracellular signalling involves the enzyme phosphatidyl inositol 3 
(PI3) kinase. Following tyrosine phosphorylation the 85 kilodalton sub-unit of PI3 kinase 
causes a conformtional change in the p110 sub-unit leading to increased 
phosphorylation of phosphotidyl inositol phosphate. This modifies cellular function by 
transcription factor induction or calcium release. The MAP kinase phosphorylation 
cascade is also activated by the cleavage of phosphatidyl inositol diphosphate by 
phospholipase C to produce inositol triphosphate and diacylglycerol which activates the 
protein kinase C proteins (Blenis 1993). These in turn phosphorylate RAF-1 in the MAP 
kinase pathway. G proteins such as Ras also act in both stimulatory and inhibitory ways 
by interaction with adenyl cyclase and phospholipase C (Kolch 1993).
The interaction between growth factors, oncogenes in tumour growth and the effect on 
signal transduction is under investigation in a wide variety of tumours in order to identify 
the mechanisms of tumour growth and induction. The role of the individual growth 
factor, its interactions and the use of this information for tumour markers, assessment 
and therapeutic intervention is important in the future of oncology.
In gastric cancer there is some knowledge of the expression of EGFr, c-erbB-2 and their 
relationship to prognostic factors. The role of insulin-like growth factors in malignancy 
is less reported, particularly in gastric cancer. In the next section of the thesis is a
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review of our current understanding of the expression of EGFr, c-erbB-2, insulin-like 
growth factor and its receptor in gastric cancer.
41
Chapter 5
Chapter 5
Epidermal growth factor receptor and gastric cancer
In studying the process of tumour formation, the role played by growth factors, growth 
factor receptors and abnormalities in their expression and function will be crucial. Much 
of the interest has attempted to correlate the clinical course of various cancers with the 
level of expression in order to develop prognostic indicators in malignancy. In gastric 
cancer, specifically, the analysis of growth factor biology may be of clinical value in 
assessing tumour aggressiveness, metastatic potential and pre-malignant conditions 
(Wright 1992).
There are a number of well recognised clinico-pathological factors associated with 
outcome in gastric cancer, including tumour differentiation, nodal involvement, serosal 
involvement and metastatic disease (Yu 1995). However, if there was a method of 
predicting the metastatic potential or aggressiveness of a tumour from a pre-operative 
biopsy specimen this would have advantages in staging and treatment plan. There may 
also be the potential to use the information on growth factor density and signal 
transduction to develop novel treatments for established gastric cancer (Tokunaga 
1994). Earlier studies looking at gastric cancer and potential relationships with growth 
factor receptors, in particular EGF have addressed some of these areas.
Section i: Relationship to tumour stage
In gastric cancer, tumours which express increased levels of EGFr are found to be at a 
more advanced stage with greater depth of invasion. Of 156 tumours studied by Yasui 
(1988), 130 were advanced lesions and 26 were cases of early gastric cancer according 
to the Classification of the Japanese Research Society for Gastric Cancer. Only one of 
the 26 early tumours showed EGFr immunoreactivity (3.8%). In the advanced tumour 
group, EGFr expression was found in 33.8% of tumours. The difference between these
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groups was statistically significant (p<0.01). When related to clinico-pathological factors, 
the level of EGFr expression correlated with the depth of invasion of the tumour 
(p<0.05). EGFr levels in metastatic lymph nodes from 45 tumours were found to be 
consistent with the primary tumour.
Sugiyama in 1989 assessed 220 gastric cancer specimens where 32% exhibited EGFr 
expression. This study correlated depth of invasion and and increased lymph node 
metastases with increased EGFr expression. In advanced disease Hirona (1995) found 
overexpression of EGFr was related to tumour size (p<0.05).
Other studies have found no relationship to pathological variables. Lemoine (1991) 
showed 18% overexpression of EGFr with no association with tumour stage, lymph 
node involvement, site of tumour or growth pattern. Similar results were published by 
Lee et al (1994) with 43% of cases demonstrating staining for EGFr but there were no 
significant relationship to clinico-pathological factors.
Section ii: Relationship to survival
Hirona (1995) found overexpression of EGFr was associated with significantly poorer 
survival (p<0.05) but in an earlier study (Yasui 1988) there was a non-statistically 
significant trend to poorer survival which increased with synchronous EGF expression. 
There are few other studies in which duration of survival allows adequate analysis and 
although Lee (1994) showed a tendency to shorter survival in positive cases.
Section iii: Relationship to tumour differentiation
Expression of EGFr is higher in intestinal type and well differentiated tumours. In the 
group of tumours studied by Lemoine (1991) expression was 18% and was higher in 
intestinal type tumours (27%) than in diffuse type tumours (12%). In the advanced 
tumour group from Yasui (1988) 51% of well differentiated, 22.9% of poorly
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differentiated and 24.2% of scirrhous tumours were EGFr positive. Well differentiated 
tumours had a significantly higher level of EGF and EGFr than the poorly differentiated 
type (p<0.05). However, of the 26 early tumours 85% were well differentiated tumours 
and one of these showed EGFr immunoreactivity (3.8%). In contrast, Sugiyama (1989) 
found the level of expression was higher in poorly differentiated tumours.
Section iv: Relationship to non-malignant and pre-malignant tissue
The difficulties encountered in comparing tumours and adjacent 'normal’ mucosa are 
highlighted in a study from Guys Hospital (Filipe 1995). Expression of EGFr, EGF and 
TGF-alpha was compared in established gastric cancer and in premalignant conditions 
in order to determine at what stage these factors appeared to influence tumour 
progression. Formalin fixed, paraffin embedded samples from 16 early gastric cancers, 
9 advanced (19 intestinal type,4 diffuse and 2 mixed) and biopsies from patients with 
benign disease were studied. The ‘normal’ biopsies had morphology varying from 
normal to intestinal metaplasia and the biopsies from the mucosa of cancer patients had 
the same range of appearance. Results of immunohistochemistry were scored 
independently by two observers without prior knowledge of clinico-pathological factors 
relating to each specimen. A semi-quantitative scoring system was established to grade 
the intensity of staining, the extent of expression and location of staining within the 
glands.
EGFr expression was moderate to weak in most types of lesion and there was no 
difference between histologically normal mucosa from cancer fields than non-cancer 
controls. However, in areas of intestinal metaplasia from cancer fields there was a 
significantly higher expression than non-cancer controls (p<0.1,z=3.8 vs z=1.07). The 
intensity of staining was found to increase serially from normal through intestinal 
metaplasia to dysplasia and EGFr staining extended throughout the glandular field.
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Using a polyclonal EGFr antibody and immunohistochemistry with formalin fixed paraffin 
embedded resection specimens, Lee et al (1994) noted significant staining on benign 
gastric tissue and that the staining tended to be diffuse. This was not confirmed by 
Hirona et al (1995) who found that all the normal gastric epithelium and non-tumour cells 
were negative.
Section v: Measuring EGF receptor expression
Although the study from Yasui (1988) clearly shows a significant difference between the 
level of EGFr in early and advanced tumours, it also highlights some of the difficulties in 
comparing studies of this nature. Firstly, even with the high incidence of gastric cancer 
in Japan the collection of 156 tumours took 11 years. Secondly, there is difficulty in 
comparing studies which use different criteria for determining EGFr expression 
specifically as to whether membrane or cytoplasmic staining is measured and the 
stratification to assess the extent of staining. Finally, the study used fixed tumour in 
paraffin blocks. Although the authors determined that the antibody used was capable of 
staining frozen and fixed tissue, the condition and antigen integrity of the tissue itself 
may differ with fixation.
Resected tissue from the patients was fixed in formalin and serial sections taken from 
paraffin blocks. A mouse monoclonal antibody to the EGF receptor which was 
developed using A431 epidermoid carcinoma cells as an immmunogen was used with a 
standard method of immunohistochemistry to determine the level of expression of EGFr. 
This antibody had previously been used in paraffin and frozen sections with 90% 
agreement in results (Tahara 1986).
Within this study a specific anti-EGF antibody was also used to determine EGF levels. A 
scoring system for the levels of EGF within tissue samples was developed depending on 
the percentage of tumour cells stained. However, a similar system was not used with the 
EGFr staining and the authors state that any staining of tumour cells was determined to 
be a positive result without significance given to the extent, intensity or position of
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staining. There was no discussion of whether membrane or cytoplasmic staining was 
considered to be relevant. Most studies suggest that positive staining occurs on the cell 
membrane but that many positive cells exhibit cytoplasmic staining possibly as a result 
of internalised receptor-ligand complexes.
Sugiyama (1989) used paraffin fixed specimens and the control sections which were 
used for comparison were human submandibular gland tissue for EGF and A431 cells 
for EGFr. Although A431 cells stain only on cell membranes the carcinoma cells 
seemed to also stain in cytoplasm and both were taken as positive. Using frozen and 
fixed preparations to study expression Lemoine (1991) employed a variety of antibodies 
to EGFr and found each reliable. For ease of interpretation he recommended in frozen 
sections EGFR1 (Gullick) which we have used in our work and the 12E rabbit anti-EGFr 
antibody for fixed/paraffin block preparations as used in the previous study. 
Overexpression was defined as staining of tumour cell membrane often accompanied by 
cytoplasmic staining.
Reports vary on the pattern of staining with Lee (1994) finding that staining for EGFr 
was always on the cytoplasm with accentuation on the cell membrane (9 diffuse and 15 
intestinal type). However, Hirona (1995) using an anti-EGFR monoclonal antibody 
(Biogenex.CA) determined positivity to be only for those cells which were definitely 
membrane stained.
These studies show wide variation in the level of expression of EGFr. There is a lack of 
a standardised definition of positivity in immunohistochemistry both in terms of 
membrane or cytoplasmic staining and a scoring system which would demonstrate 
intensity and extent. Subsequent analyses are difficult to compare with regard to 
percentage positivity, not only from the observer variability but this is compounded by 
discrepancies in the scoring systems used.
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Section vi: Ligand binding to determine EGFr expression
To determine the EGFr expression of gastric carcinoma, Pfeiffer (1990) examined the 
binding capacity of EGF receptors using 125-iodine labelled EGF binding assays. This 
was at the time the only available method of quantitatively determining the receptor level 
of EGFr. Frozen sections of tumour and adjacent mucosal tissue from the specimens 
were selected. The tissue was prepared using a homogeniser, filters and centrifuges in 
a standard way. Incubation of the tissue with radio-labelled EGF and binding determined 
by the equilibration-saturation method. The results were analysed using a programme to 
correct for non-specific binding but the heterogeneity of gastric tumour within blocks of 
tissue makes binding studies more difficult to accurately determine.
Specific binding of labelled EGF was observed in all 15 carcinomas and 13 of 15 
samples of normal mucosa. In 9 of 15 cases and 8 of 10 fundic carcinomas, statistical 
comparison of the paired individual binding curves suggested a significantly higher 
binding capacity in the carcinomas than in mucosa from the same patient. Overall 
comparison of the binding capacities showed no significant difference.
Of the nine cases with increased binding capacity, 8 cases had a 5.1+/_1.2 fold 
increase with one case of a young patient with a metastatic tumour having a 320 fold 
increase. Samples of mucosa were taken from patients undergoing surgery for benign 
disease and the binding capacity was found to lie within the same range as the mucosa 
taken from those patients with tumour. On further experiments the mucosa from tumour 
patients exhibited a 2 fold regional variation.
The difficulties with interpretation of ligand binding studies on gastric cancer specimens 
are two-fold. Ligand binding uses preparations of tissue which include malignant, non- 
malignant and potentially premalignant tissue. Contamination of the preparation in this 
way may be important but in addition, gastric cancer is recognised as having a 
heterogenious appearance in terms of differentiation and on immunohistochemical 
staining. A method of measurement of EGFr expression which would recognise these 
variables would be of some advantage.
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Section vii: EGF receptor gene amplification
The reported gene amplification of EGFr is 2 to 6%. Using Southern blotting Lemoine 
(1991) found 2 cases of gene amplification from 30 tumours analysed (6.6%) with one of 
these not overexpressing EGFr. Yoshida (1989) using the same technique in 37 gastric 
carcinomas found amplification in one case (2.7%). This was a poorly differentiated 
tumour which showed positive EGFr staining.
In summary, EGFr expression in gastric cancer ranges from 18 to 43%. There is 
increased expression in advanced disease and associated with a greater depth of 
invasion. In those studies with detailed follow-up, survival tends to be poorer in those 
patients with tumours expressing increased levels of EGFr. These are often advanced 
tumours. In general, increased expression of EGFr is found in differentiated tumours. 
Intestinal metaplasia and dysplasia from cancer fields showed increasing expression 
compared to intestinal metaplasia in non-cancer fields and this suggests EGFr may be a 
possible marker to determine the potential invasiveness of lesions.
There is considerable variation among studies in the method of scoring expression used 
with immunohistochemistry. The most important determinant of any relationship is the 
measurement of EGFr expression and I will attempt to use a novel method of detection 
to get over some of the inconsistencies that seem to have arisen. The method of 
immunohistochemistry is reproduceable but the different interpretations of images in 
terms of scoring area and intensity can be difficult. Differences in expression between 
frozen and fixed sections may also be an important factor in level of expression 
particularly in mucosal samples. I will attempt to bring together the elements if 
immunohistochemistry using frozen tissue sections with a quantitative method of 
scoring; the aim being to exclude the observer variables as much as possible.
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Chapter 6 
C-erbB-2 and gastric cancer
The c-erbB-2 gene which has been mapped to chromosome 17 at q21 (Fukushige 
1986) encodes a polypeptide with a sequence homologous but distinct from the kinase 
domain of EGFr. The gene product has been identified as a 185 kiloDalton glycoprotein 
with tyrosine kinase activity. However, kinase activity is not stimulated by EGF and a 
growth factor ligand has not been identified for c-erbB-2 (Akiyama 1986, Yamamoto 
1986). Although there is widespread expression of c-erbB-2 in fetal tissues the level of 
expression in adults is much lower and tends to be confined to epithelial tissues. The 
expression of c-erbB-2 has been studied in adenocarcinoma arising in a number of 
tissues, in particular breast tissue. Much interest has been related to its use as a 
prognostic indicator and overexpression in breast tissue has been correlated with poor 
outcome (Slamon 1987).
In gastric cancer, overexpression occurs in adenocarcinoma but to a varying degree. 
The relationships between overexpression, prognosis and clinico-pathological indicators 
of outcome have also demonstrated a number of inconsistencies between studies. The 
expression of c-erbB-2 in gastric carcinoma has been reported at a level of 5.4% 
(Livingstone 1995) to 72% (Kim 1993) but the majority of studies have found around 25 
to 30% positivity using immunohistochemistry (Table 11)
Section i: Relationship to tumour differentiation
Increased levels of c-erbB-2 have been consistently found in well differentiated gastric 
adenocarcinoma. Using a sample of 93 patients with advanced gastric adenocarcinoma 
who underwent gastrectomy between 1979 and 1989, Jain et al (1991) found 18 (19%) 
positive cases. All of the c-erbB-2 membrane positive cases were of the intestinal type 
(p<0.02) and a higher frequency of c-erbB-2 membrane staining was found in tubular
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and well to moderately differentiated tumours (p<0.05) and those with an expansile 
growth pattern (p<0.05). Further evidence of a relationship between expression of c- 
erbB-2 and differentiated tumours was found in papillary carcinomas (p<0.01), well 
differentiated cancers (Mizutani 1993) and intestinal type tumours (Lemoine 1991). In 
the intestinal type tumours reported in the latter study from London, 53% exhibited 
positive staining in comparison to 8% in diffuse type tumours. Despite the patient 
numbers being small in a number of studies there is a consistency in reporting this 
association between c-erbB-2 and well differentiated tumours from both British and 
Japanese groups (Hilton 1992, Sasaki 1992 and Motojimi 1994). In finding a significant 
relationship between these factors (p<0.01) Uchino (1993) was prompted to extend 
investigation of c-erbB-2 expression to a larger group of differentiated tumours with no 
loss of significance in the association.
Section ii: Relationship to tumour stage
A significant relationship was found between increased c-erbB-2 expression and serosal 
invasion, lymph node metastases, venous invasion and stage of disease (p<0.05) by 
Yonemura (1993) who studied 164 patients having subtotal or total gastrectomy with 
lymph node dissection. C-erbB-2 positive patients had a poorer prognosis (p<0.05).
In early tumours Mizutani (1993) found 4 out of 7 positive tumours had lymph node 
metastases but tumours without expression, were node negative. In this series, there 
was increased c-erbB-2 positivity correlating with depth of invasion. C-erbB-2 was 
detected more often in cancers with lymph node metastases but not to a significant 
extent The incidence of c-erbB-2 positivity in lymph nodes was found to be higher than 
in the primary tumour (p<0.01) particularly in well differentiated tumours. 
Overexpression of c-erbB-2 in the primary tumour with corresponding levels in lymph 
node metastases has been described (Hilton 1991) but, interestingly, increased intensity 
of staining in lymph node metastases was found and positive staining in lymph nodes 
even when the primary tumour was negative (Ohguri 1993, Mizutani 1993).
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intensity of staining in lymph node metastases was found and positive staining in lymph 
nodes even when the primary tumour was negative (Ohguri 1993, Mizutani 1993).
When c-erbB-2 positivity was compared with tumour stage by Motojima (1994), 
advanced tumours showed significantly increased immunoreactivity (p<0.001). There 
was also a correlation with depth of invasion (p<0.005) and lymph node metastases 
(p<0.01). Of the patients undergoing potentially curative resection, nodal invasion 
(p<0.003) and c-erbB-2 positivity (p<0.005) were found to be independent prognostic 
variables.
The relationship between tumour stage and c-erbB-2 expression appears to be 
significant but has not been found in all studies (Uchino 1993, Jain 1991, Lemoine 
1991).
Section iii: Relationship to metastases
Higher c-erbB-2 expression in lymph node metastases may suggest a role for c-erbB-2 
in the metastasis of gastric cancer and a significant correlation between c-erbB-2 
expression and the presence of liver metastases has been described (Mizutani 1993).
In the small group of Japanese patients (Sasaki 1992), attempts to relate expression to 
clinico-pathological factors were difficult due to the small numbers but of interest was 
the observation that the overexpressed tumours were well differentiated tumours and of 
those tumours with peritoneal metastases, 2 of the 6 had c-erbB-2 gene amplification 
(p<0.1). Of the 2 out of 9 tumours with peritoneal metastases, they were well 
differentiated tumours both with amplification (p<0.05).
Section iv: Relationship to survival
Reports of an association between c-erbB-2 expression and survival are variable. Some 
investigators have found prognosis is better in patients with tumours overexpressing c- 
erbB-2 (Jain 1991, Hilton 1991) often associated with well differentiated tumours but as
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disease but may be of importance in the survival of patients with early tumours (Mizutani 
1993).
Section v: Measuring c-erbB-2 expression
Differences in outcome for published studies of the significance of c-erbB-2 in gastric 
cancer may be explained by variations in testing methods. The most frequently used 
method of measuring c-erbB-2 is by protein immunohistochemistry (IHC). This method 
is widely available in most routine pathology laboratories and most experience in the 
field is using this method. IHC can be specific, rapid and requires few reagents but the 
sensitivity of the assay can vary depending on the particular monoclonal antibody used 
in the assay and some antibodies may occasionally reveal cytoplasmic immunoreactivity 
which is considered a non-specific pattern by most investigators (Busmanis 1994).
The description of the staining distribution which was seen in the tumours in one of the 
initial studies by Falck and Gullick (1989) is particularly valuable in outlining some of the 
difficulties in defining positivity in gastric sections and expressing that information in a 
form which can be compared to other studies. The antibody 21N was developed by this 
group to recognise the residues 1243-1255 on the carboxy terminus of the protein and 
was used in immunohistochemistry experiments. The observations of staining patterns 
show there was no significant staining in non-neoplastic epithelium whether 
histologically normal or showing metaplastic or dysplastic changes. Membrane staining 
was regarded as most specific, although in positive cases there was accompanying 
cytoplasmic staining. The few cases which were highly positive were easily recognisable 
but the majority of positive cases stained weakly. Patchy staining was common, and this 
is one of the particular difficulties in studying gastric cancer. Often there are well 
demarcated areas of positive staining but these are interspersed with negative areas in 
the same tumour field.
Positive and negative neoplastic tubules were also found in the same area of tumour by 
Ohguri (1993). Two immunoreactive staining patterns were identified; predominantly
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cytoplasmic staining and a membranous type where staining was found on the lateral 
and basal sides of tumour cells with occasional weak cytoplasmic staining. Cytoplasmic 
and membranous staining together were classified as membranous but in both staining 
patterns the proportion of positive cells varied considerably.
A large proportion of tumours which were found to have positive cytoplasmic staining but 
no membrane staining were excluded in further experiments using the 21N antibody 
from Hilton (1991).
It has been suggested that cytoplasmic staining is caused by cross-reactivity of the 
antibody to a 155kD cytoplasmic protein similar to, or a product of, the c-erbB-2 
oncogene (De Potter 1989). This was identified by immunoblotting in a small sample of 
their tumours in order to determine that the cytoplasmic staining was a 185kD protein. 
Further support for the significance of cytoplasmic staining came with a report from 
Kumar (1991) which suggested that 19% +/-4% of de novo synthesis of p185 HER2 (c- 
erbB-2) was expressed on cell membranes and the remainder in the other cellular 
compartments, in a human breast tumour cell line.
Comparison to a known positive breast control was used by Hilton (1991) and by Ohguri 
(1993) who, in addition, employed an antibody dilutional method to semi-quantify the 
strength of immunoreactivity.
Jain (1991) used the 21N antibody with formalin fixed specimens embedded in paraffin. 
Staining was scored as -, +, ++, +++ and although this study used a scoring system to 
semi-quantify the results there was no comparison with cell lines known to express 
elevated levels of c-erbB-2.
Standardisation of the control tissue used and the scoring systems which have been 
developed has led to production of commercially available kits for c-erbB-2 detection. 
The aim, with these, and other methods of c-erbB-2 detection which have been 
developed is primarily to decrease inter-laboratory differences.
There is certainly confusion in some cases in recognising which tumour specimens are 
considered to express c-erbB-2. If more than 20% of the tumour cells are stained this 
has been considered positive by some (Motojima 1994). C-erbB-2 protein detected was
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usually membranous but cytoplasmic staining was also found in most positive cases. 
Although 33 (28%) of the gastric tumours were determined to be positively stained, the 
study found that most of the tumours exhibited some degree of staining for c-erbB-2. 
However, since this was less than 20% of cells these tumours were classified as 
negative. No explanation was given for using 20% as the cut off level of expression. 
There was also lack of clarity as the investigators state “strong staining was easily 
recognisable, although most positive tumours were weakly stained".
Comparable results have been found in both paraffin and frozen sections of gastric 
cancer specimens (Lemoine 1991) and there is no doubt that with great care in the 
immunohistochemical technique and the use of control tissue IHC is a valuable tool. 
However, the methods used to process tissue, the time and nature of fixation and the 
temperature of paraffin embedding all may affect c-erbB-2 protein antigen loss or 
intensity of immunostaining in the specimens (Penault-Llorca 1994).
Staining of c-erbB-2 protein in non-neoplastic mucosa was detected by Ohguri (1993) 
and by others (Uchino 1993). Tumour fixation and subsequent methods of antigen 
retrieval,such as microwave use, may explain the variable range of expression within a 
tumour series and in mucosal samples.
In 1990 Kameda et al (1990) compared the level of c-erbB-2 expression in 34 gastric 
carcinomas and corresponding mucosa. The monoclonal anti-body used in this case 
also recognised the cytoplasmic domain without residue specificity (Nichirei,Tokyo) and 
the results were determined by a scoring system from - to +++ depending on the 
number and intensity of cells stained although details of this were not given. Well 
differentiated tumours tended to exhibit cell membrane staining whilst in poorly 
differentiated tumours it tended to be cytoplasmic. Western blotting of tumour lysates 
demonstrated low levels of c-erbB-2 in more of the poorly differentiated group with 
higher levels in the well differentiated tumours expressing membrane c-erbB-2.
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However, in some poorly differentiated tumours with low levels on Western blotting there 
was positive immunostaining. Unfortunately different commercial monoclonal antibodies 
were used in these experiments. The study suggested a higher level of expression of 
immunoreactivity in both tumour and 'normal' mucosa but the results were given as raw 
scores and are difficult to interpret. In 23 of 34 cases (68%) staining of the tumour 
scored higher than the corresponding mucosa but some samples of mucosa with 
metaplasia and regenerative epithelium expressed high levels of c-erbB-2.
Finally, Lim et el (1993) demonstrated expression of c-erbB-2 in 72% of tumours. There 
were no details of the intensity or distribution of staining or criteria of positivity, and no 
indication of controls, levels in normal mucosa and any use of a scoring system. Further 
interpretations of this data and any correlations made would obviously be misleading. In 
particular the suggestion that patients in this area of South-East Asia have tumours 
which are biologically different.
Section vi: C-erbB-2 expression in different populations
McCulloch (1994) and Livingstone (1995) have examined specimens of tumours from 
patients undergoing resection of gastric carcinoma in Japan and the U.K. These patients 
have been matched for age, time of operation, tumour differentiation, stage and site. In 
Liverpool, 89 tumours were studied from each group using a polyclonal antibody (Dako 
plc.Bucks,UK). No difference in the level of expression was observed between the two 
populations. A scoring system -, +(<5%), ++(<50%) and +++(>50%) was employed and 
no staining of normal epithelium was observed. UK tumours expressed c-erbB-2 in 13% 
of cases and 11% in Japanese tumours. In contrast, Livingstone using a similar scoring 
system and commercial antibody (NC-004,Novocastra) found that UK tumours 
expressed c-erbB2 in more cases with a level of 54% compared to 21% (p<0.01) and 
this difference was demonstrated across the spectrum of stage of disease.
55
Chapter 6
Section vii: C-erbB-2 gene amplification
Gene amplification of c-erbB-2 has been assessed in small numbers of tumours and 
ranges from 5 to 13%. Correlation with immunostaining is found but is not universal and 
further explanation of c-erbB-2 overexpression is required. In the assessment of c-erbB- 
2 status the use of techniques to measure protein expression and gene amplification will 
need to be compared. For research purposes, most studies have used Southern blotting 
to determine c-erbB-2 amplification. However, the use of fluorescence in situ 
hybridisation (FISH) is becoming more routine despite being relatively time consuming 
and complicated to perform.
ErbB-2 gene amplification was assessed using Southern blot analysis on 3 out of 34 
tumours which expressed high levels of c-erbB-2 (Kameda 1990). Two of the three 
cases showed a corresponding gene amplification (5.9%). In one of the tumours, 
although differentiation was the same throughout the tumour field, the expression and 
amplification showed considerable variation from site to site.
The absence of gene amplification in the third tumour prompted a search for 
transcriptional causes of higher protein expression. Within the promoter region of the 
erbB-2 gene is an area termed the TATA box. The levels of binding proteins to this and 
other promoter areas were examined by gel retardation assays and in general found to 
be higher in tumour than mucosa. However, the binding proteins to the TATA box 
showed a significantly higher level in the tumour identified as having high c-erbB-2 
expression without gene amplification. Using gastric cancer cell lines, the cell lines with 
a single copy gene and high expression of c-erbB-2 were found to have higher levels of 
TATA binding proteins than cell lines with poor c-erbB-2 immunoreactivity. This 
suggests a possible explanation for varying levels of c-erbB-2 expression, that in some 
cases it may be due to amplification but increased expression in some instances is due 
to transciptional changes.
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Overexpression of c-erbB-2 and amplification were also studied by Sasaki (1992). Of 
the 24 tumour specimens which were analysed using Southern blotting and 
immunohistochemistry 3 showed overexpression and 2 showed amplification (8.3%) 
although only one of these tumours overexpressed c-erbB-2. Southern blotting was also 
used in a group of forty tumours and revealed four tumours with gene amplification, all of 
which demonstrated c-erbB-2 overexpression with over 80% of the cells stained and 3 
of the 4 were intestinal type tumours.
Gene amplification has been demonstrated in several small studies of gastric 
carcinomas (Gutman 1984, Houldsworth 1990) occurring in 5 to 13% of cases with up to 
a 32 fold overexpression of erbB-2 mRNA. Some correlation of c-erbB-2 amplification 
with tubular or well differentiated tumours (Park 1989, Tal 1988, Yoshida 1989) has 
been described.
Section viii: Relationship between EGFr and c-erbB-2
There was no relationship found between expression of EGFr and c-erbB-2 (Lemoine 
1991) and this was supported by no obvious correlation in gene amplification (Yoshida 
1989).
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Table 10 Review of published data on the relationship between c-erbB-2 and 
prognostic factors
REFERENCE POSITIVE STAGE NODES GRADE GROWTH PATTERN SITE METASTASES
Falck&Gullick 19 - - well/tub/pap - - -
Kameda et al 55 no - well - - -
Lemoine et al 26 no no intestinal no no -
Hilton et al 9 - yes intestinal - - -
Jain et al 30 - no int / well expansile - -
Sasaki et al 17 no no moderate - - peritoneal
Tateishi et al 12 - - papillary - - no
Motojima et al 28 yes yes no - no -
Kim et al 72 - no no - - no
Yonemura et al 19 yes yes no - - no
Uchino et al 8 no no well/mod/pap - - no
Ohguri et al 25.7 no no no - -
Mizutani et al 14.2 yes no papillary expansile liver
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Table 11 Review of published data on the expression of c-erbB-2, with the 
tissue used and the method of immunohistochemical counting.
REFERENCE YEAR METHOD FIXATION NUMBER %POSITIVE STAINED AREA COUNTED
Falck&Gullick 1989 IHC Paraffin 126 19 membrane
Kameda et al 1990 IHC Par/frozen
(mixed)
34 55 membane/cytoplasm 
(well/poorly differentiated)
Lemoine et al 1991 IHC Par/Frozen 40 26 membrane 
(every tumour)
Hilton et al 1991 IHC Paraffin 87 9 membrane
Jain et al 1991 IHC Paraffin 93 30 membrane(11%)
cytoplasm(19%)
Sasaki et al 1992 IHC Paraffin 24 17 membrane
Tateishi et al 1992 IHC Paraffin 179 12 membrane
Motojima et al 1992 IHC Paraffin 120 28 membrane
Kim et al 1993 IHC Paraffin 100 72 unspecified
Yonemura et al 1993 IHC Paraffin 164 19 membrane
Uchino et al 1993 IHC Paraffin 106 8 membrane 
(+108 papillary)
Ohguri et al 1993 IHC Paraffin 136(92 early 
44 advanced]
25.7 (48.6% early 
51.4% adv)
Mizutani et al 1993 IHC Paraffin 226(92 early 14.2 membrane 
134 advanced) 7.6% early 
18.7% adv
McCulloch et al 1994 IHC Paraffin 89 UK 
89 Japan
30
31
unspecified
Livingstone et al 1995 IHC Paraffin 33 UK 
40 Japan
5.4
21
membrane
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The literature review is summarised in tables 10 and 11. The level of expression of c- 
erbB-2 varies from 5 to 72 % with the majority of studies suggesting a level of around 
30%. Gene amplification ranges from 5 to 13%.
There is evidence of increased expression of c-erbB-2 in well differentiated tumours and 
a significant relationship exists between increased c-erbB-2 expression, lymph node 
metastases and stage of disease (p<0.05). In some studies, c-erbB-2 positivity is found 
in lymph node metastases in the presence of c-erbB-2 negativity in the primary tumour. 
To a lesser extent the presence of liver metastases is found more often in tumours with 
increased levels of c-erbB-2.
Correlation of c-erbB-2 with survival is found for high and low expressing tumours and 
may be related to positivity in a particular histological type or stage of disease.
There is evidence that c-erbB-2 expression will be important as a prognostic factor in 
gastric cancer. Inconsistencies in the published studies are most likely to be due to 
differences in c-erbB-2 measurement. In particular, the variable scoring of sections, 
membrane and cytoplasmic staining, the use of different antibodies, the patchy nature of 
staining in adjacent areas of tumour and the effect of differing methods of fixation.
In order to overcome some of the recognised problems, a novel approach to measuring 
c-erbB-2 has been developed and I will report in detail its use in gastric cancer. Frozen 
tissue sections are used to overcome the variables in the fixation process and preserve 
antigenicity in tumour and mucosal samples. The technique of 
radioimmunohistochemistry, utilises a radio-iodinated anti-c-erbB-2 monoclonal antibody 
to label the receptors and a computor-assisted image analysis to quantify the bound 
receptor. Sections of cell pellets with known c-erbB-2 levels are processed with each 
batch of samples as internal calibration standards and comparison with expression in 
samples of non-neoplastic mucosa is made.This technique combines the objective 
quantification of ligand-binding analysis with the specificity of immunohistochemistry.
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Insulin-like growth factors and receptors
Insulin-like growth factors are a group of structurally related polypeptides which effect 
the proliferation and differentiation of a wide range of cell types.
The insulin-like growth factors (IGFs) were initially called somatomedins (Daughaday 
1972). They were discovered as a group of substances mediating the actions of growth 
hormone (somatotropin) but better understanding of the structure, function and 
mechanism of action of the IGFs has shown widespread synthesis and activity in many 
tissues.
Section i: Structure of insulin-like growth factors
IGF- I (somatomedin-c) and IGF-II (somatomedin-a) are single chain polypeptides with 
70 and 67 residues and molecular weights of 7649 and 7471 respectively. There is 60% 
amino acid sequence homology between IGF-1 and IGF-II (Daughaday 1989) and 43% 
sequence homology between IGF-I and pro-insulin which is reflected in the insulin 
activity of these factors which is not inhibited by anti-insulin antibodies (Froesch 1963). 
Homology is in the A and B domains but there is none between the C-peptide retained in 
IGF and the C-peptide present in pro-insulin but cleaved in the formation of mature 
insulin. In addition, the IGFs have a D domain. Each IGF is the product of a single 
complex gene (Rotwein 1991). The human IGF-1 gene is on chromosome 12q and the 
IGF-II gene on chromosome 11 p close to the insulin gene.
Section ii: Function and regulation of IGFs
IGFs are synthesised throughout the body in most, if not all tissues and synthesis is 
determined by the specific tissue and a number of regulatory factors. IGF expression
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often occurs in tissues at specific stages in development and in tissues undergoing rapid 
growth. Tissues which maintain rapid proliferation of cells into adulthood often exhibit 
high IGF- I expression. IGF- I circulates in the blood at readily detectable levels and 
hepatic synthesis is the main contributor to the serum concentration. The IGFs have 
insulin-like anabolic activity in adipose tissue, liver and skeletal muscle (Zapf 1986). The 
hormone acts in an endocrine fashion and is regulated by nutritional and endocrine 
factors (Underwood 1986). Nutritional deficiency reduces IGF- I and causes resistance 
to GH. GH stimulates IGF- I expression and in their specific target tissues, PTH, FSH, 
TSH and oestrogen (Murphy 1988) stimulate expression. IGF- I also has autocrine and 
paracrine activity in the tissues of synthesis (D’Ercole 1996). IGF-II also has detectable 
blood levels but seems to act more in the tissues of synthesis rather than in an 
endocrine function. The factors which regulate expression of IGF- I, influence IGF-II 
expression but to a lesser degree.
IGF expression often occurs in specific tissues at developmental stages when these 
tissues are undergoing rapid growth. IGF- I and IGF-II are important in embryonic and 
fetal development. Postnatally, IGF-II is expressed much less than IGF-1 which 
continues to play an important developmental role (Baker 1993). IGF- I and IGF-II are 
present in all species and have been isolated in several including rat (Whitfield 1984), 
mouse (Bell 1986)and bovine (Honnegger 1986) forms with minimal variation in amino 
acid sequence.
Section iii: IGF Binding Proteins
IGFs are secreted soon after synthesis. The free form of IGF-1 has a half life of 10 to 12 
minutes. The vast majority of IGFs are complexed to binding proteins (IGFBPs) which 
can prolong the half life to 12 to 15 hours (Guler 1989). These are synthesised by the 
IGF producing or nearby cells and modulate actions by inhibiting their activity at
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receptors, protecting IGFs from degradation and delivering them to the tissue cell 
surface.
There are 6 recognised high affinity IGFBPs (Baxter 1989) most of which bind IGF-1 and 
IGF-II with similar affinity and at least a further seventh IGFBP of low affinity (Ellis 1998). 
IGFBP 3 is a 150.000MW complex and binds most IGF. The smaller binding proteins 
are of 24,000 to 34,000MW. The IGFBPs are synthesised in the tissues producing IGFs. 
The role of IGFBPs is to deliver and modify the activity of IGFs. With the exception of 
IGFBP 4 they can potentiate the activity of IGFs possibly by a slow release mechanism 
which prevents down regulation of the receptors. Phosphorylation of the binding proteins 
may explain why in some circumstances they inhibit and in others potentiate the action 
of IGFs.
Section iv: Type I IGF receptor
IGFs bind to cell surface receptors. The Type I IGF receptor is most likely to be 
responsible for the mitogenic effects of IGF-1 and IGF-II (Czech 1989).
The Type I IGF receptor is a heterotetrameric glycoprotein of 300.000MW composed of 
paired disulphide linked alpha and beta subunits of 130.000MW and 95.000MW  
respectively. The particular configuration with disulphide bonding distinguishes the 
receptors from other tyrosine kinase growth factor receptors (Siddle 1993).
The Type I insulin-like growth factor receptor and the insulin receptor show 80% 
homology in their tyrosine kinase domains and 40-60% homology in other areas (Ullrich 
1986).In cells expressing both receptors a proportion of the receptors will be hybrids of 
each receptor (Siddle 1993).The Type I IGF receptor has 2 to 3 times more affinity for 
IGF- I compared to IGF-II and 100 times more affinity for IGF- I than for insulin (Czech 
1989). The subunits are derived from a single gene and subsequently a common 
precursor which is dimerized then the individual subunits cleaved. The homology with 
the insulin receptor suggests a common primordial gene (Herington 1991).
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The ligand binds to the alpha subunit, induces a conformational change in the receptor 
and the tyrosine kinase activity induces autophosphorylaton of the beta subunit. 
Thereafter phosphorylation of intracellular proteins ultimately leads to progression of the 
cell cycle and cellular differentiation. Activation of gene transcription is effected by 
signalling pathways similar to those of EGFr. There is phosphorylation of SH2 domains 
on intra cellular signalling proteins and binding to the Grb2/Sos complex as previously 
described. However, rather than direct binding to SH2, the beta subunit also 
phosphorylates ‘docking proteins’ IRS-1 and IRS-2 which when phosphorylated are 
recognised by SH2 domains (LeRoith 1996).
Section v: Type II IGF receptor
The type II insulin-like growth factor receptor has no kinase activity. It is found on nearly 
all cell types and binds IGF-II with more affinity than IGF- I with negligible binding of 
insulin. The receptor is a single polypeptide of molecular weight 250,000Da and has 
close homology with the mannose-6-phosphate receptor (Morgan 1987).
Section vi: Physiological role of IGFs
The physiological role of insulin-like growth factors involves the mediation of cellular 
proliferation by stimulation of DNA, RNA and protein synthesis. When proliferation is 
complete IGFs are potent stimulators of cellular differentiation. In most tissues IGFs 
stimulate the synthesis of extracellular matrix and in endocrine tissue IGFs effect 
hormone secretion promoting steroid synthesis in ovarian granulosa cells and Leydig 
cells. IGFs stimulate specialised cell function in the immune, haemotological and 
neuronal system and may inhibit apoptosis to enhance cell survival (Ellis 1998).
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Insulin-like growth factors in malignancy
Components of the IGF signal transduction pathway have been implicated not only in 
the proliferation of malignant cells but in the transformation of cells. With IGF II targeted 
to the mammary gland of transgenic mice, an excess of mammary gland tumours has 
been noted (Bales 1995) and in the transformation of cells by the src oncogene the 
Type I IGF receptor has been implicated as an intermediary (Westley 1995). IGF-1, IGF- 
II, the IGF receptors and binding proteins are expressed in a wide variety of cancer cell 
line and tumour specimens including those of ovary, breast, colon, bone, lung and brain.
Section vii: IGFs in breast cancer
IGF- I and IGF-II have been shown in vitro to be potent mitogens in breast cancer cell 
lines (Macauley 1992). Some studies have suggested that IGF- I is not expressed by 
tumour cells (Yee 1989) but by the supporting stroma in breast and its function is by 
endocrine or paracrine means. In contrast it is felt that breast cancer cells secrete IGF-II 
(Lee 1994). However, Gebauer (1998) found mRNA for IGF- I and IGF-II in malignant 
tissue but not cancer cell lines and Giana (1995) proposed a stromal origin for IGF- II. 
The type I IGF receptor is expressed in most human breast cancer (Cullen 1990, 
Foekens 1989) and using 125 l-IGF-1 binding studies (Jammes 1992), the receptors are 
present on epithelial cells with binding higher in the malignant cell population.
There are a higher concentration of IGFBPs 1-5 in malignant compared to normal 
epithelium (Pekonen 1992), with all breast cancers expressing IGFBPs 1-6. In 
oestrogen negative tumours there is increased expression of IGFBP 2 and 4 with 
increased IGFBP 3 in oestrogen receptor positive tumours (Helle 1995).
While the contribution of IGFs produced in the malignant tissue may be small in 
comparison to the plasma level, the availability of IGF-1 and IGF- II to the receptor may 
be increased by reduced IGFBP 3 binding. Increased levels of IGFBP 3 protease have 
been found in the plasma of breast cancer patients with metastatic disease (Frost 1996).
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This is an enzyme which proteolytically transforms IGFBP 3 into a low affinity binding 
protein with increased release of IGFs to the tissues and the consequent stimulation of 
tumour growth (Helle 1996).
There are important interactions between the IGF system and endocrine activity in 
breast cancer. Oestradiol increases the expression of IGF- II and increases the cellular 
concentration of mRNA for IGF-1 receptor. Oestrogens stimulate IGFBP 3 proteases. In 
addition it is now apparent that the IGFBPs interact with the cell membrane directly and 
in the absence of IGFs, modulate cellular function (Adamo 1992, Dubois 1995, Oh 
1998).
In vitro IGF-1 and oestradiol synergistically enhance growth in the MCF-7 breast cancer 
cell line. The interaction between IGF and oestrogen occurs at the oestrogen receptor 
(Lee 1997). The type I IGF receptor promotes the transcriptional activity of the 
oestrogen receptor by MAP kinase dependent- ER phosphorylation (Kato 1995).The 
effect of oestradiol stimulation can be reduced with antibodies to IGF- I (Stewart 1990) 
and in vitro the effect of oestrogens on the IGF system can be reversed with 
antioestrogens (Kawamura 1994, Lee 1997 ). In vivo, tamoxifen reduces plasma IGF-1 
and increases IGFBP 1. With megestrol acetate IGF-1 is increased but the reduction in 
IGFBP 3 protease may reduce the bioavailability of IGF-1 to the tissues (Helle 1996).
Section viii: IGFs in ovarian cancer
In ovarian cancer, primary epithelial cell lines derived from untreated ovarian cancers 
have shown IGF-I mRNA expression ( Yee 1991, Conover 1998) and a significant 
amount of IGF-I secreted. Cell lines expressing IGF-II mRNA have been found with 
protein expressed into the media in high concentrations. Affinity cross-linking 
experiments documented abundant type I IGF receptors and there was also significant 
125I-IGF I binding to IGFBPs on the surface of some ovarian cancer cell lines (Conover
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1998) and type I receptor mRNA found in all cell cultures and malignant ovarian tissue 
(Yee 1991). In all cultured cells there was expression and secretion of IGFBPs with 
IGFBP 2 the most abundant in all but one culture. These were associated with 
advanced, aggressive tumours and not expressed in the lowest grade/stage tumour.
In other studies on ovarian cancer cell lines there was cellular proliferation in response 
to addition of exogenous IGF-I like peptides (LR3-IGF-I) which do not bind to IGFBPs 
but activate the IGF receptor. This proliferation was not enhanced by addition of 
oestrogen. Proliferation of ovarian cancer cells in serum free media was increased by 
addition of IGF-I. This effect was inhibited by incubation of cells with anti-sense 
oligonucleotides to the type I IGF receptor (Resnicoff 1993).
Section ix: IGFs in pancreatic cancer
In pancreatic cancer, IGF-I mRNA is abundant and present in both cancer cells and the 
surrounding stroma in contrast to normal pancreas which has low levels of IGF-I only 
present in the stroma. IGF-I stimulates the growth of pancreatic cells in culture. This 
effect is inhibited by the IGF-I monoclonal antibody alpha-IR3 and IGF-I receptor 
antisense oligonucleotides. IRS-1 is overexpressed in pancreatic cancer but IGF-II and 
insulin are not detected. However, insulin and IGF-II are produced by the islet cells and 
may influence the growth of the cancer cells by endocrine means (Korc 1998).
Section x: Lung cancer and IGF-I
Most of the effects of the IGFs in lung cancer are mediated by the type I IGF receptor 
which is expressed in normal bronchial epithelial cells and primary cancer with high 
density binding sites especially prominent in squamous cell carcinoma and small cell 
lung cancer (Shigematsu 1990). IGF-I is secreted into the media of cultured cells from 
both small cell (SCLC) and non-small cell lung cancer (NSCLC) (Macauley 1990) with
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strong staining for IGF-I in squamous carcinoma. IGF-I is detected in primary lung 
tumours at higher levels than in normal lung (Minuto 1986). In NSCLC IGFs bind 
predominantly to the Type I IGF receptor but in SCLC binding was primarily to IGFBP 2 
on the cell surface.
Section xi: IGF-I in colonic carcinoma
IGF-I has been shown to stimulate the growth of colonic cancer cells using cell 
proliferation studies (Durrant 1991,Guo 1992). In contrast to the findings in breast 
cancer the concentration of Type I IGF receptor in colonic cancer cells using ligand 
binding studies has shown no statistical significance between receptor concentration in 
malignant and normal colorectal tissue (Adenis 1995). Forty six percent of normal tissue 
and 70% of malignant tissue was considered positive with no association between 
receptor concentration and prognostic variables.
Section xii: IGF-I in gastric cancer
In the human foetus the stomach and the placenta contain the highest levels of IGF-1 
mRNAs which suggests that the growth and development of the stomach may be highly 
dependent on IGF-1 (Guo 1993). Using the gastric cancer cell lines MKN 45,St 42 and St 
16, Durrant et al (1991) studied the growth of cells incubated with IGF-I and the density 
of IGF-I receptor. IGF-I was reported as significantly mitogenic for St 42 and MKN 45 (St 
16 was not tested). The concentration of receptor was found to be 250 IGF-I receptors 
per cell for St 16, 190 per cell in St 42 and 310 per cell in MKN 45.This is in contrast to 
the much higher expression of EGF receptor with 7780 receptors per cell in St 42 and 
39,700 receptors per cell in MKN 45.There was no correlation between IGF-I and EGFr 
expression, and mRNA for IGF- II was present in both cell lines.
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Cellular proliferation in gastric cancer cell lines AGS cells and SNA cells was stimulated 
only in the SNA cells by IGF-I. Ligand binding studies confirmed the presence of IGF-I
4
receptors on the AGS cells at a concentration of 4.27+/- 0.4 x 10 sites per cell and the 
alpha subunit was of MW 130,000Da. Northern blotting showed no mRNA for IGF-I in 
the AGS tumour cells and therefore no blocking of the receptors by endogenous IGF-I. 
Although IGF-I produced no growth response in AGS cells, truncated IGF-I which has 
affinity for and activates IGF-I receptors but has less affinity for IGFBPs produced a 
growth response. Gel electrophoresis confirmed the presence of proteins consistent with 
IGFBPs and it was concluded that the lack of growth response was due to the activity of 
IGFBPs sequestering IGF-I and preventing receptor interaction.
The experimental evidence which shows the importance of the activity of IGF-I and its 
receptor in tumour growth has prompted attempts to investigate whether blocking these 
effects would be inhibiting. Tamoxifen inhibits the IGF-I induced growth of breast cancer 
cell lines and this activity may explain the success of tamoxifen in oestrogen receptor 
negative tumours. In a number of experimental studies the monoclonal antibody (alpha 
IR3) to the Type I IGF receptor used in breast cancer cell lines inhibited anchorage- 
independent growth in the presence of serum but could not block serum-free growth. In 
athymic mice the antibody inhibited the growth of MDA-MB-231 cells when injected at 
the time of tumour inoculation but not in established tumours (Werner 1996). Suramin is 
a polysulfonated naphthylurea which inhibits growth-factor induced mitogenesis. It is 
cytostatic in osteosarcoma cells (Poliak 1990) and reduces serum levels of IGF-I and 
IGF-II in breast, prostate and lung cancer.
Summary
There appears to be evidence that IGF-I and its receptor have a role in the proliferation 
of cancer cells. There is high IGF-I expression in rapidly proliferating cells and foetal 
stomach. In ovarian, breast and colon cancer, accelerated cellular proliferation has been 
demonstrated with IGF-I with most but not all tissues having increased levels of the IGF-
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I receptor. In malignancies of breast and lung, in particular, drugs and monoclonal 
antibodies have inhibited the growth of cancer cells in vitro and in animal studies.
In gastric cancer, often presenting at an advanced stage, the study of growth factors 
such as EGFr and c-erbB-2 is important to understand the mechanism of the disease 
process, develop markers of aggressive disease and prognostic indicators. It is also 
important to study whether these factors have a potential role in cancer therapy. In 
conjunction with the study of level of expression of EGFr and c-erbB-2 in gastric cancer, 
information has been obtained from studies of cellular proliferation in vitro and inhibition 
of the cell growth. Progression of this research to other potential growth factor targets in 
cancer cell growth is important and to this end I have studied the role of IGF-I in 
proliferation of gastric cancer cell lines.
Within this thesis I plan to outline the preliminary proliferation studies of gastric cancer 
cells exposed to IGF-I. In addition, I have sought to demonstrate that this activity can be 
inhibited by tyrophostins, principally developed to inhibit EGFr activity but also effective 
in this setting. There are potential clinical implications with this work to develop further 
novel therapeutic agents but also a number of difficulties to overcome which I will also 
discuss further.
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STATEMENT
OF
AIMS
In the following studies the role of both Type I growth factors and the IGF-I pathway in 
gastric cancer will be studied. The review of evidence suggests a role for both EGFr and 
c-erbB-2 in gastric cancer. However, the results of studies are conflicting and this may 
be in part due to the differing methodology used for measuring the growth factor 
receptors. The methods of study most commonly used have been 
immunohistochemistry and ligand binding studies but there are technical difficulties with 
each method. Immunohistochemistry gives cellular localisation but is not quantitative 
and as discussed there were problems with reproducibility related to fixation and 
processing. Ligand binding is quantitative but does not give localisation and is 
unsuitable for c-erbB-2. To overcome these problems the technique of 
radioimmunohistochemistry has been developed for gastric cancer. The purpose of the 
current programme of experiments is to evaluate radioimmunohistochemistry in 
determining EGFr and c-erbB-2 expression in gastric cancer. The results will be 
compared to standard immunohistochemistry. The results will be related to conventional 
prognostic factors to assess them in predicting tumour behaviour and prognosis.
These aims are effected by examining a retrospective series of 67 gastric cancers in 
which EGFr and c-erbB-2 expression are measured using radioimmunohistochemistry, 
immunohistochemistry and c-erbB-2 amplification using fluorescence in situ 
hybridisation.
The effect of novel inhibitors of growth factor receptors in the N87 and MKN45 gastric 
cancer cell lines will be assessed in the presence of IGF I. Cellular proliferation and 
tyrophostin inhibition in IGF-I stimulated gastric cancer cell lines and subsequent 
changes in signal transduction will be demonstrated.
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The defined aims are as follows:
Assess the validity and reproduceability of radioimmunohistochemistry 
for EGFr and c-erbB-2 in gastric cancer cell lines and tumour 
specimens.
Evaluation of radioimmunohistochemistry in comparison to standard 
immunohistochemistry.
The determination of any relationship between the type I growth factor 
receptors EGFr, c-erbB-2 and clinico-pathological prognostic factors.
The assessment of the use of IGF-I inhibition in cell culture and the 
effect on downstream signal transduction with reference to clinical 
application in gastric cancer.
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PART III
EXPRESSION OF GROWTH 
FACTOR RECEPTORS IN 
ASSESSMENT OF GASTRIC
CANCER
Introduction to Experimental Parts of Thesis
Expression of the EGFr and c-erbB-2 varies widely in the studies we have reviewed and 
much of this may be due to methodological rather than tumour biology. In an attempt to 
more accurately measure growth factor receptor density in tumour specimens, we have 
sought to improve on the methods of investigation currently available.
Ligand binding involves the exposure of the tissue in question to radiolabelled ligand 
which subsequently binds to the receptor being studied. The membrane preparations 
are derived from tumour biopsies and include malignant and non-malignant cells. In 
tumours with high receptor levels or cell pellets from cultured cells which express high 
levels of receptor, this may not represent a significant problem but for cancers where 
receptor expression may be close to, or less than, normal tissue, these contaminants 
may be important.
Immunohistochemistry also uses receptor antigen binding detected by a complex of 
reactions resulting in staining at the site of activity. This allows localisation of receptors 
to tumour cells but is inherently subjective and at best semi-quantitative. By combining 
the localisation of immunohistochemistry in tumour specimens with a method to 
correlate this information to ligand binding we have sought to develop a quantitative, 
tumour cell specific method of determining growth factor receptor density.
The level of expression of EGFr and c-erbB-2 in specimens of gastric adenocarcinoma 
and normal gastric mucosa was measured by radio-immunohistochemistry. The 
quantitative aspect of this method of study is determined by comparison with receptor 
density in cancer cell lines as determined by ligand binding studies. In addition, tumour 
tissue was stained using standard immunohistochemistry and c-erbB-2 amplification 
measured using fluorescence in-situ hybridisation (FISH).
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Chapter 8
Methodology 
EGFr and C-erbB-2 Expression 
Section i: Tumour Specimens
The majority of tissue used in this series of investigations was collected from patients 
undergoing surgery in Glasgow Royal Infirmary during the period 1990 to 1995 where 
the operating surgeon was a member of the University Department of Surgery team. 
The patients included those undergoing both curative and palliative resections and 
several patients having palliative procedures without resection in whom laparotomy was 
performed for intubation or bypass procedures. The patients were not consecutive but 
there were no exclusion criteria and those tumours which were collected depended on 
staff availability only. Ethical approval for the study was given by the Ethical Committee 
of the Eastern Unit of Greater Glasgow Health Board (Glasgow Royal Infirmary). The 
collection of tumour specimens and data did not compromise or influence the patient 
treatment or routine pathological analysis.
At the time of surgery, the resected specimen was taken immediately to the pathologist. 
The pathologist would make an initial assessment of the fresh specimen with regard to 
the size and site of tumour. He would then remove a sample of macroscopically normal 
mucosa at the resection margin of the stomach most distal from the tumour in order to 
reduce the likelihood of malignant or pre-malignant changes within the mucosal sample 
which may alter the growth factor receptor staining. A sample of tumour was then 
removed, the full thickness of the stomach wall in the majority of cases. Both specimens 
were immediately frozen in liquid nitrogen and transported in flasks of liquid nitrogen to 
the tumour bank in the department of surgery in Glasgow Royal Infirmary. They were 
stored in the tumour bank in liquid nitrogen at -70°C. Tumour samples which were 
obtained from other hospitals were transported to the pathology department and
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assessed on site by the resident pathologist and then on to the tumour bank. Around 
five percent of tumours came from other centres in Glasgow.
Another small group of tumours originated from St. James Hospital in Leeds. The 
specimens had been collected for several projects in Leeds with ethical approval for 
tissue collection and subsequent analyses. The clinical details and pathological 
information were kindly supplied by Professor J. Primrose who was the director of the 
gastric tumour study at that time and Dr. J Wyatt, Consultant Histopathologist. The 
tumours were collected from St. James Hospital and Airedale General Hospital over a 
period of three years with inclusion of the majority of patients undergoing resection and 
no formal selection or obvious bias. Although samples from a large number of the 
tumours in this study were in the tumour bank in Glasgow many on sectioning and 
staining were found to be poorly preserved or had inadequate clinical and pathological 
information. These samples were therefore unsuitable for inclusion in this study. Those 
tumour blocks which were poorly preserved could bring a question of selection bias to 
this study. The larger tumours possibly with areas of necrosis may be less well 
preserved. However, the preservation of the blocks of tumour was more in question. 
These tumours had been selected previously as suitable for other studies but mis­
handled in transit and this is the source of poor preservation. In addition, lack of 
information may suggest many influencing factors and potential areas of bias, 
particularly shortened follow-up in advanced disease. However, the study of these 
tumours was one of resected specimens.This narrows the bias for those patients 
excluded in this group in that the tumour group as a whole comprised mainly resected 
tumours but this in itsel brings selection to those included in this study .The small number 
of specimens obtained outwith Glasgow amounted to 6%.
Gastric adenocarcinoma specimens from 67 patients were used in the study and all 
subsequent analyses used only these tumours. Samples of oesophageal 
adenocarcinoma, adenosquamous gastric cancer and gastric lymphoma were used for 
observational comparison only.
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Section ii: Patient and tumour data noted
The details which were recorded for each patient and specimen of tumour were as 
follows:
Patient data
- unit record number
- age
- sex
- presentation and symptoms
- type of operation
- clinical outcome including evidence of recurrence, further therapy, survival 
time and cause of death
Pathological data
- pathology department number
- macroscopic size of tumour
- tumour differentiation and Lauren classification if available
- nodal involvement ( number involved/number sampled )
- serosal involvement and tumour stage
- presence of metastases
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Section iii: Method of Radio-immunohistochemistry
This method allows a quantitative estimation of antibody binding. By using control 
tissues with known receptor concentration and determining the antibody binding to these 
tissues the receptor density measurement of EGFr and c-erbB-2 in tissues has been 
measured.
Using multiple sections cut from a cancer cell pellet, binding assays were performed; 
further sections were measured for area then assayed for protein content and measured 
against known cell concentration standards. Thus, for each binding assay; mean section 
area, protein content and cell number were estimated and therefore, receptors per area 
of section could be calculated. To ensure comparable cell lines to those used with 
tumour specimens in this thesis, these experiments, to calculate receptor numbers, had 
been performed just prior to the main body of work on the same cell pellets.
The control tissues used for EGFr and C-erbB-2 concentrations were cell pellets of 
tumour cells grown in tissue culture in which the receptor density has been determined. 
The cell lines used for EGFr are: A431 (2x10® receptors per cell)
BT 20 (1- 4x 10® receptors per cell)
EJ (2x10® receptors per cell)
SKBR3 (< 2 x 104 receptors per cell)
ZR 75 (1 x 104 receptors per cell)
(De Cremoux 1994; Dong 1991; Fitzpatrick 
1984; Long 1992; Stanton 1994)
The cell lines used for c-erbB-2 are: N87 (4.88 x 108 receptors per mm2)
BT 474(5.81 x 108 receptors per mm2)
MD 361 (1.309 x 108 receptors per mm2)
ZR 75(1.09 x 107 receptors per mm2)
MCF 7(2.48 x 108 receptors per mm2)
(Reeves 1995)
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Section iv: Tissue Preparation
Sections were cut from the ceif pellets and tissue blocks. The freshly collected tissue 
specimens which had been frozen in liquid nitrogen were trimmed and placed on the 
freezing block in the cryostat in order to warm the tissue to approximately -30°C. The 
tissue blocks were fixed to cork blocks using Tissue-Tek adhesive and returned to liquid 
nitrogen. The cork was then attached to a cryostat chuck with a drop of water and 
placed in the mount of the cryostat. 5pm sections were cut for immunohistochemistry, 
radio-immunohistochemistry and FISH. They were processed at the same sitting to 
ensure the same area of tumour was compared for all three techniques. Each batch had 
a haematoxylin and eosin stained reference slide. These were used to check the 
presence of tumour on sections and direct to the areas of interest for RIHC and 1HC. 
The H and E slides were checked by Dr. Colin Stewart, Consultant in the Pathology 
Department in Glasgow Royal Infirmary to confirm tumour presence and type.
Slides were stacked together in groups according to experiment with mini-dividers 
between slides to protect the tissue sections. The slides were wrapped in foil to provide 
an airtight package and stored in a -70°C freezer until required. When the sections 
were required the foil packages were removed from the freezer and allowed to warm to 
room temperature to prevent the formation of condensation.
For radio-immunhistochemistry one section was required as a control with two hot 
antibody sections (Figure 15). Each of the sections was ringed with a water repellent 
pen, to contain the reagents when applied to the slides. The slides were fixed in 
acetone for ten minutes and washed in phosphate buffered saline (PBS) for ten minutes 
through three changes of PBS. Having dried around the sections, 100ul of blocking 
serum was applied for forty-five minutes.
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Figure 15
Summary of tissue preparation of the hot and control slides
Each tumour has 3 slides treated identically in all but one step. The control 
slide has a blocking agent of excess antibody to prevent binding of the radio-labelled 
antibody.
o o o
Hot and control sections on slides 
ringed with water repellent pen
After fixation in acetone and washing in 
PBS the blocking agent is applied and the 
radiolabelled antibody
ides are incubated in a humidified chamber for 3 
then washed in PBS and fixed in buffered saline
• o •
• o o
o o •
The slides are taped in an X-ray cassette for 96 hours 
to indicate the time each slide will need to be exposed 
to emulsion
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The blocking serum for the hot sections consists of 50:50 normal rabbit serum to PBS. 
The cold section blocking agent was normal rabbit serum and the appropriate antibody 
at a concentration of one hundred times excess of that for the hot antibody.
After this time 10pl of radiolabelled antibody was added to the section without washing 
off the blocking agents.
Section v: Incubation of slides
After addition of the hot antibody the sections were incubated in humidified chambers for 
3 hours with agitation after half the time had passed. The sections were then washed in 
PBS several times and placed in neutral buffered formalin (50:50 formalin/PBS) for 10 
minutes to fix the antibody molecules cross-linked with receptors. After washes in 
distilled water and air-drying the slides were taped into an x-ray cassette. Having placed 
films on the slides in the dark room the films were developed after 96 hours. The 
autoradiographs were used to indicate the time that each slide needed to be exposed to 
emulsion. For each run of antibody there was a test run using cell pellets and a few 
tumour sections in order to test the iodinated antibody and other reagents.
In the preliminary studies, the length of exposure for each of the cell pellets was 
determined which gave the best separation of silver grains for counting. This was 
reproducible with each cell pellet requiring the same time of exposure. When the tumour 
samples were exposed in the X-ray cassettes with the cell pellets, one could match the 
tumours to cell pellets in terms of density of X-ray image and calculate the optimum 
exposure time for each tumour.
Section vi: Preparation of slides with photographic emulsion
In the dark room using the Kodak number 2 safe light filter all the slides were dipped in 
autoradiographic emulsion. The Kodak NTB-2 emulsion was diluted 1:1 with water at
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43°C and kept at this constant temperature in a water bath. When the emulsion was too 
cold it was too firm to dip the slides and when the temperature was too high there was 
silver grain transformation. The slides were allowed to dry in air and placed in racks. 
These were placed in airtight containers containing silica-gel in order to prevent 
condensation formation. They were stored at 4°C  for varying lengths of exposure as 
determined by the initial autoradiograghs and arranged in groups at times 4, 24, 48, 96 
and 164 hours. The correct exposure time allowed a sufficient density of single grains 
for counting.
After the appropriate interval the slides were allowed to return to room temperature in 
the dark room and were developed by dipping in the D19 developer at a dilution of 1:1 
with distilled water. This had to be maintained at a constant working temperature of 
10°C. In large runs of slides trays of ice were used for this and the temperature 
constantly monitored. The slides were dipped in developer for 4 minutes then placed but 
not agitated in distilled water at 10°C for 1 minute. The slides were then placed in fixer 
at room temperature for 5 minutes and finally washed in distilled water.
The sections were then washed further and placed in Scott's tap water for 1 minute prior 
to counterstaining with 0.1% safranin for 30 seconds. After washing, the slides were 
fixed and mounted ready for counting. A safranin counter stain allowed areas of tumour 
to be identified in the slides and the silver grains were counted within areas of marked 
tumour. This is illustrated in Figure 16.
Section vii: Silver grain counting
The system used to count the grains was a semi-automated counter, the Joyce-Loebl 
MiniMagiScan attached to an Olympus BH-2 microscope. The microscope and counter 
were calibrated to determine the light conditions and appropriate thresholds for 
detection of the grains and the default settings of the system established and stored in 
the programme for each session at the counter. For each slide the magnification was set 
at 40x and the image of the slide captured by the image analysis system to the monitor.
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The control cell pellets were counted as full fields of tumour cells when looking at a high 
power field. In the tumour specimens the area of tumour was identified and marked. 
Filters excluded the effect of the counter-stain and the counter determined the number 
of silver grains in the marked area and noted the area counted. The cold sections were 
used to determine the background activity, which was deducted per unit area. In each 
section this process was repeated for at least ten screens and the data stored in the 
system. Prior to counting the tumour sections, several test runs of cell pellet sections 
were used to ensure the system settings were optimal and the results reproducible.
The automated counting system worked by measuring the optical density of each 
screen pixel in the captured image (the screen was divided into 512 pixels of 2.54 x 10'8 
mm2 horizontally and 512 vertically). The grains were seen as dense objects on a light 
screen with the red filter enhancing the effect by excluding the safranin counter stain 
and at high power the stain and grains were in a different focal plane. The system 
identified each pixel with a density greater than the preset threshold and then divided 
the positive pixels into discreet objects. The number of objects counted was the grain 
count. All touching pixels are counted as one object but since the grains were not all 
focused in the same plane, the number of pixels occupied varies from one to several. 
There was, therefore, an optimum density for counting and it was for this reason that the 
slides had varying exposure times in order to ensure adequate separation of the grains 
such that the system would recognise them as discreet objects.
Calculations of the grains per unit area per hour of exposure were then made for 
tumours and cell pellet controls. The cell pellets used were of known receptor density 
calculated from ligand binding studies. The ratio of receptor to grain density was 
calculated. It had previously been found by graphical expression of the densities that the 
mean of the receptor: grain densities should be used as a conversion factor in order to 
calculate the receptor density in the areas of tumour.
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Section viii: Radioimmunohistochemical reagents and antibodies
a) Antibodies
The ICR12 monoclonal lgG2a antibody was raised to the external domain of the c-erbB- 
2 receptor and was a gift from C. Dean, Institute of Cancer Research, London (Styles 
1990).
The EGFR1 monoclonal antibody was of the lgG2 class and recognised an epitope on 
the external domain of the EGF receptor (Waterfield 1982) and was available from 
hybridomas maintained by Dr.Brad Ozanne, Beatson Oncology Unit, Glasgow.
The anti-rat and anti-mouse immunoglobulins were standard preparations purchased 
from Dako Limited (High Wycombe,UK)
b) lodogen coated tubes (Harlow 1988) from Dr. J. Reeves, University of Glasgow) 
Iodine-125 (Amersham) to iodinate the antibodies as described
c) Autoradiography
Fuji autoradiograph film
NTB-2 (Kodak) autoradiographic emulsion diluted 1:1 with double 
deionised water
D19 Developer (2g Metol,8g Hydroquinone,90g Anhydrous Sodium 
Sulphite,45g Anhydrous Sodium Carbonate and 5g Potassium Bromide per litre 
of distilled water)
Kodak Fixer
Section ix: lodination of Antibodies
lodination of antibody (Harlow 1988) was performed in a hot lab specifically allocated 
for experiments using radioisotopes adhering to the laboratory safety instructions 
regarding handling of radioactive materials. Using iodogen coated tubes, 15ug antibody
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in 125ul PBS and 2.5uL (250uCi) Iodine-125 was placed in the tube and the reactants 
allowed to mix for 5 minutes. The reaction was stopped by adding 875uL 
50%PBS/50%FCS with the dye xylene cyanole to make the total volume to ImL.The 
reactants were then passed through an equilibrated Gel Filtration Sephradex G25 
(Nap10) filtration column with PBS/FCS and the progress monitored using the dye. The 
iodinated antibody which passes through the column more quickly was collected and 
then aliquoted. The iodinated antibody was stored at -20°C in lead pots and defrosted 
only once thereafter. Free iodine should be retained within the column with the xylene 
cyanole. The iodogen tube, hot tops and filtration column were disposed appropriately. 
Aliquots of the radiolabelled antibody were then diluted and placed in scintillation tubes 
and the activity read in the gamma counter. From this the amount of incorporated 
activity was detected per unit volume. It was estimated that around 25% of the label was 
incorporated by this method. The total antibody which was added to each section was 
50ng with an activity of 50,000cpm for c-erbB-2 and 200,000cpm for EGFr. The hot 
antibody was diluted with unlabelled antibody to the required activity and weight per 
volume.
Section x: Method of Ligand Binding
There were two methods of ligand binding studies used with the tumour cell lines. 
C-erbB-2
In developing the quantitative radioimmunohistochemistry for c-erbB-2 expression, 
tumour cell lines N87, BT 474, MDA-MB 361, ZR 75 and MCF 7 were used. Frozen 
cell pellets were prepared and sectioned as in the RIHC studies. The c-erbB-2 antibody, 
ICR 12, was labelled with radiolabelled iodine-125 by the iodogen method. Briefly, 15jj,g 
of antibody in PBS was incubated with 10MBq of 1^ 5| for 5 minutes in the presence of 
50|ig iodogen in a total volume of 125uL.The reaction was stopped using 875uL 50% 
rabbit serum in PBS and the labelled antibody separated from free iodine using a gel 
filtration column.
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Cell pellet sections were rehydrated with 50uL rabbit serum in PBS for 5 minutes and 
radiolabelled antibody added to each section in concentrations of 2pM to 5nM diluted in 
rabbit serum/PBS. The control sections assessed non-specific binding with addition of a 
200 excess of unlabelled antibody. After incubation at 22°C in a humidified chamber for 
4 hours the sections were washed in PBS, dried and solubilised in 0.5% SDS and 
transferred to gamma counting vials for measurement of bound iodinated antibody. The 
binding data was analysed with the LIGAND software programme(Munson 1980).
From each of the binding assays 8 sections were used to measure the area by Imaging 
Research Inc. MCID image analysis system and then the sections dissolved in 0.5M 
NaOH and the protein content measured using the Bio-Rad reagent and method 
(Bradford 1976). From these binding experiments the cell number, mean section area 
and protein content were estimated. This allowed calculation of the receptor number per 
area used in the calculation of the conversion factor for the silver grain count in the 
RIHC experiments.
EGFr
In the binding studies using antibody to EGFr the radiolabelled antibody was prepared in 
the same way as in the RIHC studies above. Cell pellets from the cell lines A431.BT20, 
EJ, SKBR3 and ZR75 were selected and immersed in a buffer solution (Leake 1993) of 
0.01 M K2H P04, 0.01 M KH2P 04) 0.0015M Disodium EDTA, 0.003M NaN3, 0.01 M
monothioglycerol and 10% glycerol (v/v).The specimens were homogenated in the
Ultraturrax at maximum speed and then centrifuged at 500 rpm for 5 minutes at 4°C.
The resulting supernatant of membrane and cytoplasmic elements was further
centrifuged at 15,000 rpm for 30 seconds and the resulting pellet resuspended in 0.02M 
K2H P04, 0.02M KH2P 04j 0.15M NaCI and 70ug /  ml Bacitracin (Koenders 1991).
After protein estimation of the resulting membrane suspension (Bradford 1976), it was 
diluted with buffer to 1.1 mg of protein/ml and aloquated. Radiolabelled antibody was 
added in concentrations from 0.72 to 12nM with an excess of unlabelled antibody in the 
control tubes to a final concentration of 150nM.After incubation at 4°C  for 16 to 20 hours 
HAP slurry (Benradd 1990) (hydroxy apatite powder : Bacitracin containing buffer at a
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ratio of 2:3) was added to each tube and incubated for a further hour. HAP absorbs the 
EGFr protein and therefore separates EGFr bound 125I-EGF from the unbound 125l- 
EGF. The HAP slurry was centrifuged at 800 rpm for 2 minutes and the supernatant 
discarded. After washing the pellet with further buffer and centrifuging at 800 rpm for a 
further 2 minutes the resulting pellet was washed and then placed with the cut tip of the 
eppendorf in to pony vials and into a gamma counter.
The binding data was analysed using the LIGAND programme (Munson 1980).
Section xi: Method of Immunohistochemistry
Tumour sections were cut and stored as described above. Two parallel sections per 
slide for control and antibody testing were used. Each section was initially treated with 
100% acetone for fixation then washed three times in PBS. Slides were then incubated 
with 50% egg white for 30 minutes in order to block endogenous biotin (Reeves 1994). 
They were again washed in PBS and further non specific binding was inhibited with a 
serum blocking solution containing 25% normal human serum, 25% normal rabbit 
serum, 20% biotin with PBS and incubated for 10 minutes. This blocking solution was 
then aspirated and replaced by the antibody and control solutions. For c-erbB-2 the anti- 
c-erbB-2 antibody was diluted and used at a concentration of 1ug/ml and the control 
sections incubated with the control antibody non-immune rat IgG at the same 
concentration. The anti-EGFR and control antibody, lgG2b were also used at a 
concentration of 1ug/ml. After two hours of incubation in humidified chambers the 
sections were washed carefully with PBS, ensuring that there was no spillage of 
antibody onto control slides. The sections were then incubated with the secondary 
antibody for thirty minutes being biotinylated anti-rat immunoglobulin for c-erbB-2 and 
anti-mouse for EGFR. The dilution was 1 in 400. Sections were again washed in PBS 
and the streptavidin biotinylated peroxidase complex added to the sections for thirty 
minutes. Following washing in PBS the peroxidase signal was developed using a 10 
minute exposure to Nickel DAB. This produced a black precipitate and the slides were
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counter-stained by red staining safranin at a dilution of 0.1%.The slides were then 
dehydrated and mounted.
Immunohistochemistry scoring
The scoring system used for the immunohistochemistry was developed in order to 
achieve a more structured and reproduceable method of describing 
immunohistochemical staining rather than simply positive or negative. In each section 
the area of tumour was identified. Within the tumour area, the level of staining was 
graded as 1,2 or 3 with 3 being the most intense and the percentage of area stained at 
each intensity was noted. The percentage was then multiplied by the grade and the 
three scores added together. The maximum score being 100% at grade 3 equalling 
300.The tumours were all scored in this way and a random selection scored by a 
second observer to assess inter-observer variability. A high scoring section is 
demonstrated in Figure 17.
Section xii: Immunohistochemistry reagents and antibodies 
a) Antibodies
EGFR1 and ICR12 as described previously
b) Blocking solutions
i)Egg White (50:50 egg white and PBS mixed and spun at 2000rpm to
remove albumin)
ii)Rabbit and Foetal Calf serum (purchased from Sigma) Human Serum 
prepared in our laboratory.
iii)Biotin solution (20mg biotin dissolved in 1ml Dimethyl sulphoxide with 19mls 
PBS added and sodium azide to 0.05%)
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c) Streptavidin biotin peroxidase complex prepared as for the avidin-biotin 
peroxidase complex described by Hsu et el (1981) except that N-biotinyl-e-aminocaproic 
acid N-hydroxysuccinimide ester incorporating a spacer arm was used as the 
biotinylating reagent.
d )  Nickel DAB( 0.07% NiCI 2 6H 20 , 0.025% diaminobenzidine tetrahydrochloride and 
0.01%H202).
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Section xiii: Method of Fluorescence in-situ hybridisation (FISH)
FISH is a technique which uses specific proto-oncogene sequences as probes to enable 
the detection of the amplified copy number on a cell by cell basis. The labelled probes 
are detected by a complex of antibodies immunostained with a fluorescent. 
Overexpression of c-erbB-2 in tumour cells may be related to changes in the regulation 
of gene transcription but the most common method is amplification of the c-erbB-2 gene 
on chromosome 17q12-21.32. Most publications have measured gene amplification by 
Southern blot hybridisation but although valuable in providing information about genetic 
alterations which underlie the development of solid tumours there are disadvantages. 
The spatial relationship between cells is destroyed and there is contamination of the 
DNA analysis by non-specific cells such as non-malignant or stromal cells during the 
preparation. The recently introduced technique of fluorescence in situ hybridisation 
(FISH) allows the detection of the amplified copy number for each cell but preserving the 
spatial relationship of the cells (Gray 1992). This provides information on amplification 
which can be correlated with histological information and immunostaining. FISH is 
therefore ideal to investigate the heterogeneity and histological pattern of c-erbB-2 in 
gastric cancer.
During the time of the experimental work for this thesis, FISH was a recently developed 
concept. The protocol which is detailed below was developed by Dr. Nicol Keith at the 
Beatson Research Laboratories, University of Glasgow and under his close direction I 
analysed the gastric cancer specimens and together analysed the images to determine 
those which were amplified for c-erbB-2.
Sections of gastric tumour which had been cut with those for IHC and RIHC were 
removed from the -30°C freezer, allowed to come to room temperature and removed 
from the air tight packaging. The sections were digested with pepsin (0.02% pepsin in 
10mM hydrochloric acid.) for ten minutes at 37°C then washed five times in distilled
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water followed by five washes of PBS (Hopman 1992) They were fixed in Streck tissue 
fixative (Streck Laboratories Inc. Omaha N.E.) and dehydrated with ethanol.
Using 70% formamide in 2xSSC sections were denatured at 75°C  for three minutes, 
using the Omnislide modular system (Hybaid,UK).The erbB-2 sequences were probed 
with a commercial erbB-2 probe (Oncor,Gaithesburg,M.D.) and hybridisation was 
carried out overnight at 37°C. After hybridisation the slides were washed in 50% 
formamide, 1xSSC at 42°C for 20 minutes and in 2xSSC for 20 minutes. Prior to 
immunocytochemical detection (Kallioniemi 1992) the slides were blocked in 4xSSC-TB 
(4xSSC 0.05% Tween and 0.5% Boehringer blocking agent) for 30 minutes.
For two colour FISH the first detection layer consisted of FITC-avidin (Vector,Ca) in 4x 
SSC-TB for 45 minutes at room temperature then washed in 4xSSC-t for 10 minutes 
and transferred to PN buffer.(PN=0.1M NaH2P04  and 0.1 M Na2HPC>4 at pH8 with
0.05% Tween with PN-B containing 0.5% Boehringer blocking agent)
The second detection layer consisted of biotinylated anti-avidin D (Vector) and sheep 
anti-digoxigenin in PN-B for 45 minutes. After further washing in PN buffer the third 
detection layer of FITC-avidin and anti-sheep Cy5 in PN-B for 45 minutes. After further 
PN washes the slides were counterstained with propidium iodide (0.4ug/ml) and 
mounted in anti-fade medium (Vectashield,Vector).
Fluorescence was analysed on Bio-rad (Richmond,C.A.) MRC-600 laser scanning 
confocal microscope equipped with krypton argon laser. Images were processed using 
edge enhancement algorithms to aid definition of nuclear boundaries and hybridisation 
sites. Images were merged using Comos and Nexus software (Bio-Rad) and optimal 
colour balance of the pseudo colour images was achieved using image processing 
software (Photomagic,Micrografx.Arapaho Richardson,Texas,USA). Final figures were 
annotated in, and directly printed from Micrografx Draw (Micrografx) using a dye 
sublimation printer (Colour Ease, Kodak, Harrow, UK)(Murphy 1995).
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Method of Proliferation studies and Western Blotting using IGF-1 
Section i: Tissue Culture
Cell cultures of primary gastric adenocarcinoma cell lines were used in the proliferation
studies and in the biochemical analysis using Western bfottfng. The cell lines were
MKN45 (ATCC), a poorly differentiated adenocarcinoma cell line with known
overexpression of EGFr (Ochai 1988) and N87 ( kindly provided by Richter King), an
adenocarcinoma cell line which is known to overexpress c-erbB-2. The cell lines were
routinely cultured in the growth medium RPMl 1640 (Gibco BRL) containing 10% heat
inactivated foetal calf serum and supplemented with 2mM L-glutamrne, 100U penicillin
and IQQug streptomycin/ ml. They were incubated at 37°C in an atmosphere of 5%  
C 0 2 and were routinely tested and throughout the period of study remained negative for
mycoplasma contamination.
Section II: Cell growth determination
Cells were plated in 24 well plates at a density of 2.5 to 5.0 x 10^ for MKN45 and 3.0 to 
4.0 x 104 for N87. These were determined after initial experiments had used a range of 
plating densities from 2.0 to 5.0 x 104 and the cell numbers were counted for up to ten 
days. The cel! plating density was varied over time depending on the growth of the 
cultured cells in check proliferation studies in non-drug containing medium.
After twenty four hours the medium in each well was removed- and the wells washed 
twice with PBS ( phosphate buffered saline) The medium was replaced with RPMt 1640 
supplemented as before but free of foetal calf serum. Cells were supplemented with 
10nM hydrocortisone, 10ug/ml transferrin and 30nM sodium selenite (HTS). Initially the 
medium was compared to cells grown in medium also containing insulin 5ug/ml {HITS) 
to show there was inhibition of growth in the insulin free group but that adequate growth
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was clearly seen. The insulin supplemented medium was also used to compare growth 
of cells in this medium with those supplemented by IGF-I.
After the cells were incubated for a further twenty four hours the medium was changed 
and this was defined as day zero. The culture medium was changed every two days and 
the selected plates were prepared for counting. On the day of counting the cells were 
washed with two washes of PBS and incubated with 0.025% trypsin in 0.02M EDTA. An 
aliquot was taken and diluted in 0.9% sterile saline and the cells counted using a ZM1 
electronic cell counter( Coulter Electronics).
Cells were incubated in serum free medium containing IGF-I ( Santa Cruz Biotechnology 
Inc. California) at concentrations of 0.1 nm to 100nM.The optimum concentration for 
subsequent experiments was found to be 10nM and this was used in the inhibitory drug 
studies.
The inhibitory drug used was RG13022 which is a tyrophostin. These compounds were 
developed to specifically inhibit EGFr tyrosine kinase (Yaish 1988) and in particular 
EGFr autophosphorylation (Reddy 1992). RG13022 had been shown to have a 
cytostatic and reversible inhibition of the growth of breast cancer cell growth (Reddy 
1992), squamous cell carcinoma in nude mice (Yoneda 1991) and pancreatic cell 
growth (Gillespie 1993). In the human gastric cancer AGS cell line, RG13022 produced 
an antiproliferative effect and a reversible dose dependent antiproliferative effect on 
MKN45 and N87 cells stimulated with EGF as previously observed in our laboratory 
(McLaughlin 1995). As yet there have been no experiments to determine the activity of 
the tyrophostins with cells stimulated by IGF-I. To examine the effect of RG13022 a 
stock solution of 40nM was prepared in dimethyl sulphoxide and added to culture media 
(0.1%v/v) on day 0 and thereafter at two day intervals. DMSO was added to all control 
wells (0.1% v/v).
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Western Blotting 
Section iii: Cell Harvesting
In the preparation of cell lysates for Western blotting the cells were grown to 70% 
confluence in 25cm2 flasks with RPMl 1640 with 5% foetal calf serum and 
supplemented as in the medium for cell proliferation. After 24 hours cells were washed 
twice with PBS and the medium changed to the serum free medium as previously 
described. After incubation for a further 24 hours in serum free medium to ensure there 
was no residual effect of serum growth factors, drug and IGF-I were added to the flasks. 
From the proliferation studies it was evident that the optimum concentration of IGF-I for 
growth in culture of these cell lines was 10nM.Of the twelve flasks used in each 
experiment RG13022 (in 0.1% DMSO) was added to 4 flasks at a concentration of 
100uM and to 4 flasks at a concentration of 10uM with corresponding controls using 
DMSO 0.1%. After 24 hours incubation the medium was removed, the cells washed in 
PBS and the medium replaced with the drug containing medium with the addition of 
10nM IGF-I to 6 flasks each with a control flask. The cells were harvested after a further 
incubation of 5 minutes for N87 and 10 minutes for MKN45.
Medium was removed and the cells washed with chilled PBS and 400uL of lysis buffer
added ( 50mM Hepes pH 7.4, 1% Triton X-100, 150mM NaCI, 5mM EGTA, 100ug/ml
PMSF, 10ug/ml aprotonin, 100ug/ml benzamidine, 5ug/ml leupeptin and 100um 
Na3V04 ).Cells were harvested with a cell scraper and transferred to 1.5ml eppendorfs
which were rotated in the cold room for 20 minutes. After centrifugation at 15,000 g for 
10 minutes at 4°C, the supernatant was removed, aliquoted and stored at -70°C.
Protein concentration within the cell lysates was determined using the BioRad dye 
reagent method and 75 ug protein used in the protein blotting for both cell lines.
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The N87 and MKN45 cell lysates were denatured by boiling for 4 minutes in an equal
volume of Laemmli buffer (0.125 M TrisCI pH 6.7, 2% SDS, 10% glycerol, 2.5%
mercaptoethanol) with the samples made to an equal volume with lysis buffer.
The SDS-PAGE gels were prepared with a 4% stacker (30% acrylamide /0.8 
bisacrylamide solution, d ^ O , Ammonium persulphate, TEMED, 50% glycerol and
stacker buffer-0.5M Tris/HCI pH 6.7 and SDS in solutions of 0.4% and 10%) and a 10% 
resolving gel (30% acrylamide solution / 0.8 bisacrylamide , d ^ O , Ammonium
persulphate, TEMED, 50% glycerol and resolving buffer - 1 .5M Tris/HCI pH 8.9 and SDS 
in solutions of 0.4% and 10%).
After removing the stacking comb the wells were washed with running buffer and the 
proteins loaded and run through the stacker at 30mA and through the resolver at 10mA 
overnight. BioRad molecular weight markers were run with the protein lysates.
Section iv: Blotting
The proteins were transferred to PVDF membranes. They were soaked in methanol for 
1 minute and then washed in distilled water for 5 to 10 minutes and then soaked in 
transfer buffer ( 48mM Tris, 39mM glycine, 0.037% SDS) for 20 minutes. After removing 
the gel from the plates it was placed in transfer buffer for 20 minutes. Six sheets of 
Whatman 3M paper were soaked in transfer buffer. The gel was placed on 3 sheets 
followed by the membrane and a further 3 sheets of filter paper. This complex of gel and 
membrane was placed in a BioRad SemiDry blotting apparatus and transfer of proteins 
performed at 13V over 90 minutes. Coomassie staining of the protein remnants on the 
gels thereafter allowed inspection of protein loading.
Section v: Protein detection
Each of the membranes used with antibody to the IGF-I receptor were blocked in a 
solution of 5% Marvel in TTBS (0.1 M Tris/HCI pH 7.4, 1.5M NaCI, Tween 20 ) overnight
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at 4°C. When using antibodies to IRS-1 the membranes were blocked overnight in 1% 
bovine serum albumin for the monoclonal antibody and in 5% marvel / TTBS for the 
polyclonal antibody. With the antiphosphotyrosine antibody (Py54) membranes were 
blocked overnight in a solution of 5% ovalbumin with 10% normal sheep serum.
Using the IGF-I receptor antibody at a dilution of 1 in 250 in 5% Marvel / TTBS the 
membranes were incubated in a hybridisation chamber at 26°C  for 1.5 hours. After 
washing three times with TTBS the membranes were incubated with the secondary 
antibody, a peroxidase linked anti-mouse antibody at a dilution of 1 in 1000 in 5% 
Marvel / TTBS for a further 1 hour. The excess was drained and the membranes placed 
in a dry tray where ECL solution was added and the membrane covered in the solution 
for one minute. Excess ECL was drained on 3M paper and the membranes wrapped in 
Saran-wrap before exposure to Fuji film for varying times from 10 seconds to 20 
minutes.
When using the antiphosphotyrosine antibody the membranes were incubated with 
antibody at a dilution of 1 in 10,000 in the blocking solution for 1.5 hours and then 
incubated in a secondary antibody of anti-mouse antibody in 5% Marvel /  TTBS for a 
further hour.
For the monoclonal antibody to IRS-1 the membranes were incubated in antibody at a 
dilution of 1 in 2500 in 1% B.S.A. for 2 hours and in secondary anti-mouse antibody at a 
dilution of 1 in 1000 for 1 hour. With the polyclonal antibody the membranes were 
incubated in antibody at a dilution of 1 in 2500 in 5% Marvel /  TTBS for 2 hours then in 
anti-rabbit antibody at a dilution of 1 in 1000 in 5% Marvel / TTBS for 1 hour.
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Results of analysis of c-erbB-2 and EGFr
In this section, I present the results of EGFr and c-erbB-2 measurement. The details of a 
quantitative analysis using radioimmunohistochemistry in tumours are compared with 
normal gastric mucosa and to tissue sections from the same patients examined by 
conventional immunohistochemistry and FISH. Using the clinico-pathological information 
detailed below a comparison will be made of receptor density with recognised 
prognostic factors.
Of seventy five tumours which were originally studied, the results from sixty seven were 
used in the final analysis. The other specimens were rejected on pathological grounds, 
as unsuitable. One group comprised of combination histology (adenosquamous), 
lymphoma and tumours in which the pathology on review suggested a lower 
oesophageal rather than gastric primary site.
Section i: Descriptive data of population
In predicting the outcome for patients with gastric cancer there are a number of clinico- 
pathological factors which have been used in clinical studies (Harrison 1995). Within the 
sample population, information on several of these indicators is available and a 
summary of the incidence of these is shown in Table 12 and the details in Appendix B 
(Table 3).
Age of patients
Age distribution is shown in Figure 18. The commonest age at presentation was within 
the 65-74 age group in agreement with the peak age of the hospital and population 
based studies previously described. The total ages range from 44 to 83 years with a 
median of 68 ( IQ=59-72) and a male to female ratio of 2.5:1.
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Males generally present at a younger age with a range of 44 to 83 years but a median 
of 64 (IQ=55-69) compared to females a range (52-83 years) with a median of 72 
(IQ=68-80).
Figure 18 Age and sex distribution of patients
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Age of patient
Location of tumour
□  Male 
9  Female
The site of origin for each tumour was determined from the operative and pathology 
notes with 34%(23) of the samples from tumours of the cardia and fundus, 43%(29) 
from the body of the stomach and 22%(15) antral tumours. Although the antrum is still 
considered to be the most common site of presentation, the recent rise in proximal 
gastric tumours is reflected in this distribution. The tertiary referral practice of the 
hospital also accounts for higher proximal tumour numbers.
Differentiation of tumours
Tumours were classified using the standard description of well, moderately well and 
poorly differentiated adenocarcinomas ( Broders 1926 classification). Although many of 
the tumours were also classified using the Lauren (1965) classification into intestinal,
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diffuse or mixed; this was not universal and therefore unsuitable for use in subsequent 
analyses. There were 7.5%(6) well differentiated tumours, 25%(17) moderately well 
differentiated (total of well/moderately well=33%) and 67%(45) poorly differentiated.
Serosal Involvement
Of the tumours studied 92.5%(62) involved the serosa of the stomach and 7.5%(5) did 
not invade as far through the gastric wall.
Nodal involvement
In the majority of specimens, nodal involvement was determined as the number of 
nodes present and those which were positive. During the period of study the majority of 
surgeons did not practice extended lymph node dissections or marked nodal stations as 
is the more common practice now and certainly within Japanese studies. In the 
pathological descriptions, therefore, the position of positive nodes cannot be determined 
(as in the Japanese research classification) but in many cases the percentage of 
positive nodes is available and the level of nodal involvement by tumour is shown both 
as a percentage of nodes and simply the number with positive nodes. Of the 67 tumours 
25%(17) had no nodes involved and 75%(50) with positive nodes of which 33%(22) had 
less than 50% and 34%(23) with more than 50%.In 7.5%(5) cases the percentage was 
unknown.
Liver metastases
Of 11 patients with metastatic disease, 3 had liver metastases at presentation and a 
further 8 patients developed liver metastases in the period of follow-up.
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Clinico-pathological prognostic factors in gastric cancer
Table 12
No. (%)
Serosal involvement positive 62 (92.5)
n=67 negative 5 (7.5)
nodal involvement positive 51 (77.3)
n=66 negative 15 (22.7)
% nodal involvement 0 17 (27.4)
n=62 <50 24 (38.7)
>50 21 (33.8)
histological grade well 5 (7.5)
n=67 moderate 17 (25.4)
poor 45 (67.2)
well/moderate 22 (32.8)
tumour site cardia 24 (35.8)
n=67 body 29 (43.3)
antrum 14 (20.9)
liver metastases positive 11 (16.4)
n=67 negative 56 (83.6)
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Section ii: Calculation of receptor density
EGFr and C-erbB-2 receptor density estimations were made on these tumours using 
radioimmunohistochemistry and compared with conventional immunohistochemical 
scoring.
Quantitative estimation of c-erbB-2 receptor density by 
radioimmunohistochemistry
In RIHC the radiolabelled antibody binds in competition with unlabelled antibody to the 
receptor. Overnight autoradiography is carried out to determine the activity level in each 
section which is demonstrated on X-ray films with the darkest exposure correlating with 
the highest activity. This information determines the length of time that each slide should 
by exposed to photographic emulsion in order to produce a density of single silver 
grains optimal for image analysis. Using the information from exposure of cell pellets 
with varying receptor and therefore silver grain densities, the activity in tumour slides is 
compared to cell pellet slides and the time calculated.
When all the slides have been examined and counted there was a grain count for two 
hot slides and one control slide for each tumour section and cell pellet. The area which 
has been counted in each slide was calculated by the computer assisted counting 
system whilst counting the silver grains in a particular area. In addition, the length of 
time of exposure and a number corresponding to the RUN or group of cell pellets 
examined with that batch of tumour was recorded. It was possible to calculate the grain 
density for each section by taking the average count in the hot slides and subtracting the 
grain count from the control slide to exclude background activity. Thereafter, the count 
was converted to number of grains per area counted and per hour as determined by 
exposure time.
Standardisation of results for each set of test sections is achieved by concomitant 
running of sections of cell pellets. These are formed from cell lines with known receptor
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densities determined by ligand binding studies (Figures 19 and Table 13). Using RIHC, 
a grain count per area per unit time was calculated for each cell line and for each 
tumour. When one excludes the highest and lowest expressing pellets in the set of cell 
pellets which were run with each tumour batch, the ratio of receptor number over grain 
count per unit area by RIHC produces a linear graphical relationship. By incorporating 
this scale into each tumour batch and with the receptor number in each cell line known, 
it is possible to determine the number of receptors in terms of silver grains per unit area 
per hour of emulsion exposure. A conversion factor for receptor number per unit area is 
calculated by averaging the ratios for cell pellets. This is applied to grain counts for the 
tumour biopsies in the same batch and allows calculation of receptor numbers.
In Appendix B (Table 1) the grain counts for each of the tumours is shown with the 
corresponding control slide and the area of each tumour section. The exposure time is 
also shown to calculate the grain count per area per hour. The group or run in which 
each tumour was incubated is identified in order to match the cell pellet counts used to 
convert the raw counts to receptor number. In each of the three runs of staining by 
RIHC, the five cell pellets were assayed simultaneously with the tumours.
Table 13 Results of c-erbB-2 ligand binding analysis on sections
receptors / cell receptor /ug protein receptors/mm2
(x10 ) (x10 ) (x10 )
N 87 4390 9480 4880
BT474 725 1036 581
MDA-MB-361 35.7 160 131
ZR 75 7.48 16.9 10.9
MCF 7 1.33 3.5 2.48
(Reeves 1996)
The receptor density in this table has been calculated from ligand binding studies for the 
cell lines which have been used in the RIHC experiments. Figure 19 shows the linear 
relationship of the receptor density for the cell lines particularly BT474, MDA-MB-361 
and ZR 75 which are used to calculate the converting factor.
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Figure 19 Receptor numbers from ligand binding studies
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Table 14 Grain count per mm2 per hour for cell pellets in each run
Cell lines Count per mm2 per hour Variance
Mean Standard 95% Cl 
Deviation
RUN I RUN 2 RUN 3
N87 35.17 45.9 37.94
BT 474 15.53 27.4 21.8
MDA MB 361 2.65 2.73 1.59
ZR 75 0.63 0.22 0.104
MCF 7 0.04 0.02 0.035
39.7 5.57 25.8-53.5
21.6 5.94 6.8-36.3
2.3 0.63 0.7-3.9
0.32 0.28 -0.37-1
0.03 0.0104 0.00581-0.0575
The grain count per mm2 per hour for the cell lines is shown in Table 14 for the three 
batches of tumour specimens which were used. Each tumour specimen is numbered to 
correspond to a ‘RUN’ of cell lines.
In Figure 20 the linear relationship of the grain count for each cell line is similar to the 
receptor density count from the ligand binding studies and is consistently found in Runs 
2 and 3 ( detailed in Appendix B, Figures 1 and 2,Table 4).
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Figure 20 Grain count ( x102 )/mm2/hour for each of the cell lines in
RUN 1
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Calculation of converting factor
The ratio of receptor number in each cell line to grain count /area/time for the three 
middle points was calculated as shown. The mean of the three ratios was used to 
convert the grain count for each tumour sample to a receptor number. The calculation 
for RUN 1 is shown (the calculations of the converting factors for the runs 2 and 3 are 
found in the Appendix B.
RUN1
BT474 receptor number / (grains/mm^hour) = 5.81 x 108 / 1553 = 374115 
MDA MB 361 receptor number / (grains/mm2/,hour) = 1.309 x 108 / 265 = 493963 
ZR 75 receptor number / (grains/mm^hour) = 1.09 x 107 / 63 = 173016 
MEAN = 347031
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Quantitative estimation of c-erbB-2 receptor density by 
radioimmunohistochemistry
The distribution of receptor numbers for c-erbB-2 is shown in Figure 21. The range of 
values is from 0 to 3.641 x 109 with a median of 8.5 x 106 ( IQ = 2.9 to 23.5 x 106 ) and 
for ease of interpretation, the distribution has been shown graphically as a logarithmic 
transformation of the results.
Figure 21 Log10 c-erbB-2 receptor number (x106)
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T h e  histogram  shows num ber of patients on the y-axis and num ber of receptors (x 1 0 6) per cell on 
the x-axis
The mean of the receptor number was calculated for the samples of normal mucosa 
which were analysed. The grain counts are found in Appendix B (Table 4). The 
specimens had grain counts of 0,7.9,15.7 and 21.6 from a selection including those in 
which the tumours expressed the highest count and a sample of intermediate and low 
counts. Using the converting factor from that run (712620) the receptor numbers were 
calculated and the results were 0,5.63 x106,11.2 x109 and 15.4 x10®.The mean was 
8.03 x106. In this group of tumours 15/67 (22.4%) of tumours expressed c-erbB-2 at a 
level higher than the range of mucosal values.
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Estimation of EGFr expression
In studies using immunohistochemistry to analyse the expression of EGFr, early 
experiments demonstrated the high density of receptor expression in the vulval 
epidermoid cell line A 431 and EGFr expression has tended to be shown in many 
subsequent studies as a percentage of the expression in samples of A 431 cell pellets 
run with the tumour samples.
In the preceding studies of receptor density of c-erbB-2 a quantitative assessment of 
expression was made using grain counts in a series of tumour cell line pellets 
correlated with receptor density from ligand binding studies. In the expression of EGFr 
there is a narrow spread of distribution of receptor density in the tumour population and 
tumour cell lines. Ligand binding studies to determine EGFr expression in a series of 
cell pellets were performed in conjunction with the radioimmunohistochemistry (Figure 
22). The RIHC results are detailed in Table 2 in Appendix B and ligand binding data in 
Table 5.
Figure 22 Graph of grain count I mm2 / hour for runs 1,2 and 3 displayed with 
the results of ligand binding studies
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These results show that the technique of radioimmunohistochemistry gives a 
quantitative measure of receptor density of EGFr corroborated by ligand binding studies.
However, in view of the narrow distribution of cell line density we elected to express the
receptor density of EGFr in the conventional method, as a percentage of the EGFr 
density found in A 431 cell pellets.
The distribution of EGFr is demonstrated (Figure 23) with a median of 0.9% ( IQ = 0.5 to 
1.6% ) and a range of 0 to 106%.
Figure 23 EGFr receptor density as a % of A431 cell line
Frequency
EGFR receptor density excluding outlying values
30 - i
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A 1
------------------ 1--------------------------r
5 10
EGFR receptor density °/<A 431
The histogram shows the number of patients on the y-axis and the EGFr density as a percentage of A431 cells 
on the x-axis with the exception of one outlying value at 106%. This was excluded and the distribution not log 
transformed to illustrate the apparent bimodal distribution of receptor density values but with these numbers 
may simply be the effect of outliers.
There were 90% of the patients in the first group, 7% in the second group and 3% of 
outliers.
In the samples of mucosa which were analysed for EGFr expression (Appendix B, Table 
4) the level as a % of A431 cells was 0.3%,1.3%, 1.6% and 0.7% with a mean of 
0.975%. Using RIHC, 22.4% of tumours expressed EGFr at a level higher than the 
mucosal range.
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Comparison of c-erbB-2 and EGFr expression using radioimmunohistochemistry 
and immunohistochemistry
When the receptor number determined by radioimmunohistochemistry was compared to 
the scoring of slides using conventional immunohistochemistry the spread of results 
appears similar but some variable areas will be examined.
The expression of c-erbB-2 using immunohistochemistry and the scoring system 
described (Figure 24) shows a median level of 90 ( IQ = 60 - 120) and a mucosal range 
of 0 -90 with a mean of 52.5.
Figure 24 Distribution of C-erbB-2 expression using immunohistochemistry
C-erbB-2 immunohistochemistry scores
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The histoscore on the x-axis is derived from the intensity of staining (grade 1-3) multiplied by the area as a 
percentage (0-100%)
The expression of EGFr using immunohistochemistry (Figure 25) shows a median of 
100 ( IQ = 70 - 125) and a mucosal range of 40-105 with a mean of 76.25
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Figure 25 Distribution of EGFr expression using immunohistochemistry
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Those tumours which express intermediate to high levels of receptor in particular in the 
case of c-erbB-2 are gathered together at the same IHC score 300 rather than the wide 
range exposed on RIHC (1.25 x 108 to 3.61 x 109)
Using immunohistochemistry to examine EGFr the highest scores were of 300, 295 and 
290 but using RIHC the same tumours differed in level of expression from 106%, 10.1% 
and 4.6%.
Using IHC in c-erbB-2, 29/67 (43.3%) of tumours expressed levels of receptor more 
than the range of the mucosal samples.
In samples tested for EGFr, 28/67 (41.8%) expressed levels above that of the mucosal 
sample range.
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C-erbB-2 gene amplification using FISH
The tumours which showed c-erbB-2 amplification (Appendix B, Table 3) are displayed 
as the shaded area on Figure 26 displaying the relationship with c-erbB-2 expression 
using RIHC.
Figure 26 C-erbB-2 amplification as compared with receptor density ( x 106)
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The histogram shows the log transformed distribution of c-erbB-2 expression from RIHC with the shaded areas 
representing those tumours in which c-erbB-2 gene amplification has been detected by FISH.
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Section iii: Relationship between c-erbB-2, EGFr expression 
and clinico-pathological factors
Statistical analysis of C-erbB-2, EGFr expression and pathological prognostic factors 
was performed using the Minitab for Windows 9.2 software © 1993 Minitab Inc. with the 
Kruskal-Wallis and the Mann-Whitney analysis for non-parametric data.
Life tables and Kaplan-Meier analysis were used to examine the relationship between 
these factors and survival using SPSS for Windows 6.1.3.©SPSS Inc. 1989-1995. 
(Tables 15 and 16).
Tumour grade was expressed as well differentiated, moderately well differentiated and 
poorly differentiated according to Broders classification (1934). The well and moderately 
well group of tumours were further analysed as a group to provide comparable analysis 
to the differentiated and undifferentiated description of tumours in some studies.
For nodal status, receptor density is related to the presence of any positive nodes with a 
separate analysis of nodal status as a proportion of the number of nodes sampled. In 
the introduction to this thesis, data from an audit of the patients from our institution 
showed a statistically significant relationship to survival with more than 50% of nodes 
involved. Recent changes to the TNM classification of Gastric Cancer also include this 
information.
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Table 15 C-erbB-2 expression
number of patients median c-erbB-2 expression
Tumour differentiation
well 5 40
moderately well 17 17.4 h=6.99,d.f.=2 f
poor 45 7.48
well/moderately well 22 19.35 h=6.99,d.f.=1 p
poor 45 7.48
Serosal involvement
negative 5 26.2
positive 62 7.91 h=3.38,d.f.=1 [
Location of tumour
cardia 23 13.3
body 29 7.28
antrum 15 10.1 h=2.31,d.f.=2 |
i=0.031
=0.008
i=0.066
=0.316
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C-erbB-2
number of patients median c-erbB-2 expression
Nodal involvement (%)
0 17 11.8
<50 positive nodes 22 7.69
>50 positive nodes 23 7.64
unknown 5
h=0.11,d.f.=2 f
Nodal involvement
positive 17 11.8
negative 50 7.91
h=0.06,d.f.=1 F
Liver metastases
At presentation
no 64 8.245
yes 3 10.1
h=0.37,d.f.=1 p
Liver metastases
At any time
no 52 7.735
yes 12 18.4
no follow-up 3
h=1.37,d.f.=1 |
1=0.945
•=0.807
=0.544
1=0.242
116
Chapter 9
Table 16 EGFr expression
number of patients
Tumour differentiation
well 5
moderately well 17
poor 45
well/moderately well 22
poor 45
Serosal involvement
negative 5
positive 62
Location of tumour
cardia 23
body 29
antrum 15
median EGFr expression 
(%A 431)
0.9 h=4.06,d.f.=2 p=0.132
1.5 h=4.08,d.f.=2 p=0.130
0.7 (adjusted for ties)
1.0 h=3.08,d.f.=1 p=0.07
0.7 h=3.10,d.f.=1 p=0.079
(adjusted for ties)
0.9 h=0.16,d.f.=1 p=0.683
0.85 h=0.17,d.f.=1 p=0.684
(adjusted for ties)
0.9
0.7
1.0 h=2.05,d.f.=2 p=0.3
h=2.06,d.f.=2 p=0.358
(adjusted for ties)
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EGFr expression
number of patients median EGFr expression
(%A 431)
Nodal involvement
negative
positive
17
50
0.9
0.8 h=0.03,d.f.=1 p=0.857
Nodal involvement(%)
0
<50 positive nodes 
>50 positive nodes 
unknown
Liver metastases
At presentation
no
yes
At any time
no
yes
no follow-up
17
22
23
64
3
52
12
3
0.9
1.0
0.7
0.9
0.7
h=1.76,d.f.=2 p=0.415 
h=1.77,d.f.=2 p=0.413 
(adjusted for ties)
h=0.14,d.f.=1p=0.39 
h=0.14,d.f.=1 p=0.704 
(adjusted for ties)
0.9
0.7 h=0.74,d.f.=1 p=0.39 
h=0.74,d.f.=1 p=0.388
(adjusted for ties)
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Relationship between c-erbB-2 and survival
The patients in this study were followed for a period of 36 months. Survival in months 
and the status regarding death is detailed in Table 3, Appendix B. Life table analysis of 
the relationship between survival and c-erbB-2, EGFr and c-erbB-2 amplification is 
shown.
The level of expression of c-erbB-2 and EGFr have been grouped as low and high. This 
relates to the level of density (determined by radioimmunohistochemistry in this series) 
and grouped according to published series which suggest expression is high in 20 to 
30% of tumours. Survival in those tumours expressing each receptor in the upper third 
of the range is compared to survival in the remainder of the tumours.
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Figure 2 7  Kaplan-M eier analysis of the relationship between c-erbB-2 and survival
Kaplan-Meier statistic =1.16
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Survival is indicated on the y-axis, the scale shows the proportion of patients rem aining alive at the  
follow-up tim e indicated, in m onths on the x-axis. The  c -erb B -2  level is divided into 2 groups  
determ ined by c -e rb B -2  expression.
There is a trend towards better survival in the group of patients expressing the highest 
level of c-erbB-2. This does not reach statistical significance.
Survival in this and subsequent analyses were not analysed for disease specific and 
non-specific deaths. Only 3% of deaths were considered to be unrelated to gastric 
cancer all of which expressed levels of EGFr and c-erbB-2 in the moderate range.
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Figure 28 Kaplan-Meier analysis of the relationship between EGFr and survival
K aplan-M eier statistic =  0.2
p = 0.655
I>v_  1_ L - High EGFR
Low EGFR
0.0
200 10 30 40
Months
Survival is indicated on the y-axis, the scale shows the proportion of patients rem aining alive at the 
follow-up tim e indicated, in m onths on the x-axis. Th e  E G F r level is divided into 2 groups  
determ ined by E G F r expression.
Using two groups there was no statistically significant separation of the survival curves.
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Figure 29 Kaplan-Meier analysis of the relationship between c-erbB-2 gene 
amplification and survival
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K aplan-M eier statistic =0.01  
d.f. =1 
p = 0.941
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Unamplified
30 40
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Survival is indicated on the y-axis, the scale shows the proportion of patients rem aining alive at the  
follow-up tim e indicated, in m onths on the x-axis. Th e  patients are divided into groups determ ined  
by the presence of c -erbB -2  am plification.
There was no statistically significant separation of the survival curves between amplified 
and unamplified cases.
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Gastric cancer cell stimulation with IGF-I and the effect of 
the tyrophostin RG13022.
Section i: Cell growth in serum free medium
In the experiments using IGF stimulation it was vital that the cells were observed to be 
growing adequately in serum-free and in particular, in insulin free medium, in order to 
detect stimulation with exogenous IGF-I. Serum-free medium was also required to 
remove the influence of IGF binding proteins contained in serum.
The results in Figures 30 and 31 and data sheet 1 in the Appendix C demonstrate that 
there was adequate sustained growth in both cell lines in serum free medium.
Figure 30
Growth of MKN45 cells in serum free medium
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Figure 31
Growth of N87 cells in serum free medium
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In the MKN45 cells there is also growth relatively independent of culture medium but 
the rate of growth is slowed considerably after day 3 due to high cell numbers causing 
inhibition of further growth. The doubling time initially is calculated as 3.36 days and 
3.58 days respectively for HITS and HTS. The high initial plating number also causes 
the additional cells to be shed into the medium which is discarded. Therefore, the initial 
plating numbers were reduced accordingly in subsequent experiments.
The growth of N87 was observed to be less at the periphery of the plates due to 
incubator conditions (Data sheet 3 in Appendix C) and this was rectified with frequent 
rotation of the plates and careful positioning in the incubator. There was a decrease in 
growth of N87 cell at day 10 in HTS alone showing that to a degree in the longer term 
these cells were more serum dependent. The doubling time for N87 cells in HITS and 
HTS was 3.04 days and 3.4 days respectively (Figure 31 and Data sheet 2 in Appendix 
C).
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Section ii: Cell stimulation with IGF-1
To determine the most appropriate dose of IGF-I to stimulate drug treated cells, they 
were incubated with IGF-I in doses from 0.1 nM to 100nM.
In the proliferation studies, there was little difference in the growth stimulation between 
cells treated with 100,10 and 1nM IGF-I. Higher growth was observed than for cells 
incubated in HTS alone and in some cases the cells incubated with 10nM IGF-1 showed 
the highest cel! numbers in both MKN45 ( Figure 32 and Data sheet 4 in Appendix C) 
and in N87 cells (Figure 33 and Data sheet 5 in Appendix C). The growth in 10nM IGF-1 
was comparable to growth in insulin supplemented medium. Therefore, in view of the 
satisfactory growth with 10nM IGF- I this dose was chosen as most appropriate in all 
the drug treatment experiments.
Figure 32
Growth of MKN45 cells with IGF-1
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Figure 33
Growth of N87 cells with IGF-1
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With MKN45 cells in which the mean doubling time (each experiment performed in 
triplicate) was calculated in HTS to be 2.24 days, the doubling times for treatment with 
IGF- I were 1.84 days with 10nM IGF- I and 2.1 days with 1nM IGF- I (Figure 34 and 
Data sheet 6 in Appendix C). The mean was calculated using doubling times from data 
sheets 4.6 and 8.
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Figure 34
Growth of MKN45 cells with IGF-1
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Figure 35
Growth of N87 cells with IGF-1
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The proliferation of N87 cells in the presence of IGF- I is shown in Figure 35 (Data 
sheet 7 in Appendix C) and the doubling times are calculated where the mean doubling 
time for cells in HTS is 4.43 days and the stimulation by IGF- I at 10nM produces cell 
doubling in 3.17 days. With 1nM IGF- I the doubling time is 3.5 days. The mean is 
calculated from the doubling times in data sheets 5,7 and 9 in Appendix C).
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Section iii: Dose response of MKN45 and N87 to RG13022 inhibition
Cell proliferation studies were undertaken using RG13022 at concentrations of 5 to 
100uM in DMSO and compared to the growth of cells incubated in HTS and DMSO or 
with IGF-1 at concentration of 10nM in a medium of HTS and DMSO.
In the initial experiments the cells were incubated with drug with and without IGF- I 
stimulation. The effect of adding DMSO to the medium was also displayed and showed 
an apparent potentiation of growth in cells incubated in HTS alone with addition of 
DMSO in MKN45 cells (Figure 36 and Data sheet 10) and N87 cells (Figure 37 and 
Data sheet 11) This was not easily explained but since all the cells would have addition 
of DMSO to the medium in some form in the dose response series this was not relevant 
to results.
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The N87 cells incubated with RG13022 alone and with IGF- I show that there was a 
dose dependent inhibition of proliferation (Figure 38, Data sheet 12 in Appendix C). At 
high concentrations of RG13022 (100uM) there was a mean over three experiments of 
92% inhibition of cellular proliferation between the cell number from the RG and IGF- I 
treated cells and the cells treated with IGF- I alone. At a concentration of 100uM, 
RG 13022 was not only cytostatic but there was considerable mean cell loss of 72% from 
the day 3 to day 7 counts. Using serum free medium and concentrations of RG13022 
from 5uM to 100uM the mean IC 50 was found to be 38.6uM for N87 cells. From 5uM to 
50uM there was inhibition of cell growth but at 5 to 10uM there appeared to be a 
competitive reversible effect with the addition of IGF-1. The mean was calculated using 
data sheets 11,12 and 13 (Appendix C). Growth inhibition of MKN45 cells (Figure 39, 
Data sheet 14) at high concentration of RG13022 showed mean inhibition to be 71.8%  
and the effect was mainly cytostatic with a mean percentage of cell loss of 5%. The 
mean IC 50 over three experiments was found to be 64.7uM.ln contrast to the effect of 
IGF- I on the drug treated cells, in many cases the cells treated with IGF- I and drug 
showed more growth inhibition than drug alone. The mean results were calculated using 
data sheets 14,15 (Appendix C) and 16.
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Discussion of c-erbB-2 and EGFr expression
Section i: Expression of C-erbB-2
In this study of sixty-seven gastric adenocarcinomas, c-erbB-2 expression by 
immunohistochemistry demonstrated a median score of 90 (IQ=60-120) and 43.3% of 
tumours expressed a level of receptor in excess of the range found in samples of normal 
mucosa. This level of expression is high when compared to the majority of published 
studies. The proportion of tumours expressing a higher level of c-erbB-2 than 
corresponding normal mucosa was found to be 55% by Kameda et al (1990). The 
majority of studies reviewed above suggest a range of increased expression between 
9% and 28% (Hilton 1992, Motojima 1994) using a number of methods to determine 
overexpression, mainly expression in tumour sections relative to lack of staining in 
normal mucosa and comparison to control tissue.
There are a number of possible explanations for these findings.
Increased expression in tumour specimens and the presence of expression in mucosa 
are likely to be related to better preservation of antigenicity in frozen sections.
Studies to date have used a fairly standard technique of immunohistochemistry in 
paraffin embedded tissue sections following fixation with a variety of fixatives. In our 
laboratory, experiments on a series of breast tumour specimens comparing 
immunohistochemistry on frozen and paraffin-embedded sections have found the level 
of expression of c-erbB-2 was 92% and 22% respectively (Reeves 1994). Slamon 
(1989) suggested from his results in breast cancer specimens, that low levels of c-erbB- 
2 immunoreactivity may not survive the process of fixation which might explain the 
higher level of expression in frozen sections. However, Lemoine (1991) and Porter 
(1991) found no difference between the level observed in frozen or paraffin sections in 
gastric cancer and breast cancer respectively.
The staining intensity of sections has been demonstrated to differ with the use of 
cryostat or paraffin embedded sections and with the fixatives used in each case. Chiu et
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al (1994) determined the fixatives for both preparations which produced optimum 
membrane staining and found that 8 out of 16 paraffin embedded gastric tumours 
expressed c-erbB-2, of which 7 expressed a higher level than adjacent non-neoplastic 
mucosa. In contrast the frozen sections showed c-erbB-2 expression in all 16 cases with 
13 of the 16 (78%) having higher levels than adjacent non-neoplastic mucosa. Of the 
fixatives used, optimum staining was found in paraffin embedded sections with 
periodate-lysine-paraformaldehyde and in frozen sections with neutral buffered formalin. 
Although good membrane staining was achieved this was found that in the case of 
acetone fixation to be at the expense of a degree of loss of tissue morphology which is 
crucial for accurate histological examination. With other fixatives (Carnoy's and 
periodate-lysine-paraformaldehyde-dichromate) there was cytoplasmic but no significant 
membrane staining.
In both methods focal membrane staining was found in normal gastric epithelium. In 
frozen tissue there was a more uniform staining but in paraffin fixed specimens the 
staining was heterogeneous and demonstrated intracytoplasmic staining.
Falck and Gullick (1989) had also suggested variation in fixatives to be a possible factor. 
In an immunohistochemical study of c-erbB-2 in gastric cancer, they found that in 
comparing positive cases, the South African group had twice those of London. Although 
they felt that the use of a mercury-based fixative in the London tumours studied did not 
significantly influence the overall results, it highlights the ongoing difficulties of producing 
reliable, comparable data with small but possibly significant differences in methodology.
In determining the level of expression of c-erbB-2 a semi-quantitative scoring system 
was used in our own study and in several others (Jain 1991, Ohguri 1993). It is 
important to accommodate the well-recognised focal and patchy nature of the 
membrane staining, particularly in comparison to breast tumours where the staining is 
more uniform. It is also important to have explicit criteria for scoring membrane and 
cytoplasmic staining.
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The study by Ohguri (1993) demonstrated the difficulty in making comparisons because 
this group considered the total expression to consist of both membrane and cytoplasmic 
staining, of which 45% to 50% was cytoplasmic. Furthermore, the studies by Jain (1991) 
and Lemoine (1991) from the same group have achieved expression of 30% and 26% 
respectively but in the former study both cytoplasmic and membrane staining were 
considered positive.
Immunohistochemistry is specific and reliable for tumour sections in the group of 
tumours with high expression of c-erbB-2 but less so in mucosa and lesser expressing 
tumours.
In many studies the level of expression is considered to be positive or negative without 
comparison to mucosal tissue but sometimes comparison to control tissues known to 
express high levels of c-erbB-2. If tumour sections are compared to a tissue expressing 
high levels of receptor, then tumours of comparable expression are considered positive. 
The control tissues, therefore, determine the level of positivity in a series of tumour 
sections.
To give a more objective quantification the method of radioimmunohistochemistry was 
adapted to study gastric tumours. A comparison of the results from the two methods 
shows several advantages of a quantitative analysis. Although the 
immunohistochemistry scoring system provides a satisfactory separation of results it is 
within a confined range which has a predetermined minimum and maximum value. 
Those tumours expressing high levels of c-erbB-2 are found to have maximum 
histoscores but with receptor estimations using the RIHC method there is a wide 
separation of these tumours. Within the maximum histoscore group the receptor 
densities using radioimmunohistochemistry range from 150 to 3641 (x106) and includes 
9% of patients.
Using the scoring system where the level of expression is between 0 and 300, the range 
of values for the normal mucosa was 0 to 90. and 56.7% of the scores were less than or 
equal to the maximum in this range. The receptor numbers determined by
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radioimmunohistochemistry had a range of 0 to 15.4 8 x 10® with 77.6% of receptor 
values less than or equal to the maximum normal value
The variation between the percentage expressing more than the range of mucosal 
samples in the methods examined is most likely to be due to the scoring of the intensity 
of immunohistochemistry. With both methods there is staining of the cellular membrane 
and cytoplasm in tumours and in mucosa. The area of staining is calculated with a grid 
system in each field but the degree of intensity of staining is the most subjective factor. 
The silver grain counts of receptor binding determine density and this incorporates 
scoring of intensity and area.
Using both methods, there is a wide range of c-erbB-2 expression in tumour specimens 
and this study has also demonstrated a measurable level of expression in non­
neoplastic mucosa. It may appear that an arbitrary level of 'normal' expression has been 
placed to determine more easily the higher expressing tumours in order to make a 
comparison with published immunohistochemical studies. In addition, a small sample of 
mucosal sections were analysed in comparison to the number of tumour sections. If a 
section of mucosal tissue corresponding to each tumour section had been analysed this 
may have changed the range of values and consequently the number of tumours 
expressing more than this range.
The main advantages of RIHC compared to IHC are two-fold. Using a computer 
assisted analysis of silver grains corresponding to receptors diminishes subjectivity in 
deltermining staining intensity. More information is available than simply whether a 
tumour is ‘positive’ or ‘negative’ in this series using both RIHC and the more rigorous 
protocols for IHC but in RIHC there is even more scope for conformity between 
laboratories. Comparison of receptor level with prognostic factors and survival is, 
therefore, improved.
The difficulties with RIHC are related to the complicity of the methods. This is a time- 
consuming process where a number of standards must be maintained. The cell pellets 
used to calculate receptor number by ligand binding and those sections of pellets which 
are run with each group of tumours must be from the same passage of cells in culture to
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ensure conformity in receptor number. Just as fixed tissue can be variable in loss of 
antigen preservation, frozen sections and blocks require careful handling. The strict 
conditions in which the photographic emulsion is applied cannot be varied in time, 
temperature, light or humidity. Finally, reproducible calibration of the image analysis 
system is essential.
It is particularly important to highlight those tumours which express the highest levels of 
expression in this study and show gene amplification. Tumours in which there was 
amplification had significantly increased expression of c-erbB-2 and conversely those 
with single copy genes had low levels of c-erbB-2 expression. Fifteen percent of the total 
group demonstrated gene amplification. This is consistent with 13% observed by 
Lemoine (1991) by Southern Blotting but reported amplification in other studies ranged 
from 5% to 40% (Yoshida 1989, Yokota 1989).
There are, however, a number of tumours which show moderately increased expression 
without amplification. The mechanism and importance of this finding require further 
investigation. Transcriptional regulation of c-erbB-2 expression has been demonstrated 
as a likely mechanism of increased expression without gene amplification. Studies using 
binding proteins to the individual elements in the promoter region of c-erbB-2 have 
shown increased activity and a degree of correlation with expression (Kameda 1990). 
Radioimmunohistochemistry has the potential to produce a quantitative level of receptor 
density which may be more reliable in reproducing results within a group and more 
easily comparable information between centres. In addition to determining those 
tumours expressing increased levels of c-erbB-2 or those tumours with dramatic levels 
of c-erbB-2 and gene amplification, RIHC also outlines a population of tumours with 
moderately high expression but with a single gene copy. In the future, the main value of 
c-erbB-2 assessment is likely to be prediction of response to therapy targeted to the c- 
erbB-2 gene or protein. An analysis using IHC or FISH may exclude this potential target 
group which has been revealed by RIHC. Ultimately, the development of a c-erbB-2 
assay which may be integrated into routine testing is important and despite the
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invaluable information which RIHC may bring to the understanding of the role of c-erbB- 
2 in gastric cancer, its place may remain that of a research tool.
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Section ii: Comparison of c-erbB-2 expression with clinical and 
pathological information
There are a number of pathological factors which are used in the description of gastric 
tumours (Yu et al 1997). The clinical relevance of these in determining the behaviour of 
the tumour and prognosis for the patients has been established over many years. Their 
correlation with the expression of c-erbB-2 may help illustrate its biological significance. 
Histology of gastric cancers is described using one or more of the recognised 
classifications, most commonly Broders' (1926) classification which divides the tumour 
group in to well, moderately well and poorly differentiated tumours. The majority of 
tumours are poorly differentiated tumours. Difficulties arise in gastric cancer because of 
tumour heterogenicity and grading can be highly subjective. Also, when examining 
specimens for immunohistochemistry the tissue must be representative of the overall 
histological type described.
Several of the tumours were also classified using the Lauren (1964) method which 
describes the histological growth pattern as intestinal or diffuse. Intestinal type tumours 
tend to be common in areas of high risk of gastric cancer and are often found as part of 
a field change in gastric mucosa with chronic atrophic gastritis and intestinal metaplasia. 
In general the patients are older, more likely to be male and have a better prognosis. 
The intestinal type consists of moderately differentiated glands whose cells have 
intestinal type cell features where as the diffuse type displays only small groups or 
single cells which infiltrate diffusely. There are a number of tumours which do not fit into 
either type and for routine histological reporting, Broders' classification is used with the 
additional information from the Lauren typing. The WHO (Watanabe 1990) and Ming 
(1977) classifications are also used to present additional information and combinations 
of these have been employed to overcome difficulties in analysing gastric cancer due to 
the heterogeneous nature of the tumour. Within the literature there is a tendency to 
group well differentiated, intestinal and tubular tumours when describing the relationship
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relationship of histology to c-erbB-2. In this study there is a significant correlation 
between well to moderately differentiated tumours and high levels of expression of c- 
erbB-2 (p=0.008);Figure 40.
Figure 40 Correlation between tumour differentiation and c-erbB-2
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10000 - I
1000 -
-a 100 -o
10 -
CN
00
t i
0 1 -
0.01 -
well/m oderate poor
Tumour differentiation
T h e  box plot dem onstrates  the  level of expression of c -erbB -2  as the num ber of receptors x 106 
on the y axis on a log transform ed scale w ith tum our differentiation expressed as w ell to 
m oderately  w ell d ifferentiated tum ours com pared  to poorly d ifferentiated  tum ours.
There did not appear to be any relationship between the level of expression of c-erbB-2 
and the site of the primary tumour. The proportion of antral tumours is lower than found 
in population studies reflecting more the pattern of hospital referral rather than the 
exaggerated effect of the recent increased incidence of proximal lesions. Albino et al 
(1995), however, in a study of 80 patients found a higher level of expression in antral 
tumours of which all were intestinal type. Although the prognosis of antral tumours tend 
to be better the survival time of these advanced lesions was less than the other distal 
tumours but not statistically significant. There are a number of authors, however, who 
have shown no correlation with the site of the tumour (Motojima 1994, Lemoine 1991). 
The pathological staging in many countries in particular in the Far East have described 
the presence of lymph node metastases as particularly important in predicting outcome 
(Maruyama 1987). However, as previously described in the patients in the West of
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Scotland and in particular in the Centre from which the majority of tumour samples were 
taken, an extensive audit has demonstrated there is more predictive value attached to 
serosal involvement by the tumour. The advanced nature of the majority of gastric 
tumours which present in this group and the more conservative lymph node dissection 
may have a role in these findings.
Correlation of the level of expression of c-erbB-2 receptors with serosal involvement 
shows a significantly higher level of c-erbB-2 expression in tumours not involving the 
serosa (p = 0.068);(Figure 41).
Figure 41 Correlation between serosal involvement and c-erbB-2
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Th e  box plot dem onstrates  the  level of expression o f c -e rb B -2  as  the num ber of receptors x 106 
on the y axis on a log transform ed scale w ith serosai invo lvem ent expressed negative  or positive  
on histology.
There were only 8% of the tumours (5) in the serosa negative group. Three were 
moderately differentiated tumours of which one was node positive and 2 poorly 
differentiated tumours both node negative Of the group, 4 patients survived beyond 
three years and were disease free and the remaining patient died of cardiovascular 
disease after 15 months with no evidence of recurrent disease. In Glasgow patients, 
serosal involvement is a more reliable predictor of prognosis with lymph node status 
only important for those without serosal involvement. Increased expression of c-erbB-2
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in serosa negative patients may suggest a possible association with better prognosis but 
the advanced nature of disease in the patients results in a limited number of patients 
available for analysis.
There was no correlation between the number of positive lymph nodes retrieved at 
operation and the level of c-erbB-2 expression and no significant correlation when the 
number of positive lymph nodes was taken as more than or less than 50%. This may 
reflect surgical factors, particularly the number of nodes retrieved. However, the 
literature has described both Japanese and British studies reporting no correlation of 
lymph node status with c-erbB-2 expression.(Uchino 1993, Lemoine 1991).
Although we were unable to study the level of expression in lymph node metastases 
there have been a number of groups who have shown a high level of expression in the 
nodes, in some cases higher than the primary tumour (Ohguri 1993) and occasionally 
with a c-erbB-2 negative primary tumour. This gives some insight to the potential effect 
of increased expression of c-erbB-2 in gastric cancer. The results of many studies have 
suggested that tumours with higher levels of expression of c-erbB-2 may exhibit a more 
aggressive growth pattern and an increased potential to metastasise.
Gastric cancer more commonly presents as a locally advanced lesion and the presence 
of tiver metastases is often a late finding. In the box plot in Figure 42 there is a tendency 
to exhibit higher levels of c-erbB-2 in the tumours of patients presenting or subsequently 
developing liver metastases although this does not reach statistical significance (Figure 
42).
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Figuis 42 Relationship between liver metastases and c-erbB-2 expression
C-erbB-2 and liver metastases at presentation or follow up
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T h e  box plot dem onstrates the level of expression of c -erbB -2  as the num ber of receptors x 106 on 
the y axis on a log transform ed scale with liver m etastases at any tim e recorded for a patient 
expressed as yes, no or unknown.
There was no statistical relationship between the presence of liver metastases and 
tumour differentiation. 33% of the total number of tumours were well to moderately 
differentiated and 36% of the liver metastases group were of this tumour type.
Tahara (1995) acknowledges the increased incidence of c-erbB-2 expression in patients 
with liver metastases and suggests that there may be differences in the pattern of 
metastases dependant on the differentiation of the tumour. He describes differing 
patterns of the cell adhesion molecule CD 44 variant expression with differentiation of 
the tumour (Matsumara 1992). A likely suppressor gene of metastases, nm23, which 
encodes nucleotide diphosphate kinase and c-myc transcription factor, is overexpressed 
in primary gastric carcinoma but reduced in metastatic gastric cancer (Nakayama 1993). 
A 31 kDa lactose-binding lectin ( extracellular matrix binding protein) which is frequently 
overexpressed in well differentiated tumours may be associated with an increased 
incidence of liver metastases in this type and in poorly differentiated tumours an 
association with lymph node spread (Lotan 1994). Interestingly, Livingstone (1995) 
described a statistically significant reduction in nm23 in British tumours compared to
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those from Japanese patients in addition to the higher level of c-erbB-2 expression 
previously described.
Yonemura (1993), while observing that the serum levels of c-erbB-2 correlated with the 
tissue immunoreactivity showed that the incidence of positive serum erbB-2 levels was 
significantly higher in patients with liver metastases. Sasaki (1992) has reported a 
higher incidence of peritoneal metastases in c-erbB-2 positive tumours. Peritoneal 
metastases tend to be associated with serosal involvement and would not support the 
findings of this study that c-erbB-2 levels are higher in patients without serosal 
involvement.
In this study there appears to be correlation of high c-erbB-2 expression with factors 
which in general predict a better outcome, in particular differentiated tumours and those 
with no serosal involvement. However, a Kaplan-Meier analysis of the level of c-erbB-2 
expression and patient survival shows no relationship. There was also no statistically 
significant relationship between c-erbB-2 amplification and survival. With the exception 
of Jain (1991) who has shown better survival in tumours with high c-erbB-2 and well 
differentiation, the majority of studies show poorer survival or no significant relationship 
between these factors.
146
Chapter 10
Section iii: EGFr expression
Using immunohistochemistry to analyse expression of EGFr there is a much tighter 
distribution of expression of EGFr when compared to c-erbB-2. The majority of 
published studies on EGFr have used a comparison to tissue with known elevated levels 
of immunoreactivity and most commonly the vulval epidermoid carcinoma-derived cell 
line A 431 (Ozanne 1986). By using radioimmunohistochemistry a quantitative 
assessment of EGFr expression was made in our study. Comparison was made with 
receptor expression determined by ligand binding studies in a number of cell lines. 
Limited ligand binding studies to determine EGFr expression in a large group of cell 
lines were carried out and demonstrated close correlation with grain count.
Standard immunohistochemistry detects EGFr expression in neoplastic and non­
neoplastic tissue. The median value of EGFr expression in the tumours was 100 (IQ=70- 
125) and 41.8% of tumours expressed levels above the mucosal range. Expression of 
EGFr using RIHC when expressed as % of A431 cells ranged from 0 to 106% with a 
median of 0.9% (IQ= 0.5 to 1.6%). In published series the level of overexpression was 
considered to be between 18% and 43% (Lemoine 1991, Lee 1994). These studies 
used immunohistochemistry and the problems associated with this have been discussed 
fully above in relation to c-erbB-2. Studies like those of Filipe et al (1995) and Lee et al 
have determined EGFr immunostaining in neoplastic and non-neoplastic tissue with the 
former showing increasing intensity with worsening dysplasia. Some studies such as 
those of Hirona (1995) claim that non-tumour cells were negative. In our studies the 
non-neoplastic tissue stained positively in all tumours and in the small number of 
mucosal samples analysed there was a range of staining up to a score of 105 
encompassing the scores of 58% of the tumours.
There are some difficulties in defining the criteria used to determine positive staining. In 
this study positive tumours had membrane staining primarily but in addition may have 
had cytolasmic immunoreactivity as almost an incidental finding. This contrasts with the
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study of Sugiyama et al (1989) where both levels of staining were taken as positive 
independently. The level of staining in terms of intensity and extent was determined by a 
scoring system rather than simply presence or absence of staining as shown by Yasui et 
al. (1988). However, it is evident from the substantial difference in percentage 
overexpression between IHC and RIHC that there are difficulties with any subjective 
scoring.
Both methods show extensive expression but the comparative mucosal expression is 
overemphasised with IHC. The overall correlation of the expression of EGFr by the two 
methods is good (Spearman rank correlation r2 = 0.3, p<0.0005). In the distribution of 
percentage expression of EGFr there is a suggestion of a bimodal distribution. Although 
the level of overexpression is 39% and 20.9% of tumours have expression above the 
interquartile range, the 7% of tumours in the second peak may be those associated with 
significant effect. Alternatively, these may simply be outliers and to clarify this, a study of 
substantially increased numbers and statistical power would be required. The level of 
gene amplification in EGFr is not well studied but ranges from 3% (Yoshida 1989) to 7% 
(Lemoine 1991) and would be an interesting area of additional study.
These differences in the analysis of immunohistochemistry slides make the results 
difficult to compare between studies and to compare the results of analysis using 
comparison of receptor expression with clinico-pathological factors or tumour markers. 
Using radioimmunohistochemistry the difficulties of subjectivity in scoring slides are 
removed, there is better spread of results and comparison to other factors is more 
reliable, whether by using the grain count or expressed as a percentage of the grain 
count for A 431 cells.
There appears to be no relationship between the expression of C-erbB-2 and EGFr 
when analysed using the results of expression from RIHC (r2 = 0.004, p = 0.594) and 
IHC (r2 = 0.087, p = 0.015) using Spearman rank correlation.
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Section iv: Comparison of EGFr expression with clinical and pathological factors.
Although there have been a few studies in which the presence of EGFr expression has 
been associated with poor prognosis, the majority of tumour series have insufficient 
follow-up and tumour numbers to determine a significant relationship. However, it is 
possible to compare the level of EGFr expression with clinico-pathological indicators of 
prognosis and tumour aggressiveness. In comparative studies of early and advanced 
tumours there have been significant differences in the expression of EGF and EGFr and 
Yasui (1988), Sugiyama (1989) and Tokunaga (1994) have suggested the 
overexpression of EGFr is related to a biological aggressiveness and therefore higher 
levels occur in advanced lesions.
In this study, pathological indicators of advanced lesions have not shown a statistically 
significant relationship with EGFr expression. Comparing the level of EGFr expression 
both as grain count and as a percentage of A 431 cells there is no correlation with 
serosal involvement (p=0.694;p=0.489). There were only five patients with no serosal 
involvement and a significant difference between early and advanced lesions would be 
difficult to determine with small numbers but of particular note is the patient with EGFr 
receptor density/%A431 of 4.6% (count 1108). This tumour was found to be serosal and 
node negative but the level of expression was in the higher second peak in the bimodal 
distribution. In the analysis of nodal involvement there was no correlation between the 
presence of positive nodes (p=0.863) or the proportion found to be positive (p=0.413).
The relationship between the expression of EGFr and the differentiation of the tumour 
tends towards significance (p=0.130;p=0.015) and the group of well and moderately well 
differentiated tumours have higher levels of expression (p=0.08;p=0.005). Yasui (1988), 
despite finding an increased level of expression of EGFr in advanced lesions also found 
correlation with well differentiated tumours. Sugiyama (1989) and Yoshida (1989) in 
contrast found higher expression in poorly differentiated tumours. In Japanese studies of
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primary tumour and metastatic nodal tissue there have been high levels of expression in 
the involved nodes (Yasui 1988) but there was no relationship to distant, peritoneal or 
hepatic metastatic spread. We also have shown no relationship between EGFr 
expression and the presence of liver metastases either at presentation (p=0.716) or at 
any time during follow-up (p=0.394).
No association with site of tumour (p=0.358) was observed. In those tumours of 
oesophageal origin which were excluded from the final analysis it was interesting to note 
that there was an intense staining for EGFr in the tumour and mucosal specimens 
despite the fact these tumours were adenocarcinomas arising in Barretts epithelium. 
This requires further study but may indicate that the initiation of the tumour process is 
different at this site.
This must also be considered with the findings of Filipe (1995) where an increase in 
intensity of staining was found in intestinal metaplasia and dysplastic epithelium in 
gastric cancer fields when compared to these changes in mucosa from non-cancer 
fields.
This may suggest that overexpression of EGFr is a relatively early event in the 
progression to invasiveness in gastric cancer and it may be the promoting effect of EGF 
(Sugiyama 1989) which is important in tumour development. Synchronous expression is 
shown to produce poorer prognosis in gastric cancer.
Using a Kaplan-Meier analysis of the relationship between EGFr expression and 
survival there is no significant correlation between level of receptor and overall survival 
(p=0.655). No association between expression of EGFr and c-erbB-2 determined by any 
method was found despite a correlation of both with tumour differentiation. Others have 
suggested that EGFr expression is more associated with poorly differentiated tumours 
(Tahara 1995) and indicates progression to invasiveness, with a tendency to nodal 
involvement.
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In summary, this study has shown correlation of EGFr expression with better tumour 
differentiation but no correlation with involvement of serosa, lymph nodes, site of tumour 
or patient survival.
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Section v: Discussion of IGF-I studies
The tyrophostin RG13022 is one of a number of compounds developed to inhibit the 
autophosphorylation of tyrosine kinase receptors in particular EGFr. It has previously 
been shown to inhibit cellular growth in human breast cancer cell lines (Reddy 1992), 
pancreatic cancer cells (Gillespie 1993) and gastric cancer cells (Piontek 1993). The 
latter study investigated the effect of this compound on the AGS human gastric cancer 
cell line with the addition of exogenous EGF. RG13022 produced a dose dependent 
growth inhibition of the gastric cells.
In collaboration with Miss V. Morrison and under the supervision of Dr. J. M. S. Bartlett, 
a series of parallel experiments were undertaken to examine the inhibitory activity of the 
tyrophostin RG13022 on the gastric cancer cell line MKN45 and N87 and the 
modulatory effect of stimulation with EGF. Using the methods described but plating the 
cells at a density of 4 x 10^ per well for MKN45 and 6 x 10^ per well for N87 the cells 
were incubated in 1 %,2%,5% FCS or in HITS media and subsequently treated with 
DMSO and RG13022 at concentrations of 1 to 100uM. I will discuss the results of the 
effect of RG13022 on the gastric cell lines co-stimulated with IGF-1 in comparison to 
cells influenced by EGF.
In establishing the optimal conditions for culture in this way the growth of MKN45 cells 
were found to be relatively independent of culture medium. However, the rate of 
proliferation of N87 was lower in 1% FCS and in serum free medium. In both serum 
containing (5% FCS) and serum free (HITS) medium, RG13022 produced a dose 
dependent inhibition of cell growth with both MKN 45 and N 87 cells. For N 87 cells the 
IC 50 in 5% FCS was 45uM and 31 uM in HITS. In MKN45 cells the IC 50 in 5% FCS 
was 58uM and 32uM in HITS.
At high concentration (100uM) RG13022 was cytostatic and growth inhibition in both cell 
lines was approximately 90% under all conditions. When drug treatment was removed
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from the cell cultures at day 5, in MKN45 cells, there was little effect on proliferation but 
the N87 cells recovered to resume further cell growth.
Although RG13022 was developed more specifically for the inhibition of the EGF 
receptor the inhibition of cellular proliferation previously seen in serum free medium 
supplemented with IGF- I shows that there is also some inhibitory activity in the IGF- I 
receptor pathway.
The tyrophostin inhibited both cell lines in a dose dependent manner but there were 
considerable differences between the cell lines and when investigating the effect on the 
IGF receptor and EGF receptor. The IC 50 for inhibition of growth stimulated by EGF in 
both cell lines was around 30uM but inhibition in the IGF experiments showed an IC 50 
for N87 of around 40uM and for MKN45 a consistent IC 50 of 70uM.
Experiments on gastric and pancreatic cells have suggested that the effect of RG13022 
is cytostatic with minimal cell loss and reversible on removal of the drug. This was found 
to be the case in MKN45 cells with around 5% cell loss at 7 days after drug treatment. 
However, the N87 cells showed cell loss of 72%. This can in part be explained by the 
observation that the growth of N 87 cells decreased in serum-free medium at 7 to 10 
days without drug treatment but the cell loss is certainly accelerated. The concentration 
of RG13022 required for inhibition of MKN45 cells was greater and addition of IGF- I 
often caused some potentiation of the inhibitory effect. This suggested that the 
RG13022 was causing inhibition of the IGF receptor pathway at different areas in signal 
transduction.
Immunoblotting techniques were used to examine signal transduction in the EGF 
receptor and IGF receptor pathways. In the EGF experiments the immunoblotting 
methods were comparable and monoclonal antibodies to EGFr were used in addition to 
antiphophotyrosine antibody and antibodies to MAP2 kinase. The effect of tyrophostin 
treatment on EGF stimulated cells had previously shown that RG13022 reduced 
phosphorylation of a predominant 170kDa protein co-migrating with EGFr in MKN45
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cells but not N 87 cells and modulation of phosphorylation of p185 (c-erbB-2), p85 (p13 
kinase) and p42 (MAP2 kinase). In the N87 cells there was an apparent mobility shift of 
MAP2 kinase which did not occur in the MKN 45 cells and suggested that the 
antiproliferative effect of RG13022 differed in the two cell lines.
In IGF- I stimulated MKN45 cells using the antiphosphotyrosine antibody (Py 54) the 
95kDa subunit of the IGF receptor could be demonstrated in the stimulated and 
unstimulated state with the inhibitory effect of RG13022 on phosphorylation. The 
inhibitory effect was also evident in the intensity of the MAP2 kinase band but there was 
no mobility shift demonstrated (Figure 43). Using the MAP2 kinase antibody there was 
no obvious difference between IGF stimulated and drug treated cells (Figure 44). With 
N87 cells there was evidence of a modulatory effect at the 95kDa band but no evidence 
of changes at the MAP2 kinase or other sites with Py 54 (Figure 45) or the MAP2 kinase 
antibody (Figure 46).
There appeared to be some changes apparent at the 185kDa site of IRS-1 during 
stimulation of MKN45 cells with some degree of mobility shift but this was inconsistent 
and the antibody in our hands was unreliable (Figure 47).
In the gastric cancer cell lines MKN45 and N87 the tyrophostin RG13022 originally 
developed as an inhibitor of the EGF receptor has been shown to have an 
antiproliferative effect on IGF stimulated cells suggesting activity against the IGF- I 
receptor. Using immunoblotting techniques it was possible to demonstrate some 
modulation of the intracellular signalling with IGF- I stimulation and drug treatment with 
RG13022.
Observation of drug induced inhibition of gastric cancer cells in this way suggests that 
further advances in the treatment of gastric cancer could be possible. The 
demonstration of the level of expression of IGF- I receptors in gastric tumours would 
indicate whether this area would be a worth-while target for growth inhibition. The 
difficulties with inhibition at this level would need to be addressed and in particular the
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systemic effects of inhibition and the need for localised application to the target tissue. In 
the case of IGF-1 the added difficulties of the modulating effect on the receptor number 
and circulating IGF of binding proteins. Finally, the effect on insulin activity in the patient 
would require investigation. Novel growth factor inhibitors in conjunction with tissue 
targeting techniques and conventional chemotherapy may be of some benefit in the 
future particularly in the treatment of advanced gastric cancer.
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Figure 43 The effect of RG13022 on MKN45 cells co-stimulated with IGF-1
A B C D
The immunoblot uses the antiphosphotyrosine antibody and demonstrates the stimulation of 
MKN 45 cells with IGF-1 (A=control, B=IGF-1 stimulation) and the inhibitory effect of the 
RG13022 (C=RG13022 and D=RG13022 and co-stimulation with IGF-1). The stimulatory 
effect is seen as dark bands at the 95kDa subunit of IGF-1 and the 42kDa site of MAP kinase 
with corresponding loss of this effect on addition of RG13022.
Figure 44 The effect of RG13022 and IGF-1 on MKN 45 cells at the MAP kinase band
A B C D
Using the MAP kinase antibody there was obvious stimulation of MKN 45 cells at the 42kDa 
site but no distinct difference between stimulated and unstimulated cells. There was no 
evidence of a mobility shift at this site.
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Figure 45 The effect of RG13022 on N 87 cells co-stimulated with IGF-1
« •  * 9  m
A B C D
With N 87 cells there is some evidence of stimulation at the 95kDa site (A= control compared 
to B= stimulation with IGF-1). There is little difference in the density of the bands using the 
antiphosphotyrosine antibody in the cells treated with RG13022 suggesting little effect in the 
signalling pathway of this cell population.
Figure 46 The effect of RG13022 and IGF-1 on N 87 cells at the MAP kinase band
Stimulation of N 87 cells is evident at the MAP kinase site with the MAP2 kinase antibody but 
there is no difference between the bands and no mobility shift at this site.
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Figure 47 Modulation at the IRS-1 185kDA site on stimulation of MKN 45 cells with IGF-1
There is a mobility shift between the unstimulated cells (A and C) and cells stimulated with 
IGF-1 (B and D).
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GENERAL DISCUSSION
For the most part, the aims of this thesis have been fulfilled. 
Radioimmunohistochemistry has been demonstrated as a useful technique in 
determining the level of expression of EGFr and c-erbB-2 in gastric cancer. Comparison 
with standard immunohistochemistry has highlighted advantages of the former 
technique, in particular exposing the wide distribution of receptor density in the highest 
expressing tumours for c-erbB-2 and demonstrating expression in non-neoplastic tissue. 
Subsequent investigation of a relationship between EGFr and c-erbB-2 and clinico- 
pathological factors has identified some interesting areas. EGFr expression is estimated 
at 40% above that of gastric mucosa but there is no significant correlation between 
EGFr and prognostic factors or survival. As a molecular marker EGFr may provide 
valuable information in tumour biology especially with regard to expression in pre- 
malignant tissue. However, additional prognostic information is unlikely and in gastric 
cancer there is little indication for a use as a therapeutic target.
In contrast, c-erbB-2 which demonstrates higher expression than mucosal samples in 
22% of cases and 15% amplification has a significant correlation between increased 
expression and both lack of serosal involvement and differentiated tumours. This may 
indicate a subset of tumours in which tumour biology and behaviour are linked to c- 
erbB-2 expression and indicates some potential as a tumour marker.
It is unlikely that growth factors influence the proliferation and behaviour of cancer cells 
independently. This thesis has therefore also sought to investigate IGF-1 in gastric 
cancer and has demonstrated IGF-1 induced cellular proliferation with a dose 
dependent inhibition by the tyrophostin RG13022. In finding IGF-1 a less potent 
stimulator of the MAP kinase pathway than EGF in gastric cancer cells and RG13022 
less able to inhibit this pathway, our understanding of tumour biology improves despite 
lack of advances in therapeutics.
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APPENDIX A
Table 1 Survival by operative procedure
Type of operation
No. 1 2
(years)
% surviving at 
3 4 median
survival
(months)
Curative resection 129 63 46 35 27 22 19m
54 78 65 62 57 41 55m
Palliative resection 32 25 13 3 3 0 6m
115 52 31 18 10 8 12m
Bypass 33 6 0 0 0 0 4m
23 6 0 0 0 0 3m
Intubation 26 8 4 4 4 0 2m
4 0 0 0 0 0 0.8m
Laparotomy only 58 9 0 0 0 0 2m
28 8 0 0 0 0 5.2m
No surgery 51 12 6 3 3 3 1m
84 4 2 0 0 0 1m
Laser - - — . . — __ _
59 23 9 5 5 2 3.6m
All resection 161 55 39 29 22 18 14m
170 56 37 30 24 16 15m
Appendix A
Table 2 Survival by degree of involvement (Curative resections)
No.of patients
1986-1994 (1974-1984) % survival 1986-1994 (1974-1984)
1 2 3 4 5
serosa
+ve 31 (90) 69(54) 49(35) 45(26) 45(18) 23(13)
-ve 23(33) 90(85) 90(78) 90(59) 74(59) 74(47)
RM
+ve 4(31) 75(41) 25(7) 0(7) 0(0) 0(0)
-ve 52(95) 78(69) 69(58) 69(43) 63(36) 46(28)
nodes
+ve 21(65) 69(55) 39(37) 39(27) 39(22) 23(17)
-ve 33(63) 83(71) 83(57) 78(45) 69(37) 53(31)
Table 3
30 DAY MORTALITY % 1974-1984 ( % 1986-1994)
CARDIA BODY ANTRUM TOTAL
LAPAROTOMY ONLY 33% (25%) 18% (20%) 50% (50%) 29% (32%)
NO SURGERY 50% (53%) 67% (38%) 41% (60%) 51% (49%)
CURATIVE 18% (17%) 11% (9% ) 7% (4% ) 12% (7% )
PALLIATIVE 14% (19%) 12% ( 8%) 6% (10%) 9% (11%)
RESECTION
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Table 4: Results for control tissue (gastric mucosa) and cancer cell lines - RIHC and IHC
Control tissue EGFr grain count Area Exposure EGFr IHC
1 2 Control 1 2 Control
9934/94 mucosa 3610 2270 789 13.5 13.5 6.75 96 60
7787/94 mucosa 4080 3520 1060 96 105
9896/94 mucosa 1800 1950 574 96 100
4104/94 mucosa 1260 1780 598 96 40
RUN 1
A431 11400 7700 194 13.5 13.5 6.75 4
BT20 2550 1650 124 4
EJ 6180 5860 225 24
SKBR3 3000 2510 222 24
ZR75 1930 2340 682 164
RUN 2
A431 13900 13300 300 4
BT20 2160 2240 188 4
EJ 7860 5650 187 24
SKBR3 2380 3140 242 24
ZR75 2220 1970 375 164
RUN 3
A431 3550 5510 95 4
BT20 912 1190 52 4
EJ 547 712 44 24
SKBR3 910 1020 108 24
ZR75 2350 1590 313 96
BT474 6910 5930 130 96
MDA-MB-453 1240 1980 68 96
MCF7 1290 1370 926 96
MDA-MB-231 13600 10300 135 96
MDA-MB-361 1240 130 213 96
Key to table:
EGFr grain count: 
Run: 
Area: 
Exposure:
Raw EGFr silver grain counts (hot 1&2, control)
Batch number for tumour specimens and cell pellets
Area corresponding to grain count for each section )x 10'2 mm2
Length of exposure time in hours
EGFR IHC: EGFr immunohistochemistry score
Appendix B
Table 4: Results for control tissue (gastric mucosa) and cancer cell lines - RIHC and IHC
Control tissue C-erbB-2 grain
count
1 2 Control
9934/94 MUCOSA 141 245 104
7787/94 MUCOSA 301 95 79
9896/94 MUCOSA 291 187 81
4104/94 MUCOSA 93 43 54
RUN 1
N87 2030 2340 143
BT474 1050 1000 93
MDA-MB-361 1070 1070 125
ZR75 1060 1150 146
MCF7 537 564 248
RUN 2
N87 2460 2750 64
BT474 1620 1780 111
MDA-MB-361 930 1280 111
ZR75 595 512 131
MCF7 476 257 169
RUN 3
N87 2390 2040 83
BT474 1340 1290 69
MDA-MB-361 647 782 100
ZR75 625 378 183
MCF7 397 326 158
Area Exposure B2 IHC
1 2 Control
5.82 5.92 4.11 96 70
5.5 5.45 3.75 96 90
5.8 5.99 4.09 96 50
3.58 3.51 2.58 96 0
13.5 13.5 6.75 4
4
24
96
96
4
4
24
96
96
4
4
24
96
96
Key to table:
Raw c-erbB-2 silver grain counts (hot 1&2, control)
Batch number for tumour specimens and cell pellets 
Area corresponding to grain count for each section )x 10'2 mm2 
Length of exposure time in hours 
C-erbB-2 immunohistochemistry score
C-erbB-2 grain count: 
Run: 
Area: 
Exposure: 
B2 IHC:
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Data sheet 1 Growth of MKN 45 cells in serum free medium 50,000 cells per well
DAY TREATMENT COUNT 1 COUNT 2
DILUTION 25
DAYO 10%FCS 2771 2846
DAYO 10%FCS 4840 4934
DAYO 10%FCS 3406 3335
DAYO 10%FCS 4500 4405
DAYO 10%FCS 3881 3963
DAYO 10%FCS 4093 3989
DAYO 10%FCS 2953 3085
DAYO 10%FCS 3982 4038
DAYO 10%FCS 3174 3176
DAYO 10%FCS 5141 5240
DAYO 10%FCS 3630 3637
DAYO 10%FCS 3422 3334
DAYO 10%FCS 4626 4632
DAYO 10%FCS 4325 4374
DAYO 10%FCS 3654 3297
DAYO 10%FCS 4447 4546
DAYO 10%FCS 4555 4578
DAYO 10%FCS 2991 2979
DAYO 10%FCS 2539 2470
DAYO 10%FCS 3804 3855
DAYO 10%FCS 4778 4740
DAYO 10%FCS 3776 3891
DAYO 10%FCS 4296 4375
DAYO 10%FCS 4657 4688
DAY 3 HITS
DAY 3 HITS 6916 7009
DAY 3 HITS 6859 7000
DAY 3 HITS 7151 6948
DAY 3 HITS
DAY 3 HITS
DAY 3 HTS 5441 5401
DAY 3 HTS 7262 7312
DAY 3 HTS 6623 6485
DAY 3 HTS 5674 5650
DAY 3 HTS
DAY 3 HTS 5513 5343
DAY 3 HITS 6094 6189
DAY 3 HITS 6223 6346
DAY 3 HITS
DAY 3 HITS 7321 7393
DAY 3 HITS 7342 7396
DAY 3 HITS 7938 7854
DAY 3 HTS 4301 4352
DAY 3 HTS 7473 7671
DAY 3 HTS 6701 6785
DAY 3 HTS 8333 8115
DAY 3 HTS 8965 8074
DAY 3 HTS
DAY 6 HITS 5872 6111
DAY 6 HITS 4784 5331
DAY 6 HITS 6044 6086
OUNT 3 MEAN MEAN OF
COUNT REPLICATES
2933 71250
4904 122316.67
3394 84458.333 97963
4491 111633.33 18364
3804 97066.667 2
4044 101050 8213
2936 74783.333
3911 99425
3211 79675 93004
5082 128858.33 19616
3715 91516.667 2
3296 83766.667 8773
4666 116033.33
4331 108583.33
3528 87325 102197
4439 111933.33 16842
4559 114100 2
3055 75208.333 7532
2379 61566.667
3885 96200
4737 118791.67 99154 98080
3745 95100 20791 18001
4291 108016.67 2 5
4485 115250 9298 3754
7221 176216.67 175539
6818 172308.33 2951
7272 178091.67 1
2086
5171 133441.67 151417
7365 182825 21316
6547 163791.67 2
5693 141808.33 10658
5370 135216.67
6127 153416.67 174382
6198 156391.67 18584
2
7231 182875 9292
7246 183200
7731 196025
4129 106516.67 176668
7407 187925 42590
6932 170150 2
8243 205758.33 21295
212987.5
6218 151675
5079 126616.67
5832 149683.33 153646
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Data sheet 1 Growth of MKN 45 cells in serum free medium 50,000 cells per well
DAY 6 HITS 6013 6030 6044 150725
DAY 6 HITS 7071 7249 7041 178008.33
DAY 6 HITS 6605 6684 6531 165166.67
DAY 6 HTS 7316 7826 7951 192441.67
DAY 6 HTS
DAY 6 HTS 6339 6212 6468 158491.67
DAY 6 HTS 8471 8327 8370 209733.33
DAY 6 HTS 9834 9612 9704 242916.67
DAY 6 HTS
DAY 6 HITS
DAY 6 HITS 6800 6704 6789 169108.33
DAY 6 HITS 8502 8338 8222 208850
DAY 6 HITS 8922 8904 8779 221708.33
DAY 6 HITS 7862 7837 8136 198625
DAY 6 HITS 8156 8407 8195 206316.67
DAY 6 HTS 8872 8792 8777 220341.67
DAY 6 HTS 7298 7524 8082 190866.67
DAY 6 HTS 8149 8111 8062 202683.33
DAY 6 HTS 9022 9185 10037 235366.67
DAY 6 HTS 9216 8719 8461 219966.67
DAY 6 HTS 8397 8472 8162 208591.67
DAY10 HITS
DAY10 HITS 4592 4462 4368 111850
DAY 10 HITS 5224 5429 5433 134050
DAY10 HITS 7383 7177 7299 182158.33
DAY10 HITS 8171 8257 8458 207383.33
DAY10 HITS 9526 9695 9629 240416.67
DAY10 HTS 6665 6493 6529 164058.33
DAY 10 HTS 6189 6139 6146 153950
DAY 10 HTS 7072 7181 7015 177233.33
DAY10 HTS 7977 8193 7886 200466.67
DAY10 HTS 8825 8898 9061 223200
DAY10 HTS 10668 10627 10477 264766.67
DAY10 HITS 7516 7544 7721 189841.67
DAY10 HITS 6691 6842 6757 169083.33
DAY10 HITS
DAY10 HITS
DAY10 HITS 7987 7824 7865 197300
DAY10 HITS 10365 10383 10604 261266.67
DAY10 HTS 6710 6635 6507 165433.33
DAY10 HTS 7000 6842 6862 172533.33
DAY10 HTS 6176 6989 6092 160475
DAY10 HTS 7766 7665 7752 193191.67
DAY 10 HTS 9334 9316 9204 232116.67
DAY 10 HTS 11041 11170 11493 280866.67
17233
2
7707
200896
35183
2
20313
200922
19630
2
9815
212969
15611
2
6981
175172
52545
2
26273
197279
41520
2
18568
204373
39764
2
22958
200769
47170
2
21095
Appendix C
D ata sheet 2 Growth of N 87 cells in serum free medium 40,000 cells per well
DAY TREATMENT COUNT 1 
DILUTION
DAYO 10% FCS 1940
DAYO 10% FCS 1729
DAYO 10% FCS 2887
DAYO 10% FCS 1581
DAYO 10% FCS 2526
DAYO 10% FCS 2977
DAYO 10% FCS 1247
DAYO 10% FCS 2379
DAYO 10% FCS 1864
DAYO 10% FCS 1238
DAYO 10% FCS 1423
DAYO 10% FCS 2207
DAYO 10% FCS 773
DAYO 10% FCS 1102
DAYO 10% FCS 2089
DAYO 10% FCS 735
DAYO 10% FCS 1919
DAYO 10% FCS 950
DAYO 10% FCS 740
DAYO 10% FCS 860
DAYO 10% FCS 798
DAYO 10% FCS 845
DAYO 10% FCS 920
DAYO 10% FCS 580
DAY 3 HITS 3708
DAY 3 HITS 3869
DAY 3 HITS 3894
DAY 3 HITS 4383
DAY 3 HITS 3937
DAY 3 HITS 3923
DAY 3 HTS 3146
DAY 3 HTS 3530
DAY 3 HTS 3331
DAY 3 HTS 3388
DAY 3 HTS 3699
DAY 3 HTS 4037
DAY 3 HITS 3154
DAY 3 HITS 3120
DAY 3 HITS 3304
DAY 3 HITS 3429
DAY 3 HITS 3269
DAY 3 HITS 4128
DAY 3 HTS 2833
DAY 3 HTS 1821
DAY 3 HTS 2703
DAY 3 HTS 1698
DAY 3 HTS 1438
DAY 3 HTS 1144
DAY 6 HITS 4761
DAY 6 HITS 5858
DAY 6 HITS 6025
COUNT 2 COUNT 3 MEAN
25 COUNT
1997 1913 48750
1791 1721 43675
2916 2823 71883.333
1607 1711 40825
2761 2604 65758.333
2898 2931 73383.333
1222 1179 30400
2492 2307 59816.667
1813 1829 45883.333
1222 1115 29791.667
1294 1450 34725
2257 2106 54750
787 765 19375
1073 1065 27000
2047 1992 51066.667
697 725 17975
1893 1897 47575
890 882 22683.333
687 637 17200
900 929 22408.333
756 822 19800
901 918 22200
931 963 23450
466 514 13000
3698 3788 93283.333
3755 95300
4002 98700
4392 109687.5
3984 99012.5
3757 96000
3111 78212.5
3574 88800
3366 83712.5
3323 83887.5
3724 92787.5
4098 101687.5
3191 79312.5
2967 76087.5
3323 82837.5
3241 83375
3302 82137.5
3982 101375
2817 70625
1737 44475
2568 65887.5
1720 42725
1415 35662.5
1201 29312.5
4716 4853 119416.67
5815 5737 145083.33
5952 5877 148783.33
MEAN OF 
REPLICATES
57379
14649
2
6551
42561
12882
2
5761
30946
14611
2
6534
19676
3970
2
1775
98664
5814
2
2600
88181
8268
2
3698
84188
8848
2
3957
48115
16574
2
7412
159453
Appendix C
Data sheet 2 Growth of N 87 cells in serum free medium 40,000 cells per well
DAY 6 HITS 6816 6811 6862 170741.67 26447
DAY 6 HITS 7380 7381 7565 186050 2
DAY 6 HITS 7415 7547 7435 186641.67 11828
DAY 6 HTS 4442 4348 4514 110866.67
DAY 6 HTS 5176 5175 5098 128741.67 130546
DAY 6 HTS 5704 5845 5566 142625 13695
DAY 6 HTS 4826 4821 4810 120475 2
DAY 6 HTS 5295 5288 5360 132858.33 6125
DAY 6 HTS 5929 5974 5822 147708.33
DAY 6 HITS 4984 4805 4942 122758.33 141149
DAY 6 HITS 5064 5072 5046 126516.67 23906
DAY 6 HITS 5486 5438 5464 136566.67 2
DAY 6 HITS 5519 5461 5449 136908.33 10691
DAY 6 HITS 5390 5413 5481 135700
DAY 6 HITS 7100 7444 8069 188441.67
DAY 6 HTS 3836 3875 3689 95000
DAY 6 HTS 3822 3839 3801 95516.667
DAY 6 HTS 2796 2788 2716 69166.667 75453
DAY 6 HTS 2584 2557 2454 63291.667 15733
DAY 6 HTS 2841 2703 2788 69433.333 2
DAY 6 HTS 2455 2337 2445 60308.333 7036
DAY10 HITS 9244 9329 9657 235250
DAY10 HITS 10884 10483 10582 266241.67
DAY 10 HITS 9265 9305 9050 230166.67 284876
DAY10 HITS 13508 13608 13527 338691.67 54242
DAY10 HITS 11060 11168 11001 276908.33 2
DAY10 HITS 14323 14627 14490 362000 24258
DAY10 HTS 9742 9409 9401 237933.33
DAY10 HTS 10782 10942 10865 271575
DAY10 HTS 10532 10546 10610 264066.67 261364
DAY10 HTS 9464 9564 9665 239108.33 18440
DAY10 HTS 10713 10886 11959 279650 2
DAY10 HTS 12108 11758 9236 275850 8246
DAY10 HITS 9519 9524 9918 241341.67
DAY10 HITS 10557 10772 10745 267283.33 294168
DAY 10 HITS 10500 10561 10221 260683.33 44669
DAY10 HITS 12113 12371 12302 306550 2
DAY10 HITS 13475 13597 13399 337258.33 19977
DAY10 HITS 14132 14063 14032 351891.67
DAY10 HTS 9850 9736 10053 246991.67
DAY10 HTS 8731 8654 8637 216850
DAY 10 HTS 7921 7976 7982 198991.67 188094
DAY10 HTS 6094 6201 6057 152933.33 43748
DAY10 HTS 7531 7514 7431 187300 2
DAY 10 HTS 5039 5144 4877 125500 19565
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Data sheet 3 Growth of N 87 cells in serum free medium 40,000 cells per well
DAY TREATMENT COUNT 1 
DILUTION
DAYO HITS 430
DAYO HITS 573
DAYO HITS 515
DAYO HITS 474
DAYO HITS 452
DAYO HITS 596
DAYO HITS 440
DAYO HITS 359
DAYO HITS 450
DAYO HITS 375
DAYO HITS 500
DAYO HITS 506
DAYO HITS 293
DAYO HITS 286
DAYO HITS 349
DAYO HITS 291
DAYO HITS 230
DAYO HITS 294
DAYO HITS 312
DAYO HITS 275
DAYO HITS 235
DAYO HITS 301
DAYO HITS 318
DAYO HITS 365
DAY 3 HITS 1068
DAY 3 HITS 1077
DAY 3 HITS 1046
DAY 3 HITS 1282
DAY 3 HITS 1232
DAY 3 HITS 1481
DAY 3 HTS 1054
DAY 3 HTS 1014
DAY 3 HTS 1176
DAY 3 HTS 1133
DAY 3 HTS 909
DAY 3 HTS 926
DAY 3 HITS 680
DAY 3 HITS 1266
DAY 3 HITS 1040
DAY 3 HITS 1263
DAY 3 HITS 1021
DAY 3 HITS 725
DAY 3 HTS 582
DAY 3 HTS 472
DAY 3 HTS 496
DAY 3 HTS 570
DAY 3 HTS 536
DAY 3 HTS 436
DAY 5 HITS 1631
DAY 5 HITS 2624
DAY 5 HITS 1982
DUNT3 MEAN MEAN OF 
REPLICATES
435 10608 12478
599 14317 1880
486 12417 2
433 11350 841
409 10992
626 15183
462 11500 11339
415 9833 1404
469 11533 2
416 9633 628
494 12250
566 13283
256 6400 7206
277 7158 904
344 8583 2
321 7808 404
234 6125
284 7158
301 7375 7569
277 7383 821
276 6267 2
314 7658 367
311 7967
341 8767
1061 26658 30336
1213 28142 4745
1005 25567 2
1230 30658 2122
1322 32483
1547 38508
1046 26242 26268
1077 25767 2570
1255 29808 2
1175 28650 1150
961 23458
972 23683
711 17342 25463
1342 32258 6102
1079 26067 2
1224 31100 2729
1122 26867
795 19142
611 14800 13196
350 12767 1362
497 12300 2
577 14467 609
548 13625
438 11217
1681 41492 54756
2588 65183 8899
1907 48775 2
COUNT
25
408
546
489
455
458
600
478
406
465
365
476
522
219
296
337
325
271
281
272
334
241
304
327
346
1070
1087
1017
1167
1344
1593
1049
1001
1146
1130
945
944
690
1263
1009
1245
1081
777
583
710
483
589
551
472
1667
2610
1964
Appendix C
Data sheet 3 Growth of N 87 cells in serum free medium 40,000 cells per well
DAY 5 HITS 2157
DAY 5 HITS 2341
DAY 5 HITS 2493
DAY 5 HTS 1764
DAY 5 HTS 1100
DAY 5 HTS 2189
DAY 5 HTS 1604
DAY 5 HTS 1572
DAY 5 HTS 882
DAY 5 HITS 1479
DAY 5 HITS 704
DAY 5 HITS 2658
DAY 5 HITS 348
DAY 5 HITS 1730
DAY 5 HITS 1297
DAY 5 HTS 844
DAY 5 HTS 632
DAY 5 HTS 808
DAY 5 HTS 310
DAY 5 HTS 735
DAY 5 HTS 521
DAY 7 HITS 3939
DAY 7 HITS 5199
DAY 7 HITS 5983
DAY 7 HITS 5023
DAY 7 HITS 3362
DAY 7 HITS 4115
DAY 7 HTS 4454
DAY 7 HTS 4416
DAY 7 HTS 3126
DAY 7 HTS 3864
DAY 7 HTS 3790
DAY 7 HTS 4571
DAY 7 HITS 5655
DAY 7 HITS 4881
DAY 7 HITS 2648
DAY 7 HITS 4818
DAY 7 HITS 5788
DAY 7 HITS 1390
DAY 7 HTS 2861
DAY 7 HTS 2339
DAY 7 HTS 3618
DAY 7 HTS 655
DAY 7 HTS 407
DAY 7 HTS 384
1999 52050 3980
2461 59567
2497 61467
1751 43658 37446
988 26133 12169
2235 55108 2
1520 38967 5442
1580 39358
830 21450
1478 37708 33972
699 17825 20203
2686 65750 2
272 7758 9035
1674 42175
1336 32617
799 20200 15664
611 14950 4907
841 20308 2
332 8083 2195
742 18375
498 12067
4314 103608 115904
5102 130083 22259
5973 148600 2
4857 123192 9955
3578 87017
4122 102925
4472 111708 101350
4455 111658 14061
3140 78500 2
3925 97300 6288
3768 94050
4726 114883
5670 142342 105551
4732 120242 45363
2555 64500 2
4942 123125 20287
5947 147825
1425 35275
3034 73825 42556
2261 57400 34754
3411 87700 2
631 16308 15542
417 10658
366 9442
2090
2346
2386
1724
1048
2189
1552
1571
862
1568
736
2546
311
1657
1281
781
551
788
328
728
429
4180
5309
5876
4903
3502
4114
4479
4528
3154
3887
3728
4489
5756
4816
2537
5015
6004
1418
2964
2288
3495
671
455
383
Appendix C
Data sheet 4 Growth of MKN 45 cells with IGF-1 40,000 cells per well
DAY TREATMENT COUNT 1 
DILUTION
DAYO HITS 522
DAYO HITS 605
DAYO HITS 561
DAYO HITS 665
DAYO HTS 604
DAYO HTS 707
DAYO HTS 483
DAYO HTS 690
DAYO HTS 767
DAYO HTS 847
DAYO HTS 899
DAYO HTS 874
DAYO HTS 758
DAYO HTS 791
DAYO HTS 952
DAYO HTS 452
DAYO HTS 961
DAYO HTS 1099
DAYO HTS 909
DAYO HTS 751
DAYO HTS 961
DAYO HTS 1066
DAYO HTS 1076
DAYO HTS 936
DAY 3 HITS 1433
DAY 3 HITS 2100
DAY 3 HITS 2076
DAY 3 HITS 2278
DAY 3 100nM IGF1 1256
DAY 3 100nM IGF1 1253
DAY 3 100nM IGF1 1779
DAY 3 100nM IGF1 1317
DAY 3 10nM IGF1 1825
DAY 3 10nM IGF1 1858
DAY 3 10nM IGF1 2215
DAY 3 10nM IGF1 2241
DAY 3 1nM IGF1 1771
DAY 3 1nM IGF1 1841
DAY 3 1nM IGF1 1593
DAY 3 1nM IGF1 1471
DAY 3 0.1nM IGF1 1369
DAY 3 0.1nM IGF1 2053
DAY 3 0.1 nM IGF1 1861
DAY 3 0.1nM IGF1 1139
DAY 3 HTS 1791
DAY 3 HTS 2037
DAY 3 HTS 1605
DAY 3 HTS 821
DAY 5 HITS 3016
DAY 5 HITS 3782
DAY 5 HITS 4071
2 COUNT 3 MEAN MEAN OF 
REPLICATES
491 12700 14910
624 15433.3 2084
575 13958.3 2
695 17550 1203
579 14700 15469
727 18308.3 2893
448 11758.3 2
692 17108.3 1670
817 19891.7 21431
810 20775 1524
984 23466.7 2
829 21591.7 880
761 18400 18663
811 20191.7 5464
974 24600 2
459 11458.3 3155
993 24041.7 22975
1038 26933.3 3729
932 22941.7 2
689 17983.3 2153
960 23791.7 24708
1014 25500 1564
1019 26483.3 2
930 23058.3 903
1412 35633.3 48871
2133 52275 9057
2040 51450 2
2249 56125 5229
1278 31341.7 35308
1256 31591.7 6569
1791 45083.3 2
1340 33216.7 3793
1773 45100 50481
1837 46058.3 5754
2154 54208.3 2
2305 56558.3 3322
1660 43075 41615
1830 46458.3 4215
1682 40441.7 2
1403 36483.3 2434
1439 34866.7 39933
2066 51791.7 10436
1782 44825 2
1131 28250 6025
1811 44133.3 38492
2096 51491.7 14174
1592 39850 2
680 18491.7 8183
3009 75983.3 94577
3009 86916.7 15980
4261 104783 2
COUNT
25
511
623
539
746
581
763
480
671
803
836
933
888
689
821
1026
464
931
1095
912
718
934
980
1083
901
1431
2040
2058
2208
1227
1282
1840
1329
1814
1832
2136
2241
1738
1904
1578
1504
1376
2096
1736
1120
1694
2046
1585
718
3093
3639
4242
Appendix C
Data sheet 4 Growth of MKN 45 cells with IGF-1 40,000 cells per well
DAY 5 HITS 4514
DAY 5 100nM 3117
DAY 5 100nM 3012
DAY 5 100nM 2898
DAY 5 100nM 3270
DAYS 10nM 4045
DAY 5 10nM 3409
DAY 5 10nM 3949
DAY 5 10nM 3418
DAY 5 1nM 2917
DAY 5 1nM 3513
DAY 5 1nM 3724
DAY 5 1nM 1110
DAY 5 0.1nM 2056
DAY 5 0.1nM 3377
DAY 5 0.1nM 2753
DAY 5 0.1nM 1230
DAY 5 HTS 1258
DAY 5 HTS 2011
DAY 5 HTS 1773
DAY 5 HTS 799
4350 110625 9226
3157 79441.7 76646
3103 75508.3 3291
2880 72500 2
3081 79133.3 1900
4133 101667 92781
3364 85275 9733
4132 100692 2
3320 83491.7 5619
2808 70933.3 70363
3700 89925 30851
3872 93983.3 2
1017 26608.3 17812
2129 53016.7 58969
3405 84583.3 23292
2713 68408.3 2
1159 29866.7 13448
1179 30491.7 35829
1968 49991.7 13313
1707 42900 2
810 19933.3 7686
4411
3259
2946
2922
3145
4022
3460
4002
3281
2787
3578
3682
1066
2177
3368
2743
1195
1222
2020
1668
783
Appendix C
Data sheet 5 Growth of N 87 cells with IGF-1 40,000 cells per well
DAY TREATMENT COUNT 1 COUNT 2 COUNT 3 MEAN MEAN OF
DILUTION 100 REPLICATES
DAYO HITS 2288 2437 2336 235367 412322
DAYO HITS 4985 5052 5055 503067 153265
DAYO HITS 1
DAYO HITS 4974 5014 4968 498533 108375
DAYO HTS 4121 4181 4131 414433 429289
DAYO HTS 4098 4035 4022 405167 34072
DAYO HTS 1
DAYO HTS 4652 4712 4684 468267 24093
DAYO HTS 4836 4743 4765 478133 459083
DAYO HTS 4823 4867 4753 481433 24171
DAYO HTS 4451 4423 4400 442467 2
DAYO HTS 4365 4305 4359 434300 13955
DAYO HTS 471300
DAYO HTS 4921 4686 4570 472567 1791
DAYO HTS 4694 4687 4720 470033 1
DAYO HTS 1791
DAYO HTS 4792 479200 395000
DAYO HTS 3810 3685 3712 373567 56893
DAYO HTS 3740 3700 3762 373400 2
DAYO HTS 3475 3650 3490 353833 32847
DAYO HTS 3485 3452 3395 344400 378058
DAYO HTS 4227 4207 4335 425633 34940
DAYO HTS 3732 3752 3925 380300 2
DAYO HTS 3670 3540 3647 361900 20173
DAY 3 HITS 3467 3564 3527 351933 403500
DAY 3 HITS 4564 4719 4443 457533 46684
DAY 3 HITS 3844 3851 3717 380400 2
DAY 3 HITS 4293 4271 4160 424133 26953
DAY 3 100nM IGF1 4696 4722 4730 471600 624017
DAY 3 100nM IGF1 6543 6573 6528 654800 119675
DAY 3 100nM IGF1 7627 7577 7605 760300 2
DAY 3 100nM IGF1 6164 6188 5929 609367 69094
DAY 3 10nM IGF1 651900
DAY 3 10nM IGF1 6502 6571 6462 651167 80336
DAY 3 10nM IGF1 7293 7277 7408 732600 1
DAY 3 10nM IGF1 5749 5653 5756 571933 56806
DAY 3 1nM IGF1 5600 5658 5638 563200 611250
DAY 3 1nM IGF1 6344 6507 6358 640300 56265
DAY 3 1nM IGF1 5778 5543 5636 565233 2
DAY 3 1nM IGF1 6704 6757 6827 676267 32485
DAY 3 0.1nM IGF1 5599 5697 5729 567500 654508
DAY 3 0.1 nM IGF1 6644 6698 6662 666800 61862
DAY 3 0.1 nM IGF1 6774 6707 6615 669867 2
DAY 3 0.1nM IGF1 7216 7051 7149 713867 35716
DAY 3 HTS 6082 5959 6249 609667 499025
DAY 3 HTS 4816 4801 4750 478900 87221
DAY 3 HTS 5057 5152 5058 508900 2
DAY 3 HTS 3971 4092 3896 398633 50357
412322
153265
1
108375
421120
67190
4
15414
Appendix C
Data sheet 5 Growth of N 87 cells with IGF-1 40,000 cells per well
DAY 5 HITS
DAY 5 HITS
DAY 5 HITS
DAY 5 HITS
DAY 5 100nM
DAY 5 100nM
DAY 5 100nM
DAY 5 100nM
DAY 5 10nM
DAY 5 10nM
DAY 5 10nM
DAY 5 10nM
DAY 5 1nM
DAY 5 1nM
DAY 5 1nM
DAY 5 1nM
DAY 5 0.1nM
DAY 5 0.1nM
DAY 5 0.1nM
DAY 5 0.1nM
DAY 5 HTS
DAY 5 HTS
DAY 5 HTS
DAY 5 HTS
3764 3920
3893 3862
5823 5883
6434 6341
8988 9332
8488 8173
8963 9353
8418 8530
9786 9811
9472 9521
8838 9117
10461 10609
7417 7369
7712 7720
8518 8449
7760 7757
7740 7784
8337 8319
9864 10119
10282 10283
8537 8474
8039 7862
8636 8723
6564 6547
3788 382400
3789 384800
5917 587433
6461 641200
9475 926500
8229 829667
8891 906900
8690 854600
9674 975700
9732 957500
8865 894000
10581 1055033
7388 739133
7739 772367
8333 843333
7692 773633
7766 776333
8453 836967
10402 1012833
10547 1037067
8719 857667
7831 791067
8931 876333
6483 653133
498958
135004
2
77945
879417
44956
2
25955
970558
66318
2
38289
782117
43826
2
25303
915800
128824
2
74376
794550
101132
2
58389
855175
125284
3
47353
Appendix C
Data sheet 6 Growth of MKN 45 cells with IGF-1 30,000 cells per well
DAY TREATMENT COUNT 1 COUNT 2
DILUTION 25
DAYO HTS 1193 1139
DAYO HTS 1337 1262
DAYO HTS 1464 1488
DAYO HTS 1495 1486
DAYO HTS 1393 1349
DAYO HTS 1411 1367
DAYO HTS 1436 1438
DAYO HTS 1297 1285
DAYO HTS 1280 1341
DAYO HTS 1516 1502
DAYO HTS 1246 1236
DAYO HTS 1152 1203
DAYO HTS 1202 1201
DAYO HTS 1236 1220
DAYO HTS 1104 1143
DAYO HTS 1114 1168
DAYO HTS 1306 1240
DAYO HTS 908 930
DAYO HTS 1552 1493
DAYO HTS 1513 1488
DAYO HTS 1501 1394
DAYO HTS 1236 1277
DAYO HTS 1155 1155
DAYO HTS 1407 1395
DAY 3 HTS 3485 3433
DAY 3 HTS 4135 4027
DAY 3 HTS 3259 3017
DAY 3 HTS 4059 4032
DAY 3 HTS 3435 3517
DAY 3 HTS 2888 2853
DAY 3 10nM IGF1 5119 4967
DAY 3 10nM IGF1 4166 4039
DAY 3 10nM IGF1 4303 4242
DAY 3 10nM IGF1 4018 4051
DAY 3 10nM IGF1 3355 3299
DAY 3 10nM IGF1 4817 4675
DAY 3 1nM IGF1 3750 3744
DAY 3 1nM IGF1 3736 3891
DAY 3 1nM IGF1 3707 3853
DAY 3 1nM IGF1 3703 3742
DAY 3 1nM IGF1 3522 3383
DAY 3 1nM IGF1 2601 2575
DAY 3 0.1 nM IGF1 3815 3846
DAY 3 0.1 nM IGF1 4441 4334
DAY 3 0.1nM IGF1 3707 3765
DAY 3 0.1nM IGF1 3387 3252
DAY 3 0.1nM IGF1 4228 4164
DAY 3 0.1 nM IGF1 3987 3972
DAY 5 HTS 5024 5015
DAY 5 HTS 4767 4684
DAY 5 HTS 4379 4419
MEAN MEAN OF 
REPLICATES
29266.7 34083 31918
32475 2867 3759
36666.7 2 4
36925 
34775 
34391.7
1282 912
35641.7 33035
32316.7 3219
32533.3 2
37825
31000
28891.7
1440
29941.7 28636
30650 3067
28283.3 2
28633.3
31441.7
22866.7
1372
37891.7 34375
37150 3494
36358.3 2
31283.3
29133.3
34433.3
1563
86208.3 87793
103250 12833
77833.3 2
102175
86016.7
71275
5739
125100 105867
102725 14816
106408 2
99766.7
82925
118275
6626
93708.3 87690
96050 11788
93400 2
92708.3
85525
64750
5272
95358.3 97700
110892 9460
93333.3 2
83475
104450
98691.7
4231
124608 135013
118825 20069
110267 2
Appendix C
COUNT
1180
1298
1448
1450
1431
1349
1403
1296
1283
1521
1238
1112
1190
1222
1147
1154
1227
906
1502
1457
1468
1241
1186
1330
3427
4228
3064
4170
3370
2812
4926
4122
4224
3903
3297
4701
3751
3899
3648
3680
3358
2594
3782
4532
3728
3378
4142
3884
4914
4808
4434
Data sheet 6 Growth of MKN 45 cells with IGF-1 30,000 cells per well
DAY 5 HTS 5659
DAY 5 HTS 6321
DAY 5 HTS 5938
DAY 5 10nM IGF1 4314
DAY 5 10nM IGF1 5329
DAY 5 10nM IGF1 6225
DAY 5 10nM IGF1 6389
DAY 5 10nM IGF1 6774
DAY 5 10nM IGF1 6375
DAY 5 1nM IGF1 5963
DAY 5 1nM IGF1 5358
DAY 5 1nM IGF1 6078
DAY 5 1nM IGF1 5922
DAY 5 1nM IGF1 6453
DAY 5 1nM IGF1 6039
DAY 5 0.1nM IGF1 6049
DAY 5 0.1nM IGF1 6363
DAY 5 0.1nM IGF1 6045
DAY 5 0.1nM IGF1 6471
DAY 5 0.1 nM IGF1 5821
DAY 5 0.1nM IGF1 6828
DAY 7 HTS 5798
DAY 7 HTS 6669
DAY 7 HTS 6977
DAY 7 HTS 6477
DAY 7 HTS 6537
DAY 7 HTS 7458
DAY 7 10nM IGF1 7374
DAY 7 10nM IGF1 8678
DAY 7 10nM IGF1 8920
DAY 7 10nM IGF1 7947
DAY 7 10nM IGF1 9663
DAY 7 10nM IGF1 10546
DAY 7 1nM IGF1
DAY 7 1nM IGF1 6082
DAY 7 1nM IGF1 7057
DAY 7 1nM IGF1 6423
DAY 7 1nM IGF1 6774
DAY 7 1nM IGF1 5776
DAY 7 0.1nM IGF1 5867
DAY 7 0.1nM IGF1 6443
DAY 7 0.1 nM IGF1 6267
DAY 7 0.1nM IGF1 7004
DAY 7 0.1nM IGF1 7364
DAY 7 0.1nM IGF1 7966
5849 145533 8975
6702 162033
5889 148808
4421 111325 144792
5270 132017 23033
6153 153758 2
6183 157783 11517
6726 169075
6559 160258
5803 147942 147804
5218 131583 8732
6086 151617 2
6190 150742 3905
6239 157542
5757 147400
6243 153533 155513
6381 160150 8810
5960 148967 2
6382 159333 3940
5675 143192
6637 167900
5840 145033 167543
6583 166533 14531
7140 177167 2
6359 159792 6499
6921 169392
7545 187342
7460 186625 221497
8625 216450 28853
8920 223450 2
7833 195433 12903
9765 243825
10477 263200
#DIV/0! 159845
5973 150658 13247
7042 173967 2
6303 160558 6623
6799 171192
5665 142850
5721 145158 170168
6397 160275 19922
6323 156033 2
6931 176492 8909
7341 184142
7918 198908
5956
6421
6030
4624
5243
6073
6362
6789
6297
5987
5214
6030
5977
6213
5892
6132
6474
5871
6267
5687
6683
5766
6732
7143
6339
6869
7478
7561
8671
8974
7672
9831
10561
6024
6777
6541
6970
5701
5831
6393
6134
7244
7392
7985
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Data sheet 7 Growth of N 87 cells with IGF-1 40,000 cells per well
DAY TREATMENT COUNT 1 COUNT 2
DILUTION 25
DAYO HTS 1283 1280
DAYO HTS 1333 1311
DAYO HTS 1382 1349
DAYO HTS 1370 1410
DAYO HTS 1248 1214
DAYO HTS 1346 1302
DAYO HTS 1238 1285
DAYO HTS 1340 1377
DAYO HTS 1495 1452
DAYO HTS 1308 1321
DAYO HTS 1357 1377
DAYO HTS 1369 1305
DAYO HTS 1272 1264
DAYO HTS 1317 1297
DAYO HTS 1388 1268
DAYO HTS 1439 1422
DAYO HTS 1205 1211
DAYO HTS 1142 1099
DAYO HTS 1346 1337
DAYO HTS 1297 1283
DAYO HTS 1217 1230
DAYO HTS 1204 1216
DAYO HTS 1258 1209
DAYO HTS 1215 1272
DAY 2 HTS 1927 1994
DAY 2 HTS 1958 1990
DAY 2 HTS 1825 1760
DAY 2 HTS 1844 1878
DAY 2 HTS 1972 2034
DAY 2 HTS 1463 1558
DAY 2 10nM IGF1 1942 1966
DAY 2 10nM IGF1 2335 2389
DAY 2 10nM IGF1 2398 2330
DAY 2 10nM IGF1 2273 2358
DAY 2 10nM IGF1 2517 2459
DAY 2 10nM IGF1 2277 2365
DAY 2 1nM IGF1 2609 2637
DAY 2 1nM IGF1 2101 2085
DAY 2 1nM IGF1 2284 2356
DAY 2 1nM IGF1 2318 2365
DAY 2 1nM IGF1 2170 2280
DAY 2 1nM IGF1 1636 1530
DAY 2 0.1nM IGF1 2250 2235
DAY 2 0.1nM IGF1 2439 2405
DAY 2 0.1 nM IGF1 2182 2178
DAY 2 0.1nM IGF1 2142 2133
DAY 2 0.1nM IGF1 2313 2340
DAY 2 0.1nM IGF1 2353 2430
DAY 5 HTS 2921 3087
DAY 5 HTS 2898 2948
DAY 5 HTS 2337 2389
DUNT3 MEAN MEAN OF 
REPLICATES
1317 32333.3 32943 32791
1274 32650 1465 2040
1370 34175 2 4
1419 34991.7 655 495
1237 30825
1274 32683.3
1281 31700 33751
1338 33791.7 1660
1466 36775 2
1363 33266.7 742
1304 33650
1325 33325
1225 31341.7 31678
1282 32466.7 2573
1220 32300 2
1412 35608.3 1151
1255 30591.7
1090 27758.3
1372 33791.7 31433
1271 32091.7 1323
1249 30800 2
1202 30183.3 592
1204 30591.7
1250 31141.7
1938 48825 46168
1986 49450 4602
1718 44191.7 2
1896 46816.7 2058
1983 49908.3
1517 37816.7
1967 48958.3 57706
2442 59716.7 4582
2415 59525 2
2290 57675 2049
2498 62283.3
2327 58075
2435 64008.3 53933
2110 52466.7 8222
2243 57358.3 2
1962 55375 3677
2180 55250
1531 39141.7
2290 56458.3 57008
2493 61141.7 2794
2218 54816.7 2
2125 53333.3 1250
2252 57541.7
2268 58758.3
2890 74150 71203
2930 73133.3 8410
2189 57625 2
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Data sheet 7 Growth of N 87 cells with IGF-1 40,000 cells per well
DAY 5 HTS 2928 2898 2815 72008.3 3761
DAY 5 HTS 3328 3367 3272 83058.3
DAY 5 HTS 2707 2713 2649 67241.7
DAY 5 10nM IGF1 4923 4911 4914 122900 136997
DAY 5 10nM IGF1 5804 5900 5952 147133 13098
DAY 5 10nM IGF1 4901 4838 4975 122617 2
DAY 5 10nM IGF1 5994 5983 5828 148375 6549
DAY 5 10nM IGF1 5760 5707 5808 143958
DAY 5 10nM IGF1 3573 3484 3370 86891.7
DAY 5 1nM IGF1 4483 4456 4476 111792 114900
DAY 5 1nM IGF1 5075 5047 4939 125508 15528
DAY 5 1nM IGF1 4724 4758 4619 117508 2
DAY 5 1nM IGF1 5182 5279 5080 129508 6944
DAY 5 1nM IGF1 4905 4622 4782 119242
DAY 5 1nM IGF1 3210 3750 3341 85841.7
DAY 5 0.1 nM IGF1 3915 3798 3892 96708.3 98503
DAY 5 0.1 nM IGF1 4412 4421 4476 110908 16071
DAY 5 0.1nM IGF1 3718 3487 3622 90225 2
DAY 5 0.1nM IGF1 4951 4939 5031 124342 7187
DAY 5 0.1nM IGF1 3449 3402 3377 85233.3
DAY 5 0.1nM IGF1 3362 3342 3328 83600
DAY 7 HTS 3456 3201 3224 82341.7 95669
DAY 7 HTS 3385 3354 3404 84525 27520
DAY 7 HTS 2813 2803 2804 70166.7 2
DAY 7 HTS 5348 5026 5101 128958 12307
DAY 7 HTS 5343 5298 5221 132183
DAY 7 HTS 3037 3062 3002 75841.7
DAY 7 10nM IGF1 7732 7650 7670 192100 177906
DAY 7 10nM IGF1 8251 8133 8063 203725 21261
DAY 7 10nM IGF1 7724 7613 7618 191292 2
DAY 7 10nM IGF1 5898 6055 6029 149850 9508
DAY 7 10nM IGF1 6375 6255 6330 158000
DAY 7 10nM IGF1 6831 6882 6983 172467
DAY 7 1nM IGF1 5801 5834 5710 144542 146819
DAY 7 1nM IGF1 6352 6352 6397 159175 9950
DAY 7 1nM IGF1 5475 5529 5458 137183 2
DAY 7 1nM IGF1 6322 6439 6297 158817 4450
DAY 7 1nM IGF1 5695 5774 5810 143992
DAY 7 1nM IGF1 5450 5515 5500 137208
DAY 7 0.1nM IGF1 5873 5882 5960 147625 157518
DAY 7 0.1nM IGF1 6391 6303 6214 157567 16559
DAY 7 0.1nM IGF1 7223 7163 7119 179208 2
DAY 7 0.1nM IGF1 6722 6872 6695 169075 7405
DAY 7 0.1nM IGF1 6202 6302 6681 159875
DAY 7 0.1 nM IGF1 5272 5296 5243 131758
Appendix C
Data sheet 8 Growth of MKN 45
DAY TREATMENT COUNT 1 COUNT
DILUTION 25
DAYO HTS 914 873
DAYO HTS 993 952
DAYO HTS 986 981
DAYO HTS 850 878
DAYO HTS 936 961
DAYO HTS 970 952
DAYO HTS 795 827
DAYO HTS 878 797
DAYO HTS 1031 1058
DAYO HTS 667 711
DAYO HTS 722 729
DAYO HTS 932 924
DAYO HTS 706 680
DAYO HTS 743 757
DAYO HTS 858 852
DAYO HTS 825 730
DAYO HTS 791 732
DAYO HTS 872 787
DAY 3 HTS 4054 4065
DAY 3 HTS 4144 3974
DAY 3 HTS 4183 4132
DAY 3 HTS 3805 3741
DAY 3 HTS 4160 4285
DAY 3 HTS 4919 4919
DAY 3 10nM IGF1 3675 3685
DAY 3 10nM IGF1 3887 3716
DAY 3 10nM IGF1 4739 4673
DAY 3 10nM IGF1 4110 3990
DAY 3 10nM IGF1 4756 4631
DAY 3 10nM IGF1 5177 5228
DAY 3 1nM IGF1 4519 4652
DAY 3 1nM IGF1 4840 4827
DAY 3 1nM IGF1 4272 4299
DAY 3 1nM IGF1 5080 5012
DAY 3 1nM IGF1 5482 5559
DAY 3 1nM IGF1 5051 5032
DAY 5 HTS 7129 7062
DAY 5 HTS 7605 7553
DAY 5 HTS 7075 6910
DAY 5 HTS 6419 6337
DAY 5 HTS 7808 7751
DAY 5 HTS 6928 6618
DAY 5 10nM IGF1 7965 7872
DAY 5 10nM IGF1 8423 8691
DAY 5 10nM IGF1 9112 8847
DAY 5 10nM IGF1 8482 8513
DAY 5 10nM IGF1 9738 9506
DAY 5 10nM IGF1 8349 8479
DAY 5 1nM IGF1 7745 7458
DAY 5 1nM IGF1 8189 7994
DAY 5 1nM IGF1 6970 7136
IGF-1 30,000 cells per well
3 MEAN MEAN OF 
REPLICATES 
22375 23483 21251
24350 1136 2640
24483.3 2 4
21791.7 508 640
23650
24250
19966.7 20889
21300 3198
25858.3 2
17108.3 1430
18216.7
22883.3
17500 19382
18866.7 1359
21250 2
19216.7 608
18816.7
20641.7
101550 104894
101217 9992
103658 2
93458.3 4468 
106133
123350
93150 109290
95216.7 15061
117692 2
100767 6735
118450
130467
115175 122243
120492 10644
106783 2
127367 4760
137508 
126133
176108 177150
189233 12779
174458 2
159908 5715
194350 
168842
196875 215950
212175 14456
224283 2
213492 6465
239392 
209483
189992 182671
199583 13343
174550 2
cells with
2 COUNT
898
977
971
887
941
988
774
881
1014
675
735
890
714
764
840
751
735
818
4067
4028
4124
3669
4291
4964
3818
3823
4711
3992
4827
5251
4650
4792
4243
5192
5460
5053
6942
7550
6950
6433
7763
6715
7788
8347
8955
8624
9483
8310
7596
7767
6840
Appendix C
Data sheet 8 Growth of MKN 45 cells with IGF-1 30,000 cells per well
DAY 5 1nM IGF1 7672
DAY 5 1nM IGF1 7239
DAY 5 1nM IGF1 6508
DAY 7 HTS 11245
DAY 7 HTS 11430
DAY 7 HTS 9296
DAY 7 HTS 8492
DAY 7 HTS 10429
DAY 7 HTS 11067
DAY 7 10nM IGF1 14452
DAY 7 10nM IGF1 15961
DAY 7 10nM IGF1 17082
DAY 7 10nM IGF1 12405
DAY 7 10nM IGF1 15077
DAY 7 10nM IGF1 14442
DAY 7 1nM IGF1 13509
DAY 7 1nM IGF1 14121
DAY 7 1nM IGF1 14716
DAY 7 1nM IGF1 11062
DAY 7 1nM IGF1 12630
DAY 7 1nM IGF1 12631
7487 190442 5967
7076 179067
6492 162392
11178 277800 256236
11131 281408 28727
8985 227300 2
8524 214000 12847
10501 261108
10922 275800
14073 358783 368574
15335 388458 40236
16942 423267 2
11924 301375 17994
15012 376625
14548 362933
13103 333533 324144
13992 351117 36036
14505 366267 2
9604 262892 16116
12630 316717
12732 314342
7694
7173
6487
10913
11208
8995
8664
10403
11107
14529
15319
16768
11836
15106
14562
13412
14021
14731
10881
12746
12358
Appendix C
Data sheet 9 Growth of N 87 cells with IGF-1 40,000 cells per well
DAY TREATMENT COUNT 1 
DILUTION
DAYO HTS 1864
DAYO HTS 1592
DAYO HTS 1524
DAYO HTS 1609
DAYO HTS 1422
DAYO HTS 1469
DAYO HTS 1743
DAYO HTS 1507
DAYO HTS 1670
DAYO HTS 1536
DAYO HTS 1594
DAYO HTS 1660
DAYO HTS 1695
DAYO HTS 1775
DAYO HTS 1785
DAYO HTS 1892
DAYO HTS 1826
DAYO HTS 1868
DAY 3 HTS 2572
DAY 3 HTS 2577
DAY 3 HTS 1773
DAY 3 HTS 2460
DAY 3 HTS 2561
DAY 3 HTS 2714
DAY 3 10nM IGF1 4220
DAY 3 10nM IGF1 3792
DAY 3 10nM IGF1 4332
DAY 3 10nM IGF1 4063
DAY 3 10nM IGF1 4501
DAY 3 10nM IGF1 4501
DAY 3 1nM IGF1 3645
DAY 3 1nM IGF1 4187
DAY 3 1nM IGF1 3905
DAY 3 1nM IGF1 3363
DAY 3 1nM IGF1 2713
DAY 3 1nM IGF1 2587
DAY 6 HTS 2547
DAY 6 HTS 2950
DAY 6 HTS 2931
DAY 6 HTS 2481
DAY 6 HTS 2902
DAY 6 HTS 3417
DAY 6 10nM IGF1 4885
DAY 6 10nM IGF1 5633
DAY 6 10nM IGF1 5435
DAY 6 10nM IGF1 5586
DAY 6 10nM IGF1 5534
DAY 6 10nM IGF1 5873
DAY 6 1nM IGF1 4862
DAY 6 1nM IGF1 5458
DAY 6 1nM IGF1 4803
2 COUNT 3 MEAN MEAN OF 
REPLICATES
1842 46825 39258
1553 38766.7 4071
1457 37541.7 2
1664 40375 1821
1460 35691.7
1465 36350
1717 42550 39411
1437 36800 2210
1544 39950 2
1431 37025 988
1554 39400
1632 40741.7
1729 42541.7 44879
1657 43058.3 1924
1767 44675 2
1882 47333.3 860
1811 44875
1867 46791.7
2481 63233.3 60365
2500 62825 8506
1745 43341.7 2
2478 61791.7 3804
2515 64291.7
2689 66708.3
4329 107375 106201
3788 94525 7700
4483 109067 2
3918 99416.7 3444
4636 113917
4505 112908
3625 91500 85375
4110 104067 15930
4040 98600 2
3432 84900 7124
2613 67333.3
2633 65850
2350 61258.3 71039
2847 72733.3 8889
2961 73158.3 2
2499 61725 3975
2932 72025
3452 85333.3
4942 123800 138814
5626 142233 8387
5526 136450 2
5656 141175 3751
5622 140358
6045 148867
4873 123100 122739
5301 134083 10496
4694 119142 2
COUNT
25
1913
1507
1524
1572
1401
1428
1646
1472
1580
1476
1580
1597
1681
1735
1809
1906
1748
1880
2535
2462
1683
2477
2639
2602
4336
3763
4273
3949
4533
4543
3710
4191
3887
3393
2754
2682
2454
2931
2887
2427
2809
3371
5029
5809
5413
5699
5687
5946
5037
5331
4800
Appendix C
Data sheet 9 Growth of N 87 cells with IGF-1 40,000 cells per well
DAY 6 1nM IGF1 4916
DAY 6 1nM IGF1 5202
DAY 6 1nM IGF1 4171
DAY 8 HTS 3525
DAY 8 HTS 4172
DAY 8 HTS 2122
DAY 8 HTS 4045
DAY 8 HTS 3440
DAY 8 HTS 2847
DAY 8 10nM IGF1 8475
DAY 8 10nM IGF1 9711
DAY 8 10nM IGF1 9118
DAY 8 10nM IGF1 10264
DAY 8 10nM IGF1 11258
DAY 8 10nM IGF1 9200
DAY 8 1nM IGF1 6993
DAY 8 1nM IGF1 7796
DAY 8 1nM IGF1 4232
DAY 8 1nM IGF1 6764
DAY 8 1nM IGF1 5498
DAY 8 1nM IGF1 4398
4907 123700 4694
5365 131750
4224 104658
3649 90700 83731
4062 102367 19615
2068 51883.3 2
4144 102208 8772
3350 84591.7
2762 70633.3
8357 210258 238393
9487 239692 22089
9011 227183 2
9717 251008 9878
10427 273892
9155 228325
6923 174850 148335
7834 195983 37122
4370 107600 2
6704 168725 16601
5544 135450
4252 107400
5021
5243
4164
3710
4050
2036
4076
3361
2867
8399
9565
9133
10140
11182
9044
7066
7888
4310
6779
5212
4238
Appendix C
Data sheet 10 Growth of MKN 45 cells with RG 13022 and IGF-1 25,000 cells per well
DAY TREATMENT COUNT 1
DAY0 HTS
DILUTION
2140
DAY0 HTS 1933
DAY0 HTS 1745
DAY0 HTS+DMSO 1985
DAY0 HTS+DMSO 2022
DAY0 HTS+DMSO 1858
DAY0 100RG 1744
DAYO 100RG 1722
DAYO 100RG 1865
DAYO 100RG+IGF1 1830
DAYO 100RG+IGF1 1931
DAYO 100RG+IGF1 1644
DAYO 50RG 1835
DAYO 50RG 1860
DAYO 50RG 1669
DAYO 50RG+IGF1 1835
DAYO 50RG+IGF1 1656
DAYO 50RG+IGF1 1235
DAYO 10RG 2171
DAYO 10RG 2149
DAYO 10RG 1601
DAYO 10RG+IGF1 2005
DAYO 10RG+IGF1 1889
DAYO 10RG+IGF1 1789
DAYO IGF1 2202
DAYO IGF1 2258
DAYO IGF1 1909
DAYO IGF1+DMSO 1897
DAYO IGF1+DMSO 1947
DAYO IGF1+DMSO 1835
DAY 3 HTS 4200
DAY 3 HTS 4756
DAY 3 HTS 5219
DAY 3 HTS+DMSO 5552
DAY 3 HTS+DMSO 5891
DAY 3 HTS+DMSO 5816
DAY 3 100RG 3343
DAY 3 100RG 3634
DAY 3 100RG 3176
DAY 3 100RG+IGF1 3393
DAY 3 100RG+IGF1 3677
DAY 3 100RG+IGF1 2611
DAY 3 50RG 4903
DAY 3 50RG 4202
DAY 3 50RG 4009
DAY 3 50RG+IGF1 4278
DAY 3 50RG+IGF1 4073
DAY 3 50RG+IGF1 3868
DAY 3 10RG 5252
DAY 3 10RG 5240
DAY 3 10RG 4954
2 COUNT 3 MEAN MEAN OF 
REPLICATES
2049 52516.7 47492
1806 46700 4680
1737 43258.3 1
1982 49675 48261
1921 48658.3 1649
1873 46450 1
1725 42425 43306
1752 42708.3 1288
1766 44783.3 1
1899 46641.7 45064
1894 47333.3 3350
1670 41216.7 1
1822 45850 44669
1864 46116.7 2280
1681 42041.7 1
1801 45583.3 39353
1630 41400 7468
1254 31075 1
2127 54050 49864
2213 54891.7 7991
1644 40650 1
1995 50083.3 47408
1851 46475 2352
1852 45666.7 1
2179 54525 52586
2240 56341.7 5014
1838 46891.7 1
1956 48625 47058
1901 47758.3 2010
1783 44791.7 1
4218 105258 118353
4661 117900 13327
5300 131900 1
5493 137167 142933
5829 146783 5087
5714 144850 1
3433 84300 84453
3547 89083.3 4556
3163 79975 1
3399 84700 80586
3739 93166.7 15065
2520 63891.7 1
5010 125733 110403
4345 105933 13656
3904 99541.7 1
4320 107492 101492
3945 100633 5620
3813 96350 1
5186 130942 128219
5165 129717 3705
4914 124000 1
COUNT
25
2113
1865
1709
1994
1896
1843
1622
1651
1743
1868
1855
1632
1845
1810
1695
1834
1682
1240
2188
2225
1633
2010
1837
1839
2162
2263
1880
1982
1883
1757
4213
4731
5309
5415
5894
5852
3340
3509
3258
3372
3764
2536
5175
4165
4032
4301
4058
3881
5275
5161
5012
Appendix C
Data sheet 10 Growth of MKN 45 cells with RG 13022 and IGF-1 25,000 cells per well
DAY 3 10RG+IGF1 4798
DAY 3 10RG+IGF1 5171
DAY 3 10RG+IGF1 4838
DAY 3 IGF1 5640
DAY 3 IGF1 5950
DAY 3 IGF1 4658
DAY 3 IGF1+DMSO 4797
DAY 3 IGF1+DMSO 4800
DAY 3 IGF1+DMSO 4877
DAY 5 HTS 6976
DAY 5 HTS 6934
DAY 5 HTS 7018
DAY 5 HTS+DMSO 8062
DAY 5 HTS+DMSO 8270
DAY 5 HTS+DMSO 7533
DAY 5 100RG 4063
DAY 5 100RG 3019
DAY 5 100RG 2884
DAY 5 100RG+IGF1 2807
DAY 5 100RG+IGF1 2859
DAY 5 100RG+IGF1 2153
DAY 5 50RG 3280
DAY 5 50RG 2811
DAY 5 50RG 2885
DAY 5 50RG+IGF1 2623
DAY 5 50RG+IGF1 2133
DAY 5 50RG+IGF1 2354
DAY 5 10RG 9146
DAY 5 10RG 9184
DAY 5 10RG 7301
DAY 5 10RG+IGF1 7405
DAY 5 10RG+IGF1 7363
DAY 5 10RG+IGF1 8390
DAY 5 IGF1 5312
DAY 5 IGF1 4818
DAY 5 IGF1 4869
DAY 5 IGF1+DMSO 4646
DAY 5 IGF1+DMSO 4939
DAY 5 IGF1+DMSO 4293
DAY 7 HTS 10478
DAY 7 HTS 9304
DAY 7 HTS 9347
DAY 7 HTS+DMSO 11771
DAY 7 HTS+DMSO 13730
DAY 7 HTS+DMSO 12103
DAY 7 100RG 3986
DAY 7 100RG 2874
DAY7 100RG 2412
DAY 7 100RG+IGF1 3011
DAY 7 100RG+IGF1 2226
DAY 7 100RG+IGF1 2845
DAY 7 50RG 4180
DAY 7 50RG 4097
4863 121008 124569
5275 130717 5346
4902 121983 1
5618 140575 134917
5620 145742 14507
4814 118433 1
4821 120158 119311
4702 117933 1204
4726 119842 1
6845 172758 173614
6811 170775 3350
7110 177308 1
8026 200767 199536
8238 206267 7423
7638 191575 1
4384 106642 85211
3091 76708.3 18691
2862 72283.3 1
2738 69491.7 64867
2843 71050 9393
2176 54058.3 1
3332 81925 73856
2513 67991.7 7224
2805 71650 1
2556 64858.3 59283
2156 54175 5357
2333 58816.7 1
8849 225083 212564
9094 229758 25839
7218 182850 1
7438 186042 193681
7488 186017 13253
8246 208983 1
5115 130483 125756
4912 121933 4346
5024 124850 1
4702 116658 113853
4663 120125 8050
4149 104775 1
10482 265083 243650
9255 229650 18850
9502 236217 1
11674 294308 315236
13651 342067 24420
12434 309333 1
3785 96758.3 81453
2775 70391.7 13686
3411 77208.3 1
3020 75266.7 67575
2408 57050 9433
2813 70408.3 1
4193 104083 96492
4146 102983 12209
4860
5240
4898
5611
5919
4740
4801
4650
4778
6910
6748
7149
8004
8244
7818
4350
3095
2928
2794
2824
2158
3219
2835
2908
2604
2212
2371
9015
9293
7423
7482
7471
8442
5231
4902
5089
4651
4813
4131
10850
8999
9497
11872
13667
12583
3840
2798
3442
3001
2212
2791
4117
4115
Appendix C
Data sheet 10 Growth of MKN 45 cells with RG 13022 and IGF-1 25,000 cells per well
DAY 7 50RG 3296
DAY 7 50RG+IGF1 3632
DAY 7 50RG+IGF1 2967
DAY 7 50RG+IGF1 2571
DAY 7 10RG 14646
DAY 7 10RG 14146
DAY 7 10RG 12278
DAY 7 10RG+IGF1 13319
DAY 7 10RG+IGF1 13632
DAY 7 10RG+IGF1 12957
DAY 7 10RG+IGF1 12978
DAY 7 IGF1 10413
DAY 7 IGF1 11801
DAY 7 IGF1 12018
DAY 7 IGF1+DMSO 16606
DAY 7 IGF1+DMSO 14527
DAY 7 IGF1+DMSO 15848
DAY 7 IGF1+DMSO 16782
3289 82408.3 1
3548 89258.3 75589
2849 73516.7 12760
2574 63991.7 1
14366 363500 339689
13897 348908 29521
12325 306658 1
13775 334767 328658
13557 339525 10133
12308 318100
12873 322242 2
10435 261725 281408
11361 287217 17517
11665 295283 1
16004 408175 396054
14656 365900 22404
15697 393092 2
16511 417050 12935
3304
3531
3006
2534
14608
13826
12196
13078
13554
12907
12818
10559
11304
11751
16371
14725
15626
16753
Appendix C
Data sheet 11 Growth of N 87 cells with RG 13022 and lOnM IGF-1 40,000 cells per well
DAY TREATMENT COUNT 1 
DILUTION
DAYO IGF-1 2805
DAYO IGF-1 3992
DAYO IGF-1 3382
DAYO IGF-1 7587
DAYO IGF-1+DMSO 4840
DAYO IGF-1+DMSO 4936
DAYO IGF-1+DMS0 3375
DAYO IGF-1+DMS0 3510
DAYO 100RG 4537
DAYO 100RG 4607
DAYO 100RG 3952
DAYO 100RG 3882
DAYO 100RG+IGF1 5206
DAYO 100RG+IGF1 5003
DAYO 100RG+IGF1 4214
DAYO 100RG+IGF1 5035
DAYO 50RG 4500
DAYO 50RG 4914
DAYO 50RG 4310
DAYO 50RG 3606
DAYO 50RG+IGF1 3918
DAYO 50RG+IGF1 3224
DAYO 50RG+IGF1 4870
DAYO 50RG+IGF1 3548
DAYO 10RG 5664
DAYO 10RG 5043
DAYO 10RG 4714
DAYO 10RG 4479
DAYO 10RG+IGF1 4962
DAYO 10RG+IGF1 4542
DAYO 10RG+IGF1 4661
DAYO 10RG+IGF1 4292
DAYO 5RG
DAYO 5RG 3987
DAYO 5RG 4165
DAYO 5RG 4402
DAYO 5RG+IGF1 4999
DAYO 5RG+IGF1 4270
DAYO 5RG+IGF1 4482
DAYO 5RG+IGF1 4193
DAYO HTS 4553
DAYO HTS 4370
DAYO HTS 4566
DAYO HTS 4330
DAYO HTS+DMSO 4478
DAYO HTS+DMSO 4477
DAYO HTS+DMSO 4404
DAYO HTS+DMSO 3778
2 COUNT 3 MEAN MEAN OF 
REPLICATES
2747 68742 110777
3948 99508 54123
3351 85117 2
7602 189742 31248
4926 121767 104670
123338 102894
84413 2
89163 59406
114663 106878
115563 9539
99463 2
97825 5507
130338 123266
127788 10851
107088 2
127850 6265
113713 107938
121825 14902
109213 2
87000 8604
98675 98119
81963 17673
122563 2
89275 10204
136575 123863
126150 9926
119213 2
113513 5731
124838 116091
116325 6823
114975 2
108225 3939
#DIV/0! 104038
100363 3813
103775 1
107975 2696
125950 112731
108450 9580
112863 2
103663 5531
112375 111584
110613 2761
114938 2
108413 1594
111563 106728
112338 9257
110100 2
92913 5345
COUNT
25
2697
4001
3481
7580
4846
4931
3378
3623
4636
4638
4005
3944
5221
5220
4353
5193
4597
4832
4427
3354
3976
3333
4935
3594
5262
5049
4823
4602
5025
4764
4537
4366
4042
4137
4236
5077
4406
4547
4100
4437
4479
4629
4343
4447
4510
4404
3655
Appendix C
Data sheet 11 Growth of N 87 cells with RG 13022 and lOnM IGF-1 40,000 cells per well
DAY 3 IGF-1 6449
DAY 3 IGF-1 5413
DAY 3 IGF-1 3598
DAY 3 IGF-1 2903
DAY 3 IGF-1+DMSO 8224
DAY 3 IGF-1 +DMSO 8290
DAY 3 IGF-1+DMSO 6170
DAY 3 IGF-1+DMSO 3547
DAY 3 100RG 2534
DAY 3 100RG 2272
DAY 3 100RG 1716
DAY 3 100RG 928
DAY 3 100RG+IGF1 1734
DAY 3 100RG+IGF1 1850
DAY 3 100RG+IGF1 1466
DAY 3 100RG+IGF1 969
DAY 3 50RG 2414
DAY 3 50RG 2547
DAY 3 50RG 2049
DAY 3 50RG 1204
DAY 3 50RG+IGF1 953
DAY 3 50RG+IGF1 1263
DAY 3 50RG+IGF1 788
DAY 3 50RG+IGF1 899
DAY 3 10RG 1572
DAY 3 10RG 2780
DAY 3 10RG 2006
DAY 3 10RG 1415
DAY 3 10RG+IGF1 4025
DAY 3 10RG+IGF1 4705
DAY 3 10RG+IGF1 2367
DAY 3 10RG+IGF1 2124
DAY 3 5RG 1451
DAY 3 5RG 2286
DAY 3 5RG 2004
DAY 3 5RG 2088
DAY 3 5RG+IGF1 1671
DAY 3 5RG+IGF1 1895
DAY 3 5RG+IGF1 1687
DAY 3 5RG+IGF1 1975
DAY 3 HTS 1628
DAY 3 HTS 2253
DAY 3 HTS 2038
DAY 3 HTS 2102
DAY 3 HTS+DMSO 2255
DAY 3 HTS+DMSO 2484
DAY 3 HTS+DMSO 2172
DAY 3 HTS+DMSO 2672
DAY 5 IGF-1 11721
DAY 5 IGF-1 12960
7851 182525 194538
10102 212258 16441
10525 204650 2
9430 178717 9492
12617 279617 277356
13748 297275 14717
12937 267250 2
14169 265283 8497
6902 135692 123390
6816 131708 16396
6783 126742 2
5475 99417 9466
7113 131975 130046
7487 139133 9339
7364 132108 2
6514 116967 5392
8222 155858 152142
8570 163650 16919
8736 161800 2
7066 127258 9768
9845 173375 179306
10427 183692 6293
10781 185700 2
10044 174458 3633
9040 162292 177510
10520 198042 21645
10708 194067 2
8661 155642 12497
10029 203283 220292
12614 249700 20266
11633 214825 2
11622 213358 11700
8091 147275 162094
9932 184917 16139
8293 155983 2
8634 160200 9318
9476 172242 181623
10598 196533 10720
9905 175767 2
9984 181950 6189
7940 146975 150302
8538 161517 8071
7571 142650 2
8003 150067 4660
7620 145292 156271
7960 152667 13368
7926 151392 2
9246 175733 7718
8151 235058 256319
10164 277042 22886
7603
9956
10435
9113
12713
13635
12963
14118
6847
6717
6710
5527
6990
7359
7023
6553
8067
8521
8631
7001
10007
10353
10715
9992
8863
10465
10574
8601
10340
12645
11779
11857
8131
9972
8421
8502
9522
11091
9500
9875
8069
8591
7509
7903
7560
7876
8069
9170
8335
10121
Appendix C
Data sheet 11 Growth of N 87 cells with RG 13022 and lOnM IGF-1 40,000 cells per well
DAY 5 IGF-1 10799 8836 8927 238017 2
DAY 5 IGF-1 15043 9023 8953 275158 13213
DAY 5 IGF-1 +DMSO 14177 9683 9770 280250 296410
DAY 5 IGF-1 +DMSO 13393 10411 10889 289108 20485
DAY 5 IGF-1+DMSO 11144 14094 13934 326433 2
DAY 5 IGF-1+DMSO 14152 10241 10389 289850 11827
DAY 5 100RG 4340 3121 3024 87375 53802
DAY 5 100RG 2713 1564 1519 48300 22874
DAY 5 100RG 2072 1514 1548 42783 2
DAY 5 100RG 1614 1419 1377 36750 13206
DAY 5 100RG+IGF1 1951 1206 1197 36283 34052
DAY 5 100RG+IGF1 1552 1219 1208 33158 1492
DAY 5 100RG+IGF1 1460 1288 1262 33417 2
DAY 5 100RG+IGF1 1496 1248 1258 33350 861
DAY 5 50RG 3433 2579 2588 71667 77946
DAY 5 50RG 3004 3109 3204 77642 9144
DAY 5 50RG 2548 4205 4164 90975 2
DAY 5 50RG 1359 3641 3580 71500 5279
DAY 5 50RG+IGF1 1884 3931 3907 81017 78575
DAY 5 50RG+IGF1 1417 3968 4058 78692 7976
DAY 5 50RG+IGF1 1259 4555 4605 86825 2
DAY 5 50RG+IGF1 891 3581 3660 67767 4605
DAY 5 10RG 10744 9660 10005 253408 229244
DAY 5 10RG 7980 10566 10430 241467 28041
DAY 5 10RG 5314 11223 11423 233000 2
DAY 5 10RG 3812 9450 9430 189100 16190
DAY 5 10RG+IGF1 4393 13224 13482 259158 233338
DAY 5 10RG+IGF1 7993 11316 11201 254250 34354
DAY 5 10RG+IGF1 3206 12428 12674 235900 2
DAY 5 10RG+IGF1 2263 10003 9819 184042 19835
DAY 5 5RG 4837 9685 9833 202958 188023
DAY 5 5RG 5718 10293 10726 222808 34109
DAY 5 5RG 2829 9745 9437 183425 2
DAY 5 5RG 1341 7867 7940 142900 19693
DAY 5 5RG+IGF1 3983 12659 12448 242417 205965
DAY 5 5RG+IGF1 3320 10567 10536 203525 27617
DAY 5 5RG+IGF1 4080 10113 10125 202650 2
DAY 5 5RG+IGF1 2297 9359 9376 175267 15945
DAY 5 HTS 4666 8516 8465 180392 189715
DAY 5 HTS 2952 10870 11010 206933 11785
DAY 5 HTS 2699 9733 9737 184742 2
DAY 5 HTS 2643 9816 9956 186792 6804
DAY 5 HTS+DMSO 4107 9119 9348 188117 174435
DAY 5 HTS+DMSO 3108 9257 9289 180450 12571
DAY 5 HTS+DMSO 3209 8732 8449 169917 2
DAY 5 HTS+DMSO 3263 7819 8029 159258 7258
DAY 7 IGF-1 18421 9801 9706 316067 374902
DAY 7 IGF-1 22278 13641 13596 412625 41668
DAY 7 IGF-1 22266 12405 12438 392575 2
DAY 7 IGF-1 22845 11315 11241 378342 24057
Appendix C
Data sheet 11 Growth of N 87 cells with RG 13022 and lOnM IGF-1 40,000 cells per well
DAY 7 IGF-1+DMSO 22115 24707 22790 580100 519592
DAY 7 IGF-1 +DMSO 24608 22237 22492 577808 79051
DAY 7 IGF-1+DMSO 22105 19400 19508 508442 2
DAY 7 IGF-1 +DMSO 18451 15448 15543 412017 45640
DAY 7 100RG 6995 4713 4716 136867 61948
DAY 7 100RG 3431 1399 1260 50750 51455
DAY 7 100RG 2843 968 920 39425 2
DAY 7 100RG 1346 580 564 20750 29707
DAY 7 100RG+IGF1 3024 689 655 36400 28746
DAY 7 100RG+IGF1 2248 630 615 29108 7285
DAY 7 100RG+IGF1 2062 779 829 30583 2
DAY 7 100RG+IGF1 982 653 632 18892 4206
DAY 7 50RG 4937 2227 2186 77917 81902
DAY 7 50RG 3008 4052 4047 92558 18820
DAY 7 50RG 3292 4422 4275 99908 2
DAY 7 50RG 1711 2488 2668 57225 10866
DAY 7 50RG+IGF1 3130 4871 4890 107425 97621
DAY 7 50RG+IGF1 2460 5759 5831 117083 24540
DAY 7 50RG+IGF1 1925 5259 5325 104242 2
DAY 7 50RG+IGF1 1357 3098 2953 61733 14168
DAY 7 10RG 9868 13778 13316 308017 336996
DAY 7 10RG 13971 17394 17697 408850 51909
DAY 7 10RG 9110 15815 15834 339658 2
DAY 7 10RG 5294 14805 14876 291458 29970
DAY 7 10RG+IGF1 11828 23315 22430 479775 419390
DAY 7 10RG+IGF1 13750 18777 18752 427325 74578
DAY 7 10RG+IGF1 13330 20793 20858 458175 2
DAY 7 10RG+IGF1 3948 16931 16595 312283 43057
DAY 7 5RG 14225 14479 14368 358933 341352
DAY 7 5RG 16749 14948 15104 390008 78264
DAY 7 5RG 12563 17292 16994 390408 2
DAY 7 5RG 4725 11471 10931 226058 45186
DAY 7 5RG+IGF1 10554 18104 17417 383958 393785
DAY 7 5RG+IGF1 11769 22701 22941 478425 63383
DAY 7 5RG+IGF1 8774 18951 18829 387950 2
DAY 7 5RG+IGF1 5010 16622 17345 324808 36594
DAY 7 HTS 9594 15807 16060 345508 340396
DAY 7 HTS 9194 17658 17396 368733 47953
DAY 7 HTS 7618 18607 18914 376158 2
DAY 7 HTS 6165 13379 12998 271183 27686
DAY 7 HTS+DMSO 8550 15198 15320 325567 318004
DAY 7 HTS+DMSO 9663 19001 18878 396183 58357
DAY 7 HTS+DMSO 7175 13705 13772 288767 2
DAY 7 HTS+DMSO 6782 12281 12317 261500 33693
Appendix C
Data sheet 12 Growth of N 87 cells with RG 13022 and IGF-1 40,000 cells per well
DAY TREATMENT COUNT 1 
DILUTION
DAYO HTS 4093
DAYO HTS 5172
DAYO HTS 4571
DAYO HTS 5102
DAYO HTS 5758
DAYO HTS 5576
DAYO HTS 5214
DAYO HTS 5017
DAYO HTS 5662
DAYO HTS 5312
DAYO HTS 5378
DAYO HTS 4801
DAYO HTS 5089
DAYO HTS 5418
DAYO HTS 5525
DAYO HTS 5015
DAYO HTS 4924
DAYO HTS 4555
DAYO HTS 5548
DAYO HTS 3888
DAYO HTS 4889
DAYO HTS 5085
DAYO HTS 4664
DAYO HTS 3977
DAY 3 IGF1+dmso 10066
DAY 3 IGF1+dmso 11806
DAY 3 IGF1+dmso 11660
DAY 3 IGF1+dmso 12465
DAY 3 100RG 8480
DAY 3 100RG 8363
DAY 3 100RG 8411
DAY 3 100RG
DAY 3 50RG 10438
DAY 3 50RG 11612
DAY 3 50RG 12001
DAY 3 50RG
DAY 3 10RG 15605
DAY 3 10RG 14450
DAY 3 10RG 15945
DAY 3 10RG
DAY 3 5RG 16835
DAY 3 5RG 15107
DAY 3 5RG 17392
DAY 3 5RG
DAY 3 HTS 11501
DAY 3 HTS 12225
DAY 3 HTS 10947
DAY 3 HTS 9750
DAY 5 IGF1+dmso 14079
DAY 5 IGF1+dmso 16783
DAY 5 IGF1+dmso 15539
DAY 5 IGF1+dmso 16437
MEAN OF 
REPLICATES 
118278 
15873 
1
11224
135683
9558
1
6759
131765
8267
2
4773
136204
1821
1
1821
118783
16910
2
9763
117533
13381
2
7726
289533
26848
2
15501
210058
2694
1
1905
284475
20908
1
14784
381228
15947
1
11276
405888
39592
1
39592
11534 11514 287908 211676
12412 12350 308225 137246
11414 11135 10287 2
9476 9608 240283 79239
14507 14318 357533 393960
16774 16679 418633 26797
15857 15547 391192 2
16353 16228 408483 15471
COUNT 2 COUNT 3 MEAN
25
3865 4040 99983.3
5121 5114 128392
4487 4614
5043 5030 126458
5845 5791 144950
5269 5504 136242
5314 5289
5004 5082 125858
5617 5632 140925
5344 5203 132158
5225 5372 133125
4895 4806 120850
5145 5068
5385 5387 134917
5486 5488 137492
4844 5071
5010 4986 124333
4622 4601 114817
5539 5487 138117
3895 3961 97866.7
5151 4898 124483
5103 5170 127983
4808 4870 119517
3904 3897 98150
10218 9940 251867
12149 12067 300183
11657 11666 291525
12789 12493 314558
8440 8659 213158
8270 8361 208283
8251 8386 208733
10606 10241 260708
11924 11586 292683
12143 11860 300033
15530 15527 388850
14631 14467 362900
15699 15388 391933
17322 16897 425450
15134 15106 377892
17433 17241 433883
126575
13722
4
3148
Appendix C
Data sheet 12 Growth of N 87 cells with RG 13022 and IGF-1
DAY 5 100RG 3438 3409 3227 83950
DAY 5 100RG 2337 2155 2174 55550
DAY 5 100RG 1521 1428 1406 36291.7
DAY 5 100RG
DAY 5 50RG 6875 6787 6962 171867
DAY 5 50RG 7826 7835 8016 197308
DAY 5 50RG 8063 8033 8124 201833
DAY 5 50RG
DAY 5 10RG 20753 20428 21164 519542
DAY 5 10RG 19559 18969 18997 479375
DAY 5 10RG 23556 23596 23354 587550
DAY 5 10RG
DAY 5 5RG 20769 20616 21074 520492
DAY 5 5RG 23891 23881 23582 594617
DAY 5 5RG 21699 21887 21763 544575
DAY 5 5RG
DAY 5 HTS 14489 14837 14613 366158
DAY 5 HTS 14230 14284 14346 357167
DAY 5 HTS 15120 14648 14809 371475
DAY 5 HTS
DAY 7 IGF1+dmso 18018 18370 18218 455050
DAY 7 IGF1+dmso 19292 19522 19239 483775
DAY 7 IGF1+dmso 19020 18295 18685 466667
DAY 7 IGF1+dmso 18371 18218 18445 458617
DAY 7 100RG 1460 1046 1011 29308.3
DAY 7 100RG 1086 977 1137 26666.7
DAY 7 100RG 681 622 595 15816.7
DAY 7 100RG
DAY 7 50RG 848 779 817 20366.7
DAY 7 50RG 787 698 732 18475
DAY 7 50RG 1067 1043 999 25908.3
DAY 7 50RG 986 990 963 24491.7
DAY 7 10RG 11741 11967 11908 296800
DAY 7 10RG 14336 14263 14027 355217
DAY 7 10RG 19582 19490 19362 486950
DAY 7 10RG 14557 14254 14524 361125
DAY 7 5RG 19743 19481 19496 489333
DAY 7 5RG 15443 15762 15796 391675
DAY 7 5RG 18266 18524 18407 459975
DAY 7 5RG
DAY 7 HTS 11776 11899 11996 297258
DAY 7 HTS 10529 10591 10568 264067
DAY 7 HTS 10854 10656 10437 266225
DAY 7 HTS
40,000 cells per well
58597
23975
1
16953
190336
16154
1
11423
528822
54681
1
38666
553228
37812
1
26737
364933
7232
1
5114
466027
12791
2
7385
23931
7150
1
5056
22310
3473
2
2005
375023
80067
2
46226
446994
50106
1
35431
275850
18572
1
13132
Appendix C
Data sheet 13 Growth of N 87 cells with RG 13022 and lOnM IGF-1 30,000 cells per well
DAY TREATMENT COUNT 1 
DILUTION
DAYO HTS 1331
DAYO HTS 1317
DAYO HTS 1276
DAYO HTS 1470
DAYO HTS 1598
DAYO HTS 1367
DAYO HTS 1374
DAYO HTS 1368
DAYO HTS 1576
DAYO HTS 1379
DAYO HTS 1455
DAYO HTS 1406
DAYO HTS 1564
DAYO HTS 1372
DAYO HTS 1574
DAYO HTS 1581
DAYO HTS 1380
DAYO HTS 1171
DAY 4 HTS 6291
DAY 4 HTS 6112
DAY 4 HTS 5953
DAY 4 IGF1 6310
DAY 4 IGF1 7516
DAY 4 IGF1 7067
DAY 4 5 RG 6381
DAY 4 5 RG 6184
DAY 4 5 RG 5302
DAY 4 10RG 5456
DAY 4 10RG 6130
DAY 4 10RG 6159
DAY 4 50 RG 5037
DAY 4 50 RG 4139
DAY 4 50 RG 4118
DAY 4 100 RG 2220
DAY 4 100 RG 2232
DAY 4 100 RG 2220
DAY 6 HTS 7415
DAY 6 HTS 8282
DAY 6 HTS 8026
DAY 6 IGF1 10497
DAY 6 IGF1 11503
DAY 6 IGF1 10533
DAY 6 5 RG 9517
DAY 6 5 RG 10538
DAY 6 5 RG 10622
DAY 6 10 RG 7802
DAY 6 10 RG 9003
DAY 6 10 RG 9476
DAY 6 50 RG 4968
DAY 6 50 RG 4194
DAY 6 50 RG 3636
DAY 6 100 RG 1260
2 COUNT 3 MEAN MEAN OF
REPLICATES
1338 33233.33 32486
1287 32616.67 820
1266 31608.33 1
1494 37158.33 36675
1544 39433.33 3029
1333 33433.33 1
1436 34808.33 36222
1356 34966.67 2313
1522 38891.67 1
1410 34841.67 35786
1454 36825 995
1464 35691.67 1
1506 38708.33 36942
1286 33583.33 2910
1499 38533.33 1
1582 39625 34825
1487 35750 5323
1143 29100 1
6251 157066.7 152628
5979 151191.7 3923
5970 149625 1
6449 160225 174369
7310 185766.7 12991
7083 177116.7 1
6481 161558.3 151175
6431 158300 15250
5325 133666.7 1
5520 137883.3 147539
6128 153375 8423
6026 151358.3 1
4738 123825 102500
4087 101875 884
4180 103125 1
2231 55416.67 55561
2197 55075 572
2229 56191.67 1
7493 186675 201636
8469 209333.3 12959
8100 208900 1
10137 258516.7 269667
11522 288858.3 16693
10429 261625 1
9678 241166.7 257953
10561 265175 14584
10879 267516.7 1
8276 205325 221939
9149 226891.7 14774
9331 233600 1
5007 123375 104950
3985 101533.3 16977
3610 89941.67 1
1294 31300 36897
COUNT
25
1319
1310
1251
1495
1590
1312
1367
1472
1569
1392
1510
1413
1575
1372
1551
1592
1423
1178
6306
6052
6032
6468
7466
7104
6525
6381
5413
5570
6147
5978
5084
3999
4077
2199
2180
2294
7493
8369
8942
10388
11638
10433
9745
10722
10601
8561
9075
9225
4830
4005
3547
1202
Appendix C
Data sheet 13 Growth of N 87 cells with RG 13022 and lOnM IGF-1 30,000 cells per well
DAY 6 100 RG 1459
DAY 6 100 RG 1743
DAY 8 HTS 11766
DAY 8 HTS 13311
DAY 8 HTS 13436
DAY 8 IGF1 15384
DAY 8 IGF1 17829
DAY 8 IGF1 15496
DAY 8 5 RG 11995
DAY 8 5 RG 13091
DAY 8 5 RG 13091
DAY 8 10 RG 10052
DAY 8 10 RG 9898
DAY 8 10 RG 8858
DAY 8 50 RG 4340
DAY 8 50 RG 3477
DAY 8 50 RG 3060
DAY 8 100 RG 1111
DAY 8 100 RG 1049
DAY 8 100 RG 1243
1454 36616.67 5743
1725 42775 1
11681 294341.7 318981
13075 329600 21406
13320 333000 1
15324 384250 404725
17828 446516.7 36195
15270 383408.3 1
12094 302058.3 319678
13330 329133.3 15273
13085 327841.7 1
9930 250208.3 238550
9805 245808.3 16529
8703 219633.3 1
4179 105591.7 90528
3451 86233.33 13441
3270 79758.33 1
1031 26175 27519
1001 25691.67 2758
1189 30691.67 1
1481
1665
11874
13166
13204
15402
17925
15243
12158
13075
13165
10043
9794
8795
4152
3420
3241
999
1033
1251
Appendix C
Data sheet 14 Growth of MKN 45 cells with RG 13022 and IGF-1 50,000 cells per well
DAY TREATMENT COUNT 1
DAYO HTS
DILUTION
1907
DAYO HTS 2379
DAYO HTS 2326
DAYO HTS 2676
DAYO HTS 3018
DAYO HTS 2980
DAYO HTS 2930
DAYO HTS 2871
DAYO HTS 2853
DAYO HTS 2875
DAYO HTS 3072
DAYO HTS 3321
DAYO HTS 2947
DAYO HTS 3170
DAYO HTS 2984
DAYO HTS 2405
DAYO HTS 3132
DAYO HTS 3351
DAYO HTS 2396
DAYO HTS 1890
DAYO HTS 2822
DAYO HTS 2839
DAYO HTS 3370
DAYO HTS 1596
DAY 3 IGF1+dmso 9216
DAY 3 IGF1+dmso 12991
DAY 3 IGF1+dmso 11949
DAY 3 IGF1+dmso 11404
DAY 3 100RG 4273
DAY 3 100RG 3029
DAY 3 100RG 2493
DAY 3 100RG 1612
DAY 3 50RG 3758
DAY 3 50RG 3838
DAY 3 50RG 4060
DAY 3 50RG 1800
DAY 3 10RG 7484
DAY 3 10RG 8535
DAY 3 10RG 8664
DAY 3 10RG 4228
DAY 3 5RG 9436
DAY 3 5RG 9687
DAY 3 5RG 9426
DAY 3 5RG 4594
DAY 3 HTS 12756
DAY 3 HTS 6130
DAY 3 HTS 5524
DAY 3 HTS 4598
DAY 5 IGF1+dmso 9605
DAY 5 IGF1+dmso 12107
DAY 5 IGF1+dmso 12405
DAY 5 IGF1+dmso 11052
2 COUNT 3 MEAN MEAN OF 
REPLICATES
1919 48150 59165
2430 60541.7 7780
2476 61541.7 2
2614 66425 4492
2933 74300 73015
3024 75425 2470
2985 72583.3 2
2753 69750 1426
2868 72666.7 74700
2692 69541.7 4661
3003 76225 2
3148 80366.7 2691
2903 73791.7 71754
3110 78641.7 7805
2969 74050 2
2431 60533.3 4506
3137 77983.3 66050
3189 81400 16683
2373 58916.7 2
1839 45900 9632
2654 68233.3 65460
2916 72016.7 18327
3228 82166.7 2
1526 39425 10581
9310 232042 283460
12817 322150 38024
11946 297433 2
11179 282217 21953
4097 104800 70104
3061 76800 27798
2306 59725 2
1556 39091.7 16049
3670 93450 84058
3620 95091.7 25887
4110 102058 2
1773 45633.3 14946
7603 189050 179579
8465 212467 53052
8646 214858 2
3909 101942 30629
9447 236092 198683
9875 245642 72514
9464 235242 1
4618 115167 51275
12962 321633 149674
6115 152267 129412
5449 10287 2
4592 114508 74716
9547 238525 280140
12048 300550 30994
11901 306692 2
10995 274792 17895
COUNT
25
1952
2456
2583
2681
2965
3047
2795
2746
2999
2778
3072
3175
3005
3157
2933
2428
3089
3228
2301
1779
2712
2887
3262
1609
9319
12850
11797
11283
4206
3126
2368
1523
3786
3953
4077
1903
7599
8496
8473
4096
9448
9915
9339
4608
12878
6027
5371
4551
9471
11911
12497
10928
Appendix C
Data sheet 14 Growth of MKN 45 cells with RG 13022 and IGF-1 50,000 cells per well
DAY 5 100RG 3652 3630 3623 90875 68269
DAY 5 100RG 2993 2842 2859 72450 20332
DAY 5 100RG 2718 2670 2791 68158.3 2
DAY 5 100RG 1629 1720 1642 41591.7 11739
DAY 5 50RG 3388 3304 3336 83566.7 75488
DAY 5 50RG 3702 3512 3185 86658.3 22354
DAY 5 50RG 3539 3608 3601 89566.7 2
DAY 5 50RG 1669 1719 1671 42158.3 12906
DAY 5 10RG 7119 7046 7130 177458 217067
DAY 5 10RG 10701 10757 10702 268000 61311
DAY 5 10RG 10929 11184 10380 270775 2
DAY 5 10RG 5498 5602 7144 152033 35398
DAY 5 5RG 10503 10709 11369 271508 271946
DAY 5 5RG 11179 11129 11270 279817 53898
DAY 5 5RG 13405 13373 13290 333900 2
DAY 5 5RG 8021 8204 8082 202558 31118
DAY 5 HTS 12422 12170 12249 307008 303771
DAY 5 HTS 13505 13386 13089 333167 36322
DAY 5 HTS 13209 12810 12761 323167 2
DAY 5 HTS 9926 10170 10113 251742 20970
DAY 7 IGF1+dmso 18167 17884 18644 455792 448381
DAY 7 IGF1+dmso 16120 17202 17244 421383 20622
DAY 7 IGF1+dmso 18905 18733 18813 470425 2
DAY 7 IGF1+dmso 18074 17804 17633 445925 11906
DAY 7 100RG 5429 5501 5471 136675 123779
DAY 7 100RG 7821 7924 7979 197700 57657
DAY 7 100RG 3933 3889 3855 97308.3 2
DAY 7 100RG 2555 2560 2497 63433.3 33288
DAY 7 50RG 6808 6626 6645 167325 186856
DAY 7 50RG 9444 9750 9403 238308 50570
DAY 7 50RG 8772 8430 8761 216358 2
DAY 7 50RG 5081 5022 4949 125433 29197
DAY 7 10RG 15482 15458 15250 384917 420506
DAY 7 10RG 16995 17138 16923 425467 28244
DAY 7 10RG 18443 18083 17907 453608 2
DAY 7 10RG 16651 16702 16811 418033 16306
DAY 7 5RG 18935 18703 17959 463308 438513
DAY 7 5RG 20981 20478 20635 517450 78022
DAY 7 5RG 17555 17721 17714 441583 2
DAY 7 5RG 13047 13410 13348 331708 45046
DAY 7 HTS 15980 15854 15831 397208 410479
DAY 7 HTS 18629 18829 18501 466325 45668
DAY 7 HTS 16788 16893 16869 421250 2
DAY 7 HTS 14157 14357 14342 357133 26366
Appendix C
Data sheet 15 Growth of MKN 45 cells with RG 13022 and 1 OnM IGF-1 40,000 cells per well
DAY TREATMENT COUNT 1
DAYO HTS
DILUTION
1689
DAYO HTS 2098
DAYO HTS 2047
DAYO HTS 2125
DAYO HTS+DMSO 2155
DAYO HTS+DMSO 2356
DAYO HTS+DMSO 2351
DAYO HTS+DMSO 2628
DAYO 100RG 2026
DAYO 100RG 2110
DAYO 100RG 2291
DAYO 100RG 2367
DAYO 100RG+IGF1 2006
DAYO 100RG+IGF1 2006
DAYO 100RG+IGF1 2317
DAYO 100RG+IGF1 2525
DAYO 50RG 2145
DAYO 50RG 1909
DAYO 50RG 2150
DAYO 50RG 1935
DAYO 50RG+IGF1 1935
DAYO 50RG+IGF1 2008
DAYO 50RG+IGF1 1906
DAYO 50RG+IGF1 1584
DAYO 10RG 3761
DAYO 10RG 2624
DAYO 10RG 1514
DAYO 10RG 1272
DAYO 10RG+IGF1 2182
DAYO 10RG+IGF1 2460
DAYO 10RG+IGF1 1624
DAYO 10RG+IGF1 1185
DAYO 5RG 2241
DAYO 5RG 2291
DAYO 5RG 1651
DAYO 5RG 1122
DAYO 5RG+IGF1 2470
DAYO 5RG+IGF1 2172
DAYO 5RG+IGF1 1863
DAYO 5RG+IGF1 1120
DAYO IGF1 2055
DAYO IGF1 2079
DAYO IGF1 1236
DAYO IGF1 890
DAYO IGF1+DMSO 1649
DAYO IGF1+DMSO 1127
DAYO IGF1+DMSO 1016
DAYO IGF1+DMSO 697
DAY 3 HTS 6449
DAY 3 HTS 5413
DAY 3 HTS 3598
2 COUNT 3 MEAN MEAN OF 
REPLICATES
1714 42841.7 49921
2180 52716.7 4752
2008 51500 2
2106 52625 2743
2109 53816.7 59250
2347 58783.3 4737
2313 59025 2
2605 65375 2735
2007 49841.7 55063
2229 53800 4078
2314 58183.3 2
2355 58425 2355
1933 47625 53867
1985 49925 6726
2139 55125 2
2467 62791.7 3884
2113 53800 49938
1831 46550 3796
2121 52591.7 2
1842 46808.3 2192
1839 45558.3 45769
2052 49775 4680
1911 48475 2
1566 39266.7 2702
3673 93425 56956
2649 66375 28770
1437 36425 2
1260 31600 16610
2077 53066.7 46088
2439 60850 13813
1660 41108.3 2
1189 29325 7975
2185 54816.7 39207
2284 57450 24923
1621 41175 2
1077 3387 14389
2475 61458.3 47433
2168 54741.7 14514
1802 45550 2
1161 27983.3 8380
1967 50041.7 38258
2001 51183.3 14722
1196 30325 2
895 21483.3 8500
1640 40650 27727
1089 27466.7 9595
1010 25200 2
678 17591.7 5540
6799 166075 116242
5530 136025 42452
3430 88800 2
COUNT
25
1738
2048
2125
2084
2194
2351
2419
2612
1948
2117
2377
2289
1776
2000
2159
2543
2198
1846
2040
1840
1693
1913
2000
1562
3777
2692
1420
1260
2109
2403
1649
1145
2152
2319
1669
1148
2430
2229
1801
1077
1983
2062
1207
793
1589
1080
998
736
6681
5380
3628
Appendix C
Data sheet 15 Growth of MKN 45 cells with RG 13022 and 1 OnM IGF-1 40,000 cells per well
DAY 3 HTS 2903
DAY 3 HTS+DMSO 8224
DAY 3 HTS+DMSO 8290
DAY 3 HTS+DMSO 6170
DAY 3 HTS+DMSO 3547
DAY 3 100RG 2534
DAY 3 100RG 2272
DAY 3 100RG 1716
DAY 3 100RG 928
DAY 3 100RG+IGF1 1734
DAY 3 100RG+IGF1 1850
DAY 3 100RG+IGF1 1466
DAY 3 100RG+IGF1 969
DAY 3 50RG 2414
DAY 3 50RG 2547
DAY 3 50RG 2049
DAY 3 50RG 1204
DAY 3 50RG+IGF1 953
DAY 3 50RG+IGF1 1263
DAY 3 50RG+IGF1 788
DAY 3 50RG+IGF1 899
DAY 3 10RG 1572
DAY 3 10RG 2780
DAY 3 10RG 2006
DAY 3 10RG 1415
DAY 3 10RG+IGF1 4025
DAY 3 10RG+IGF1 4705
DAY 3 10RG+IGF1 2367
DAY 3 10RG+IGF1 2124
DAY 3 5RG 1451
DAY 3 5RG 2286
DAY 3 5RG 2004
DAY 3 5RG 2088
DAY 3 5RG+IGF1 1671
DAY 3 5RG+IGF1 1895
DAY 3 5RG+IGF1 1687
DAY 3 5RG+IGF1 1975
DAY 3 IGF1 1628
DAY 3 IGF1 2253
DAY 3 IGF1 2038
DAY 3 IGF1 2102
DAY 3 IGF1+DMSO 2255
DAY 3 IGF1+DMSO 2484
DAY 3 IGF1+DMSO 2172
DAY 3 IGF1+DMSO 2672
DAY 5 HTS 11721
DAY 5 HTS 12960
DAY 5 HTS 10799
DAY 5 HTS 15043
DAY 5 HTS+DMSO 14177
DAY 5 HTS+DMSO 13393
DAY 5 HTS+DMSO 11144
DAY 5 HTS+DMSO 14152
3008 74066.7 24510
8106 204450 163617
8578 210158 57550
6116 153733 2
3231 86125 33227
2363 61325 45865
2300 56975 17311
1704 42158.3 2
918 23000 9994
1625 41816.7 37283
1840 46250 9583
1503 36991.7 2
980 24075 5533
2329 59191.7 51052
2529 63116.7 14801
2094 51933.3 2
1207 29966.7 8545
965 24108.3 24360
1209 30875 4637
832 20133.3 2
910 22325 2677
1528 38166.7 47871
2787 69158.3 15406
1889 49066.7 2
1422 35091.7 8895
4026 100308 82656
4630 116833 30778
2387 59825 2
2176 53658.3 17770
1432 35758.3 48596
2395 59116.7 9664
1846 48758.3 2
1978 50750 5579
1663 40725 44323
1861 46891.7 4591
1593 40191.7 2
1932 49483.3 2651
1574 39408.3 48964
2183 55683.3 8500
2082 51800 1
2130 6010
2239 56166.7 59806
2376 59375 5589
2249 55841.7 2
2688 67841.7 3227
11369 290225 315850
13320 328650 47751
10545 267775 2
15026 376750 27569
14389 356283 331358
13460 334725 34803
11208 281150 2
13961 353275 20094
2977
8204
8351
6162
3557
2462
2265
1639
914
1659
1860
1470
940
2360
2498
2089
1185
975
1233
796
870
1480
2732
1993
1374
3986
4685
2425
2139
1408
2413
2001
2024
1553
1871
1543
2031
1527
2246
2096
2072
2246
2265
2280
2781
11737
13158
10789
15141
14188
13314
11386
14280
Appendix C
Data sheet 15 Growth of MKN 45 cells with RG 13022 and 1 OnM IGF-1 40,000 cells per well
DAY 5 100RG 4340
DAY 5 100RG 2713
DAY 5 100RG 2072
DAY 5 100RG 1614
DAY 5 100RG+IGF1 1951
DAY 5 100RG+IGF1 1552
DAY 5 100RG+IGF1 1460
DAY 5 100RG+IGF1 1496
DAY 5 50RG 3433
DAY 5 50RG 3004
DAY 5 50RG 2548
DAY 5 50RG 1359
DAY 5 50RG+IGF1 1884
DAY 5 50RG+IGF1 1417
DAY 5 50RG+IGF1 1259
DAY 5 50RG+IGF1 891
DAY 5 10RG 10744
DAY 5 10RG 7980
DAY 5 10RG 5314
DAY 5 10RG 3812
DAY 5 10RG+IGF1 4393
DAY 5 10RG+IGF1 7993
DAY 5 10RG+IGF1 3206
DAY 5 10RG+IGF1 2263
DAY 5 5RG 4837
DAY 5 5RG 5718
DAY 5 5RG 2829
DAY 5 5RG 1341
DAY 5 5RG+IGF1 3983
DAY 5 5RG+IGF1 3320
DAY 5 5RG+IGF1 4080
DAY 5 5RG+IGF1 2297
DAY 5 IGF1 4666
DAY 5 IGF1 2952
DAY 5 IGF1 2699
DAY 5 IGF1 2643
DAY 5 IGF1+DMSO 4107
DAY 5 IGF1+DMSO 3108
DAY 5 IGF1+DMSO 3209
DAY 5 IGF1+DMSO 3263
DAY 7 HTS 18421
DAY 7 HTS 22278
DAY 7 HTS 22266
DAY 7 HTS 22845
DAY 7 HTS+DMSO 22115
DAY 7 HTS+DMSO 24608
DAY 7 HTS+DMSO 22105
DAY 7 HTS+DMSO 18451
DAY 7 100RG 6995
DAY 7 100RG 3431
DAY 7 100RG 2843
DAY 7 100RG 1346
DAY 7 100RG+IGF1 3024
4358 108517 66940
2707 68208.3 30258
2101 52533.3 2
1550 38500 17469
1939 48125 40017
1543 38575 5480
1444 36558.3 2
1469 36808.3 3164
3383 84766.7 64696
3004 75300 22561
2676 65808.3 2
1295 32908.3 13025
1926 47116.7 33667
1355 34325 10425
1226 31366.7 2
853 21858.3 6019
10613 266875 172733
7803 196675 75934
5327 134792 2
3670 92591.7 43841
4076 105417 111265
8296 202867 64334
3158 80925 2
2240 55850 37143
4701 119825 91035
5736 141558 48687
2668 68475 2
1375 34283.3 28109
3997 99308.3 86433
3452 84241.7 20566
4198 103908 2
2408 58275 11874
4775 118867 81598
3038 74883.3 25185
2556 65308.3 2
2719 67333.3 14541
4019 101967 85640
3143 78858.3 10938
3213 80241.7 2
3184 81491.7 6315
18702 464025 537994
22119 555725 49712
22890 561283 2
22668 570942 28701
22110 554800 546865
24541 614850 62298
22408 554050 2
18481 463758 35968
6939 173858 90583
3331 84725 59509
2763 70016.7 2
1374 33733.3 34358
3038 76133.3 51810
4324
2765
2131
1456
1885
1534
1483
1452
3356
3028
2673
1295
1844
1347
1279
879
10668
7818
5534
3629
4181
8055
3347
2199
4841
5533
2720
1398
3937
3337
4191
2288
4823
2996
2582
2718
4110
3212
3207
3332
18560
22290
22198
23000
22351
24633
21973
18719
6929
3405
2796
1328
3074
Appendix C
Data sheet 15 Growth of MKN 45 cells with RG 13022 and lOnM IGF-1 40,000 cells per well
DAY 7 100RG+IGF1 2248
DAY 7 100RG+IGF1 2062
DAY 7 100RG+IGF1 982
DAY 7 50RG 4937
DAY 7 50RG 3008
DAY 7 50RG 3292
DAY 7 50RG 1711
DAY 7 50RG+IGF1 3130
DAY 7 50RG+IGF1 2460
DAY 7 50RG+IGF1 1925
DAY 7 50RG+IGF1 1357
DAY 7 10RG 9868
DAY 7 10RG 13971
DAY 7 10RG 9110
DAY 7 10RG 5294
DAY 7 10RG+IGF1 11828
DAY 7 10RG+IGF1 13750
DAY 7 10RG+IGF1 13330
DAY 7 10RG+IGF1 3948
DAY 7 5RG 14225
DAY 7 5RG 16749
DAY 7 5RG 12563
DAY 7 5RG 4725
DAY 7 5RG+IGF1 10554
DAY 7 5RG+IGF1 11769
DAY 7 5RG+IGF1 8774
DAY 7 5RG+IGF1 5010
DAY 7 IGF1 9594
DAY 7 IGF1 9194
DAY 7 IGF1 7618
DAY 7 IGF1 6165
DAY 7 IGF1+DMSO 8550
DAY 7 IGF1+DMSO 9663
DAY 7 IGF1+DMSO 7175
DAY 7 IGF1+DMSO 6782
2299 56950 21888
2015 50958.3 2
887 23200 12637
4918 123717 80879
3021 76133.3 33893
3296 82608.3 2
1648 41058.3 19568
3014 77266.7 55238
2416 61200 18408
1950 48450 2
1362 34033.3 10628
10078 248942 239263
13944 348392 87979
8881 225467 2
5297 134250 50795
11676 293917 266735
13507 341017 114021
13220 333475 2
3893 98533.3 65830
14050 353792 298010
16300 413967 129910
12322 310442 2
4344 113842 75004
10477 262767 225627
11915 297400 75735
8792 219883 2
4888 122458 43726
9277 234942 199692
9021 226558 38667
7293 185833 2
5907 151433 22324
8542 213692 200365
9589 240950 33461
7115 179767 2
6511 167050 19319
2287
2038
915
4991
3107
3325
1568
3128
2468
1939
1365
9927
13892
9065
5519
11766
13665
13467
3983
14180
16627
12368
4592
10501
12004
8820
4797
9322
8972
7389
6100
8551
9662
7282
6753
Appendix C
Data sheet 16 Growth of MKN 45 cells with RG 13022 and 1 OnM IGF-1 40,000 cells per well
DAY TREATMENT COUNT 1 
DILUTION
DAYO HTS 3632
DAYO HTS 4689
DAYO HTS 3409
DAYO HTS 2803
DAYO 100uM RG 4084
DAYO 100uM RG 5257
DAYO 100uM RG 3690
DAYO 100uM RG 2218
DAYO 100RG+10nM IGF1 4680
DAYO 100RG+10nM IGF1 4043
DAYO 100RG+10nM IGF1 3429
DAYO 100RG+10nM IGF1 2265
DAYO 10uM RG 4121
DAYO 10uM RG 4271
DAYO 10uM RG 3515
DAYO 10uM RG 2525
DAYO 10RG+10nM IGF1 4330
DAYO 10RG+10nM IGF1 5383
DAYO 10RG+10nM IGF1 3789
DAYO 10RG+10nM IGF1 2133
DAYO 10nM IGF1 3327
DAYO 10nM IGF1 3496
DAYO 10nM IGF1 2891
DAYO 10nM IGF1 1949
DAY 3 HTS 12751
DAY 3 HTS 12478
DAY 3 HTS 12659
DAY 3 HTS 8444
DAY 3 100uM RG 7511
DAY 3 100uM RG 8250
DAY 3 100uM RG 8684
DAY 3 100uM RG 4253
DAY 3 100RG+10nM IGF1 6507
DAY 3 100RG+10nM IGF1 7256
DAY 3 100RG+10nM IGF1 7229
DAY 3 100RG+10nM IGF1 3505
DAY 3 10uM RG 11706
DAY 3 10uM RG 15307
DAY 3 10uM RG 14159
DAY 3 10uM RG 9237
DAY 3 10RG+10nM IGF1 10801
DAY 3 10RG+10nM IGF1 13024
DAY 3 10RG+10nM IGF1 13406
DAY 3 10RG+10nM IGF1 8381
DAY 3 10nM IGF1 12281
DAY 3 10nM IGF1 14052
DAY 3 10nM IGF1 12155
DAY 3 10nM IGF1 8465
DAY 5 HTS 12843
DAY 5 HTS 18240
DAY 5 HTS 21189
2 COUNT3 MEAN MEAN OF 
REPLICATES
3614 90291.7 90540
4654 117150 19706
3369 84750 2
2790 69966.7 11377
3777 100317 94631
5188 130858 30949
3580 91708.3 2
2276 55641.7 17868
5012 122000 91619
4152 102475 27903
3464 85908.3 2
2191 56091.7 16110
3931 100525 87925
4119 105025 19382
3191 83908.3 2
2450 62241.7 11190
4358 108167 98315
5476 135783 33948
3744 95108.3 2
2168 54200 19600
3332 83566.7 72706
3396 85516.7 16892
2880 72991.7 2
1984 48750 9753
12615 317233 288177
12603 312725 52693
12376 313558 2
8318 209192 30423
7494 187892 178846
8485 209842 52955
8636 216133 2
3960 101517 30574
6424 161067 130501
6969 176050 85182
7145 181500 2
3387 3387 49180
11383 290625 313008
15242 379967 67007
13972 351925 2
9261 229517 38686
10713 268992 284925
13002 325717 58826
13576 336350 2
8198 208642 33963
12069 304683 290863
13753 346292 58559
12144 304333 2
8027 208142 33809
13279 328508 432188
17641 442700 83082
21323 531250 2
COUNT
25
3589
4715
3392
2803
4177
5258
3735
2183
4948
4102
3416
2275
4011
4213
3363
2494
4292
5435
3880
2203
3369
3370
2988
1917
12702
12446
12592
8341
7542
8446
8616
3969
6397
6901
7406
3388
11786
15047
14100
9044
10765
13060
13380
8458
12212
13750
12221
8485
13299
17243
21238
Appendix C
Data sheet 16 Growth of MKN 45 cells with RG 13022 and 1 OnM IGF-1 40,000 cells per well
DAY 5 HTS 17347 17014 16794 426292
DAY 5 100uM RG 6354 6323 6361 158650
DAY 5 100uM RG 7059 6903 6845 173392
DAY 5 100uM RG 6712 6747 6742 168342
DAY 5 100uM RG 6648 6286 6870 165033
DAY 5 100RG+10nM IGF1 5633 5661 5518 140100
DAY 5 100RG+10nM IGF1 7255 7171 7078 179200
DAY 5 100RG+10nM IGF1 8097 8015 7873 199875
DAY 5 100RG+10nM IGF1 6095 6147 6011 152108
DAY 5 10mcM RG 16593 16467 16399 412158
DAY 5 10mcM RG 17364 17245 17282 432425
DAY 5 10mcM RG 19577 19590 19422 488242
DAY 5 10mcM RG 14101 14064 13998 351358
DAY 5 10RG+10nM IGF1 13366 13535 13737 338650
DAY 5 10RG+10nM IGF1 16388 16424 16319 409425
DAY 5 10RG+10nM IGF1 14894 13496 12559 341242
DAYS 10RG+10nM IGF1 11199 11166 11230 279958
DAY 5 10nM IGF1 15482 15541 15213 385300
DAY 5 10nM IGF1 17221 17047 17121 428242
DAY 5 10nM IGF1 17248 16782 16795 423542
DAY 5 10nM IGF1 13606 14116 13974 347467
DAY 7 HTS 15041 15720 15344 384208
DAY 7 HTS 18969 18867 18878 472617
DAY 7 HTS 16043 16375 16309 406058
DAY 7 HTS 18093 17620 17921 446950
DAY 7 100uM RG 7701 7680 7646 191892
DAY 7 100uM RG 6864 6822 6909 171625
DAY 7 100uM RG 6623 6715 6274 163433
DAY 7 100uM RG 3136 3173 3184 79108.3
DAY 7 100RG+10nM IGF1 6358 6418 6348 159367
DAY 7 100RG+10nM IGF1 7526 7272 6768 179717
DAY 7 100RG+10nM IGF1 6941 6931 7009 174008
DAY 7 100RG+10nM IGF1 3228 3187 3193 80066.7
DAY 7 10uM RG 15559 15692 15803 392117
DAY 7 10uM RG 18567 18666 18977 468417
DAY 7 10uM RG 21963 21881 21630 545617
DAY 7 10uM RG 15799 15933 15392 392700
DAY 7 10RG+10nM IGF1 17270 17527 17849 438717
DAY 7 10RG+10nM IGF1 17811 18505 16282 438317
DAY 7 10RG+10nM IGF1 16833 17280 17830 432858
DAY 7 10RG+10nM IGF1
DAY 7 10nM IGF1 19910 20317 20698 507708
DAY 7 10nM IGF1 20619 21181 21233 525275
DAY 7 10nM IGF1 18279 18071 18098 453733
DAY 7 10nM IGF1 17768 18416 19109 460775
GLASGOW
UNnrERSITY
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47968
166354
6180
2
3568
167821
26909
2
15536
421046
56510
2
32626
342319
52936
2
30563
396138
37718
2
21777
427458
39782
2
22968
151515
49731
2
28712
148290
46282
2
26721
449713
73292
2
42315
436631
3273
1
2314
486873
35063
2
20243
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